Evaluating the use of resistant starch as a beneficial dietary fiber and its effect on physiological response of glucose, insulin, and fermentation by Haugabrooks, Esther
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2013
Evaluating the use of resistant starch as a beneficial
dietary fiber and its effect on physiological response
of glucose, insulin, and fermentation
Esther Haugabrooks
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Nutrition Commons, and the Toxicology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Haugabrooks, Esther, "Evaluating the use of resistant starch as a beneficial dietary fiber and its effect on physiological response of
glucose, insulin, and fermentation" (2013). Graduate Theses and Dissertations. 13625.
https://lib.dr.iastate.edu/etd/13625
  
 
 
 
Evaluating the use of resistant starch as a beneficial dietary fiber and its effect on 
physiological response of glucose, insulin, and fermentation 
 
 
by 
 
 
Esther Haugabrooks  
 
 
 
 
A dissertation submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY  
 
 
Major: Toxicology 
 
Program of Study Committee: 
Suzanne Hendrich, Major Professor  
Donald Beitz 
Diane Birt 
Manju Reddy 
Michael Wannemuehler 
 
 
 
 
 
 
 
Iowa State University 
Ames, Iowa 
2013 
 
Copyright © Esther Haugabrooks, 2013. All rights reserved.
ii 
DEDICATION 
 
 
 
 
To Don and Mini for always believing. 
 
 
 
iii 
TABLE OF CONTENTS 
          Page 
ACKNOWLEDGEMENTS ....................................................................................... vii 
ABSTRACT ............................................................................................................... ix 
CHAPTER 1  GENERAL INTRODUCTION ....................................................... 1 
 Research introduction .......................................................................................... 1 
 Dissertation organization  .................................................................................... 3 
CHAPTER 2 LITERATURE REVIEW ............................................................... 5 
 A.  Resistant Starch .............................................................................................. 5 
  A.1 General structure and classification ................................................... 6 
  A.2 Methods of analysis for RS content ................................................... 10 
  A.3 Resistant starch as functional foods and functional ingredient .......... 12 
  A.4 Bioavailability .................................................................................... 15 
  A.5 Interactions of RS with dietary components ...................................... 17 
 B. Beneficial health effects of RS ......................................................................  18 
  B.1 Resistant starch as dietary fiber ......................................................... 20 
  B.2 Resistant starch as a prebiotic ............................................................ 21 
  B.3 Postprandial glucose and insulin ........................................................ 24 
  B.4 Satiety and obesity ............................................................................. 25 
  B.5 Gastrointestinal health ....................................................................... 27 
  B.6 Lower intestinal microbiota and fermentation ................................... 30 
   B.6.1 Overview of gut microbiota and implications for health and  
    disease ....................................................................................... 31 
    
   B.6.2 Effects of microbial fermentation products .............................. 33 
 
 
 
iv 
   B.6.3 Gut microbial interactions with RS as substrate ....................... 35 
 C.  In vitro fermentation for metabolic analysis of RS….  .................................. 37  
  C.1 Defining in vitro fermentation Systems ............................................. 37  
  C.2 Media selection .................................................................................. 38 
  C.3 Preparation of fecal samples for microbial analysis .......................... 41 
  C.4 In vitro RS fermentation studies ........................................................ 43 
 D. Human study with RS .................................................................................... 44  
   D.1 Methodology of human feeding studies ............................................. 44 
   D.1.1. Experimental setup .................................................................... 45 
   D.1.2 Selection and design of RS food treatments ............................. 47 
   D.1.3 Screening participants ............................................................... 49  
   D.1.4 Dissertation methodology employed  ....................................... 50  
   D.2 Glycemic and insulin response .......................................................... 51  
   D.3   Fermentation studies .......................................................................... 64  
   D.3.1 Quantification of fermentation .................................................. 66 
  D.3.2 Short chain fatty acids (SCFA) .................................................  69  
     D.3.2.a  Acetate ...................................................................  70  
     D.3.2.b Propionate ..............................................................  71  
     D.3.2.c Butyrate  ................................................................ 72 
  D.3.3  Breath  .......................................................................................  75 
D.3.3.a   Hydrogen ............................................................... 75  
D.3.3.b  Methane ................................................................. 77 
D.3.3.c  Carbon dioxide ...................................................... 78 
 
 
 
v 
   D.3.4 RS comparisons in fermentation studies ................................... 79 
   D.4 Symptoms to RS consumption ........................................................... 81 
 E.  References ...................................................................................................... 83 
 
CHAPTER 3 THE EFFECTS OF NATURALLY OCCURRING RESISTANT  
STARCH IN MAIZE ON POSTPRANDIAL GLYCEMIC RESPONSE IN  
HEALTHY HUMANS .............................................................................................. 98 
  
 Abstract   ......................................................................................................... 98 
 Introduction ......................................................................................................... 99 
 Materials and methods  ........................................................................................ 102 
 Results   ......................................................................................................... 106 
 Discussion ......................................................................................................... 107 
 References ......................................................................................................... 111 
 Figures and tables   .............................................................................................. 116  
 Appendix  ......................................................................................................... 118 
 
CHAPTER 4 INFLUENCE OF CRACKERS CONTAINING RESISTANT  
STARCH V ON POSTPRANDIAL GLUCOSE, INSULIN, AND  
FERMENTATION RESPONSE IN HEALTHY HUMANS .................................... 119 
  
 Abstract   ......................................................................................................... 119 
 Introduction ......................................................................................................... 120 
 Materials and methods  ........................................................................................ 121 
 Results   ......................................................................................................... 127 
 Discussion ......................................................................................................... 130 
 References ......................................................................................................... 136 
 
 
 
vi 
 Figures and tables   .............................................................................................. 140  
 Appendix ......................................................................................................... 147 
 
CHAPTER 5 IN VITRO SCREENING OF LIPID MODIFIED RESISTANT  
STARCHES AND MEDIA COMPARISON ON SHORT CHAIN FATTY ACID 
PRODUCTION IN BATCH FERMENTATION    ................................................... 150 
 
 Abstract   ......................................................................................................... 150 
 Introduction ......................................................................................................... 151 
 Materials and methods  ........................................................................................ 153 
 Results   ......................................................................................................... 158 
 Discussion ......................................................................................................... 159 
 References ......................................................................................................... 163 
 Figures and tables ................................................................................................ 167 
 Appendix ......................................................................................................... 171 
 
CHAPTER 6  SUMMARY AND CONCLUSIONS ............................................. 172 
 
 
 
 
vii 
ACKNOWLEDGEMENTS 
To whom much is given, there are so many things to be thankful for and subsequently so 
many people to acknowledge. Throughout the course of study and research at ISU, I have been 
fortunate to encounter exemplary people; therefore, this author wishes to express deepest 
gratitude by acknowledging the following supporters.  
Firstly, all honor, praise and glory to my Heavenly Father where it not for His loving 
presence and grace, I would have snapped long time ago.  To my parents Charles and Minerva 
Haugabrooks, thank you so much for helping me become the women I am today.  Thanks for 
encouraging me to continue this journey with integrity through the tears, stress, and indifference.   
I give special thanks to my POS committee members, especially my advisor Suzanne 
Hendrich who always made herself available to talk and kept it “real”, particularly when I 
needed it most.  I thank each of my committee members Donald Beitz, Diane Birt, Manju Reddy, 
and Michael Wannemuehler for your patient and accommodating spirit, even when I would 
ambush each one of you at times along the way.  
During the course of my research, at times the process felt lonely but always most 
challenging.  However, I leaned of the expertise of my POS committee and many others like Li 
Li who never tired of going over procedures with me and would find the time to coach and talk 
with me even though we lived in separate time zones.  Likewise, thanks to Patricia Murphy for 
being a mentor and unofficial therapist while conducting research.  Thanks to Hyun Jung Kim, 
who during my first human study, ran samples for me in an extremely timely manner and later 
spent time teaching me analytical methods. To Jay-lin Jane and Tong Wang, thank you for 
letting me use your laboratories to run experiments.  Thank you Dr. Wang for allowing me 
unlimited access to your lab, it made things a whole lot easier.  Special thanks to Milton Allison 
for playing a major role in helping me set up my in vitro experiment and the media samplers that 
I affectionately called contraptions. To the graduate students of Dr. Jane laboratory, thank you 
Yongfeng Ai, Michael Reed and Samuel Moore for your involvement in the many aspects of 
Resistant Starch type 5 and its preparation. 
Financial Support of for this dissertation research was made possible in part by AFRI and 
Plant Science Institute of Iowa State; likewise, special thanks to GMAP of ISU for awarding me 
the George Washington Carver Fellowship. 
 
 
 
viii 
Thanks to the many participants of the human studies.  Thanks to the volunteers and my 
workers, especially the self-proclaimed “Bloodsuckers” team.  Yes, we ran a tight ship and 
without each worker and volunteer playing his or her part, this research would not have been 
possible.  For all studies and help around the lab, I was blessed with great student workers.  Terri 
Boylston, thank you for your help in formulating crackers.  Dr. Boylston must have tasted every 
modification (and there were lots) and you gave so many useful suggestions.  Thanks Ken Prusa 
for donating supplies and making suggestions for the formulation of the test cracker.  Thanks to 
the Keck Lab with Ann Perera and Zhihong Song. It seemed, at times, I was living in that lab.  
Yet, at every turn the above Dr. Perera and Dr. Song were there helping and making it a 
complete joy to run every sample.  Great thanks for the statistical consulting of Ignacio Castro, 
Dason Kurkiewicz, and Sekou Mosley.  
To all my dear friends at ISU and prior to ISU, I say thank you.  Thank you for all the 
good times but particularly the good time that gave me much reprieve from the times that were 
“not so good”.  Thank you for being there for me no matter what.  I extend a very special thanks 
to my dear friends Richard and Barbra Judson, Theodoric Weston, Monique Vassell-Orizaga, 
Samantha Bromfield-Burt, Michelle Durant-Stover, and Merlaine Bissainthe-Mosley. Some of 
you are a part of the reason I am at ISU but all of you are a large part of the reason I finished. 
Gracious acknowledgements to Jennifer Rayner, Barbra Woods, Thelma Harding, Dan Chen, 
Jean Tilly, Linda Wild, Brenda Emery, and Erica Burkheimer for just being great and memorable 
people while I was at ISU.    
It is quite easy to give tribute or show gratitude to those who have performed 
monumentally in your life. Yet, the smaller contributors are just as emphatic.  I stand grateful to 
both. The experience of ISU, the good and the bad, has shaped me into a better person. Above all 
I am most thankful for this experience.  
 
 
 
ix 
ABSTRACT 
Resistant starches (RS) are complex partly indigestible carbohydrates that have shown 
promise in improving digestive health, lowering postprandial blood glucose (PPG) and insulin 
(PPI) concentrations among other beneficial health effects. There are four types of RS and a fifth 
type is emerging; although there is very little experimental data on the physiological responses of 
RS type V.  Three experiments were constructed to test the overarching hypothesis that RS (type 
II and V) can favorably impact human physiological responses of PPG, PPI, and microbial 
fermentation in the colon with minimal gastrointestinal distress.  Two of the three experiments 
were randomized blind crossover human feeding studies. Study one, restricted to PPG response, 
was conducted using conventional and novel crossbred corn starches (type II) fed to 11 
participants in pudding product.  Study two investigated the effects of stearic acid-modified RS 
and its parent high amylose starch in crackers on PPG, PPI, and microbial fermentation in 30 
participants. The third experiment was an in vitro batch-fermentation of human fecal microbiota 
from lean and obese individuals.  Short chain fatty acids (SCFA) fermentation patterns and shifts 
in pH were assessed with RS type V, type IV, and type II starch residues (SR) inoculated in brain 
heart infusion broth, brain heart infusion broth without dextrose, and a basal nutrient growth 
medium. Overall in vivo results supported the use of RS type II and type V to lower PPG, RS 
type II to lower PPI, and for type II and V to be more fermentable than type II, based on breath 
hydrogen production at 8 h after RS intake. Both types of RS were very well tolerated by 
participants based on gastrointestinal symptom scores after RS-containing meals.  In vitro 
analysis of human fecal batch anaerobic fermentations showed no differences in SCFA 
production by SR of RS types V and II or body mass index (BMI) of fecal donors.  More 
investigation on the fermentability of RS type V is needed, but so far results support the role of 
both types of starches in lower PPG with favorable implications for people with diabetes and 
metabolic syndrome.  
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CHAPTER 1.  GENERAL INTRODUCTION 
 
Research Introduction 
It would seem this is the era of resistant starch (RS).  Since the discovery of RS in 1982, 
there have been numerous publications on the effects and application of RS (Abell et al., 2008; 
Asp et al., 1996; Bassaganya-Riera et al., 2011; Fässler et al., 2006a; Silvester et al., 1995; 
Storey et al., 2007; Topping et al., 2003; Willis et al., 2009).  Research studies utilizing RS cover 
a wide scope of interest including digestion rates and bioavailability (Cummings et al., 1996; 
Fässler et al., 2006b; Granfeldt et al., 1993; Hoebler et al., 1999; Holm and Björck, 1992); 
product development and sensory evaluation1 (Aigster et al., 2011; Baixauli et al., 2008; Maziarz 
et al., 2013); incorporation or efficacy of RS as a functional ingredient (Fuentes-Zaragoza et al., 
2010); metabolic responses and health benefits (Brouns et al., 2007; Heijnen et al., 1995; Higgins 
et al., 2004; Johnston et al., 2010); and other aspects.  Test species in these studies have included 
rats (Bauer-Marinovic et al., 2006; Perrin et al., 2001), pigs (Giuberti et al., 2013), and humans 
(Worthley et al., 2009);  in additions, observations have been made in vivo and in vitro when 
assessing certain attributes such as physiological responses of glucose, insulin, and fermentation 
(Al-Tamimi et al., 2010; García-Rodríguez et al., 2012; Li et al., 2010; van Munster et al., 1994a; 
Zhou et al., 2013).  Furthermore, scientific evaluation of the benefits of RS has also generated 
commercial interest. 
 The ‘RS movement’ came around the advent of efforts to increase dietary fiber and has 
become the new diet craze.  However, the use of RS as a dietary fiber is not its only application. 
                                                
1 Defined as “a scientific discipline used to evoke, measure, analyze, and interpret reactions to 
the characteristics of food and materials as they are perceived by the senses of sight, smell, taste, 
touch, and hearing” by IFT’s Sensory Evaluation Division. (from http://sfs.wsu.edu/sensory/ and 
Moskowitz et al., 2012) 
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Within the past couple of decades, the potato diet emerged in which the objective was to lose 
weight by eating copious amounts of potatoes. Though scientific communities have not rendered 
enough evidence to strongly support the use of RS in weight loss, the underlying premise was 
that potatoes contain RS that facilitate weight loss.  Another use of RS is as a prebiotic.  
Arguably, the chief nutritional hot topics of the day include prebiotics and probiotics. Thus, in 
the area of prebiotic research, RS is of major interest for its potential as an effective prebiotic.  
With much ado about RS in the scientific community, a central question pertains: how 
effective is the use of RS?  Implications such as RS providing benefit toward inhibiting 
carcinogenesis, inflammatory bowel diseases, and metabolic disorders are at issue.  For example, 
due to the slow digestive rates of RS suggestions have been made that RS will lower postprandial 
glucose and be of benefit to people with diabetes.  There is evidence to support pros and cons as 
to the efficacy of RS to benefit human health. RS has been observed to be effective in lowering 
postprandial glucose response (Achour et al., 1997; Granfeldt et al., 1995; Raben et al., 1994)and 
RS has been observed not to be effective in lowering postprandial glucose response (Jenkins et 
al., 1998; Noakes et al., 1996).  Because the majority of this type of research is done in healthy 
individuals or animal models, there is not enough evidence to support the benefit to people with 
diabetes, thus, the question of efficacy remains unresolved.  
Similar to the focus of this dissertation research introduction, throughout this dissertation 
careful attention has been given to human studies for this is the main focus of the dissertation.  
Furthermore, humans tend to be the main interest in many RS physiological response studies.  
The dissertation’s review of the literature has aimed to establish the growing interest in RS as a 
dietary fiber and as a functional ingredient in connection to human health. Undoubtedly, the 
platform for RS is expanding along with our knowledge of gut microbiota and human host 
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interactions.  RS can be used as a substrate to influence events of digestion in addition to the 
capacity of colonic microbiota for carbohydrate fermentation. However, the role of gut 
microbiota and gastrointestinal status has been implicated in far more aspects of human health 
than fermentation.  
The goal of this dissertation research is to evaluate in vivo and in vitro effects of RS and 
how it pertains to human health.  The forms of RS that will be used are RS2 and RS5.  If there 
was a postulation on which form of RS is used the most in human studies, it would probably be 
RS2. But without a doubt, RS2 is used in human studies more frequently than RS5.  The types of 
RS will be covered in the literature review. The objectives of the dissertation research is to 
investigate the role of RS in glucose, insulin, and fermentation responses in vivo; assess in vitro 
fermentation patterns of the degradation of RS; and address if different types of RS influence 
physiological responses. Moreover, through this dissertation literature review and research, the 
author hopes to provoke discussion on meticulously defining parameters and conditions under 
which the use of RS is effective. 
 
 
Dissertation organization 
The organization of the dissertation is comprised as follows: 
• Review of RS literature largely from a human health perspective 
• Three papers for journal submission, authors, and author contributions 
1) The Effects Of Naturally Occurring Resistant Starch In Maize On 
Postprandial Glycemic Response In Healthy Humans 
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! Esther M. Haugabrooks – drafting of manuscript, data acquisition, 
analysis, and interpretation 
! Hyun Jung Kim – data analysis 
! Linda Pollak – production of study material 
! Suzanne Hendrich – revision of content 
2) Influence Of Crackers Containing Resistant Starch V On Postprandial 
Glucose, Insulin, And Fermentation Response In Healthy Humans  
! Esther M. Haugabrooks - drafting of manuscript, data acquisition, 
analysis, and interpretation 
! Yongfeng Ai – production of study material (RS5) 
! Jay-lin Jane – study conception, production of study material 
(RS5) 
! Suzanne Hendrich – revision of content 
3) In Vitro Screening Of Lipid Modified Resistant Starches And Media 
Comparison On Short Chain Fatty Acid Production In Batch Fermentation 
! Esther M. Haugabrooks - drafting of manuscript, data acquisition, 
analysis, and interpretation, study conception and design 
! Yongfeng Ai – production of study material (RS5) 
! Jay-lin Jane – production of study material (RS5) 
! Suzanne Hendrich – study conception and design, revision of 
content 
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CHAPTER 2.  LITERATURE REVIEW 
A. Resistant Starch 
Worldwide, carbohydrates are the main staple in the human diet.  Sources of 
carbohydrates come from a myriad of foods and beverages that act largely as a supply of fuel to 
energize the body.  Components of biological systems like the brain, blood, and nervous use 
carbohydrates in their simplest for as a principal source of energy.  Additionally, the use of this 
vital nutrient provides an array of health benefits when certain types of carbohydrates are 
consumed and potential protection from diseases (Asp et al. 1996; Fuentes-Zaragoza et al. 2010; 
Nugent 2005).  
Investigation into identifying and classifying types of carbohydrates, especially those that 
convey added benefit other than sources of energy, has become multitudinous.  Broad 
classification of carbohydrates ranges from basic simple sugars to complex carbohydrates while 
encompassing type of sugar, number of sugar units, and type of bond for further specification.  
Simple sugars, or monosaccharaides, are one sugar unit. Two or more sugars linked by 
glycosidic bonds are termed di-, oligo-, or poly- saccharides.   Starch and glycogen are examples 
of polysaccharides.  Furthermore, polysaccharides can also be categorized as complex 
carbohydrate and simple carbohydrates can be monosaccharaides and disaccharides.  Some 
complex carbohydrates are classified as dietary fiber, which are the leading carbohydrate 
currently under great investigation. 
An estimated 50% or more of a typical Western diet is carbohydrates, making it the most 
common and abundant nutrient.  A concerning fact when considering carbohydrates that are 
rapidly digested, such as simple carbohydrates, pose a risk of deteriorating health issues such as 
diabetes mellitus and coronary heart disease (Liu, 2002), although dietary fiber, a subset of 
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carbohydrates has been widely accepted for the ability to improve aspects of health.  
Recommendations have been given for daily intake of carbohydrates and dietary fiber; however, 
over the past couple decades carbohydrate consumption is increasing while dietary fiber 
consumption is decreasing (Gross et al., 2004).  Thus, nutritional advances are being made to 
increase overall dietary fiber consumptions and in unsuspecting carbohydrate-rich foods.   
Perhaps the most interesting carbohydrate currently being investigated for that role is 
resistant starch (RS) because of its physiological benefit as a dietary fiber.  Though the discovery 
of resistant starches among dietary components is fairly recent, resistant starch is rapidly 
becoming a hot topic among functional foods as the scientific knowledge accumulates on 
structure, uses, function, and biological effects.  
 
A.1   General structure and classification 
Starch and cellulose are examples of complex carbohydrates found in plants. Both are 
storage polysaccharides composed of monomeric glucose, which makes starch and cellulose 
chemically the same.  Furthermore, they both can be classified as dietary fiber, though in the 
case of cellulose that is strictly the case: whereas, starches are only considered dietary fibers if 
they are digestion resistant.  However, these two compounds are not identical.  The biggest 
distinction between starch and cellulose is the glycosidic linkages.  Cellulose contains !- (1-4)-
glucosidic bonds that link monomeric glucose units, while starch uses starch "- (1-4) glucosidic 
bonds.  Depending on the polymer composition, starch also contains "- (1-6) glucosidic bonds.   
The main structural composition of starches is made up of two polymers: amylose and 
amylopectin. Amylose is mainly a linear polymer with "- (1-4) bonds, though some branching 
can occur.  Amylopectin is a highly branched polymer with "- (1-4) and "- (1-6) bonds.  
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Amylopectin is a larger molecule and is typically the more abundant polymer in starches (Buléon 
et al., 1998).  The ratio of amylose to amylopectin has a strong influence on the rate of digestion.   
In humans, enzymatic digestion of starches begins in the mouth and ends in the small 
intestine.  However, some starches were found to resist enzymatic digestion.  Not long after this 
discovery (Englyst et al., 1982), the term resistant starch (RS) was coined. RS was described as 
the sum or fraction of starch that is not absorbed in the small intestine of healthy humans.  This 
fraction of starch was not hydrolyzed in vitro after 120 minutes of incubation with "-amylase and 
pullulanase (Berry, 1986; Englyst et al., 1982, 1999).  Classifications of starches then began to 
be categorized by the degree of digestion or its crystalline structure, which also gives insight to 
how the starch will be digested.   
The most simplistic way to classify all starches is under the umbrella of three general 
categories: rapidly digestible starch (RDS), slowly digestible starch (SDS), and resistant starch 
(RS).  Because of the straightforward nomenclature, this classification is commonly used to 
describe the rate of digestion in starches particularly regarding postprandial glucose response 
(see section D.2).   Simple carbohydrates are examples of RDS, which tend to be refined 
carbohydrates.   Starches with slower digestion rates such as SDS and RS can be examples of 
dietary fibers.  
A different method to classify starches is through crystalline structure.  Using x-ray 
diffraction patterns starches can be categorized into types A, B, C, and sometimes V. Type A and 
type B are somewhat similar in structure because both have starch granules with structural 
polymers packed in a double helical formation.  Type B differs from type A due to water 
molecules dispersed inside helices, whereas type A has densely packed polymers with typically 
less water molecules than type B. Type A is commonly found in cereals and type B is found in 
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raw potatoes (Sajilata et al., 2006).   Pure amylose has also been used to understand type A and 
type B starches (see figure 1), which have been shown to crystalize in both forms (Wu and 
Sarko, 1978a, 1978b). Type C is a combination of type A and B, while type V is an x-ray 
diffraction pattern observed in swollen starch granules.  
 
 
Figure 1.  Type A and B starch granular structure. Double helix formation and packing of type A 
amylose on the left and type B amylose to the right (Wu and Sarko, 1978b). 
 
 
Though Wu and Sarko (1978a,b) showed crystallinity in amylose, type A, B, and C 
starches are also typed from the crystallinity of amylopectin, which has been attributed with the 
crystalline nature of starch granules.  Amylopectin has branched chains.  Short branched chains 
are more abundant in type A, longer branched chains are abundant in B, and reiteratively type C 
has a mix of both long and short branched chains (Jane, 2006).  Type A is more susceptible to 
enzyme hydrolysis, which in part could be attributable to shorter double helices in comparison to 
type B; therefore, this makes type A more digestible and a common type seen in RDS and SDS 
than type B, whilst type B is found more in RS (Jane et al., 1997).  This method of x-ray 
diffraction classification, though relevant, is infrequently used especially in biological in vivo 
studies.  
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 Typing of starches by x-ray diffraction patterns favors more to the physicochemical 
nature of starch, which gives insight to physiological responses through in vitro structural 
behavior or visual characterization of starch.  For example, a x-ray pattern of a bread rich in 
amylose exhibited a B-type pattern in vitro and showed an in vivo trend of a lower postprandial 
peak (Hoebler et al., 1999), supporting B type starches having lower digestibility.  However, as 
previously stated, this type of classification is rarely used to describe starches used in in vivo 
carbohydrate studies.  Broader classification terms of starches like RDS, SDS, and RS are 
commonly used in biological studies where the terms are applicable.   RS is further subdivided 
into four main categories or types (Eerlingen et al., 1993; Englyst et al., 1992): 
 
Type I (RS1) is physically inaccessible to digestive amylolytic enzymes for degradation 
due to entrapment in a non-digestible matrix; found in starchy foods that are not 
fractionated or refined.   
Examples:  whole grains, coarsely ground cereals/partly-milled grans, legumes, seeds 
Type II (RS2) refers to native resistant starch granule crystallinity with high amylose 
content; primary structure and conformation of starch granules results in its natural 
resistance to degradation. 
Examples: green banana, crude potato, and raw starch granules 
Type III (RS3) comprises retrograded starches, which is a recrystallization or re-
association of the starch molecules that can form a gel.  
Examples: bread (stale), cooked and cooled potatoes, cornflakes, pasta salad 
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Type IV (RS4) is chemically modified starch with a high amount of chemical 
modifications normally through crosslinking (etherized, esterified, or cross-bonded - 
distarch phosphate ester); synthetic and not found in nature. 
Examples: chemically modified starches used as additives, such as Fibersym® RW 
(MGP Ingredients, Inc., Atchison, KS)  
 
Classifying RS by RS1-RS4 is perhaps the most common way RS is described in 
literature. There is an emerging classification of RS proposed unlike RS type I –IV.  This new 
class of RS is classified as RS type V or RS5.  RS5 are starch granules that have been modified 
with lipids forming a starch-lipid complex (Hasjim et al., 2010; Jane et al., 2009), which can be 
found in native starch granules or processed starch.  Differentiation of RS types has become 
essential in biological research studies because differences in physiological effects of RS have 
been found between RS types.  As a whole, RS is known for its benefit but when addressing 
particular advancements in health and food productions, specific detail should be given on type 
and dose of RS.  
 
A.2   Methods of Analysis for Resistant Starch Content 
Measurement of RS is quantified as a portion of total starch, mathematically represented 
as the difference between total starch from the rapidly or slowly digested starch (equation 1).  
Where TS is total starch, RDS is rapidly digested starch, and SDS is slowly digested starch.  
 
Equation 1: RS% = TS – (RDS + SDS) 
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 The first method developed for the analysis resistant starch seemed to be serendipitous 
(Englyst et al., 1982). In reporting a method to measure non-starch polysaccharides, Englyst and 
colleagues recognized starch “made resistant” to pancreatic "-amylase and pullulanase 
hydrolysis during incubation.  Nearly a decade after their discovery of resistant starch, Englyst 
and others developed a method specifically for the measurement of RDS, SDS, and RS (Englyst 
et al., 1992). 
At first, Englyst’s methods were accepted, but scrutinized for employing non- 
physiological parameters such as a 100°C incubation.  Subsequently, investigation of other 
techniques or modifications to Englyst’s original methods have been made to produce analytical 
in vitro RS measurements that reflect in vivo conditions in human digestion: modifications 
involve added ethanol or industrial methylated spirits precipitation, protein removal, elimination 
of acetone washing and drying, increased sample size, removal of pullulanase digestions, and 
increased incubation pH (Berry, 1986; Björck et al., 1986; Champ, 1992; Goni et al., 1996; 
McCleary et al., 2011).   Various analytical methods for measurements of dietary fiber have also 
been used to measure RS; however, McCleary and Monaghan developed a method exclusively to 
measure RS (McCleary and Monaghan, 2002) that has become a widely accepted method of RS 
analysis.  Though this method still employs incubation temperatures (50°C) normally not 
encountered under healthy conditions in vivo, it is currently viewed as an extremely reliable 
method to predict in vivo conditions of RS digestion.  
 At present, the two popular methods of analysis of RS are both accepted by AACC 
International, formerly the American Association of Cereal Chemists (AACCI or AACC), and 
Association of Analytical Communities International (AOAC).  Lee and company (1992) 
optimized a method for Total, Soluble, and Insoluble Dietary Fiber in Foods that became official 
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method AACC 32-07.01-AOAC 991.43; and McCleary and Monaghan Resistant Starch assay 
became official method AACC 32-40.01-AOAC 2002.02 (Lee et al., 1992; McCleary and 
Monaghan, 2002).  Both employ enzymatic digestions, but AOAC 991.43 is a gravimetric test 
and AOAC 2002.02 is a colorimetric test (see table 1 for method comparison).  AOAC 991.43 is 
a non-specific method for all dietary fiber and as such has been criticized as an analytical method 
to measure RS.  Some report AOAC 991.43 to overestimate RS content, while in some food 
preparations it is thought to underestimate RS content in comparison to AOAC 2002.02 (Sanz et 
al., 2010).  
 
A.3   Resistant Starches as Functional foods or Functional Ingredients  
The term “functional food” or “functional ingredient” is quickly gaining popularity.  
Functional foods fundamentally have been defined as natural and/or modified components with 
physiological value beyond basic nutrition, which aid in the improvement of human health 
(Henry, 2010).  Functional ingredients can be food additives used to fortify foods or nutritional 
components naturally present in food.  These definitions are loosely accepted because in the US 
the terms have no legal definition.  Notwithstanding that in the US, functional foods are reported 
to be purchased for health issues such as weight loss, cholesterol reduction, and digestive health 
(Arvanitoyannis and Van Houwelingen-Koukaliaroglou, 2005).  Functional foods span a wide 
range of foods and beverages.  Examples of functional foods or ingredients are salmon, green 
vegetables, cereals, breads, garlic, onion, vitamins, calcium, and yogurt.  RS is also a functional 
ingredient (Fuentes-Zaragoza et al., 2010) that is naturally present or incorporated into products 
to make functional foods. 
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Table 1: Comparison of simplified methods to quantify insoluble fiber and resistant starch.   
 
 
Insoluble Fiber  
AOAC 991.43 
AACC 32-07.01 
     
 Resistant Starch 
    AOAC 2002.02 
   AACC 32-40.01 
Step 1: Grind sample*  Step 1: Grind sample 
Step 2: Heat-stable "-amylase 
digestion at 100°C  
Step 2: 16 hour "-amylase digestion at 
37°C 
Step 3: Protease digestion at 60°C  Step 3: Treat with ethanol 
Step 4: Adjust pH 4.0-4.7  Step 4: Centrifuge and re-suspend pellet in ethanol 
Step 5: Amyloglucosidase digestion  Step 5: Treat with potassium hydroxide at 4°C 
Step 6: Filter and wash with water, 
ethanol, and acetone  
Step 6: Amyloglucosidase digestion at 
50°C 
Step 7: Dry and weigh residue  Step 7: Incubate with glucose oxidase/peroxidase solution 
Step 8: Calculate RS  Step 8: Measure the absorbance 
- Corrections for protein and ash can 
be made  
Calculate RS – normally standard error 
± 5% 
* If fat content > 10% defat samples 
 
 
Commercial companies have developed functional foods with dietary fiber, but more 
specifically products are being formulated with RS or RS as an additive (Aigster et al., 2011).  
Many research studies have successfully used RS as a functional ingredient to evaluate 
physiological efficacy and health benefits such as lower cholesterol or improved lipid profile, 
modulation of glycemic and insulin response, and improved bowel health (Fuentes-Zaragoza et 
al., 2010);  although the term ‘functional ingredient’ might not always be used.  
Efforts to enrich low-fiber foods with dietary fiber have encountered setbacks due to 
sensory issues.  Breads, muffins, and crackers are foods commonly fortified with whole grain 
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dietary fiber.  However, sensory evaluation of appearance/color, taste, and feel of high fiber 
fortified foods has been somewhat unfavorable.   For example, fiber-fortified bread has been 
summarized to have a dark color, reduced loaf volume, poor mouthfeel, and flavor masking 
properties (Sajilata et al., 2006).  Breads formulated to be functional foods, can replace part of 
rapidly digestible flour with RS to improve sensory concerns.  Sanz and associates (2009) 
replaced 15% of wheat flour with four different types of RS (2 type RS2, 2 type RS3) for final RS 
g (%) of muffin product to be between 8.3g (1.55% RS) and 12.5 g (1.76) as compared to the 
wheat control 0.65g (0.031% RS) (Sanz et al., 2009). 
The appearance of RS can range from a coarse to fine powder that is white in color.  RS 
has a bland taste, which makes it desirable as a food additive.  Other desirable traits that are 
present in types of RS are small particle size, low water-holding capacity, viscosity, solubility, 
gel formation, light texture, and high gelatinization temperatures. One or more of these traits 
allow for successful incorporation of RS into a food product while still maintaining a fairly 
palatable food product, although other sensory attributes such as grittiness, chewiness, and 
cohesiveness have been affected by the addition of RS to bread products (Baixauli et al., 2008). 
Baixauli and associates (2008) noticed an increase in grittiness, sweetness, and an overall 
increase in moisture as RS % increased, while springiness, chewiness, and cohesiveness 
decreased as RS% increased.   
Because of desirable physicochemical characteristics of RS, it improves sensory 
properties in baked goods compared to control baked goods (Maziarz et al., 2013), and in some 
cases, addition of RS can improve sensory properties above other dietary fibers.  This allows RS 
to be used to increase dietary fiber in foods not typically viewed to be good sources of dietary 
fiber, as in the case of Maziarz et al (2013) who also tested the use of RS in a meat entrée, 
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chicken curry, for sensory evaluation.   However, RS is more commonly incorporated into baked 
goods to modify texture and act as a crisping agent (Sajilata et al., 2006). With the increase of 
RS and its use as a functional ingredient, understanding physicochemical dynamics of RS when 
incorporated into food products is not only good for the improvement of human health but also 
has monetary importance for the food industry. 
 
A.4   Bioavailability  
The concept of bioavailability is important in the fields of toxicology and nutrition.  In 
toxicology, bioavailability focuses on the form of toxin and its effects to target tissues through 
various routes of exposure.  Oral exposure is the predominate route in nutrition; although in 
intravenous is an employed route of exposure by comparison.  After ingestion, nutrients that are 
broken down through digestive enzymes can be absorbed from the GI tract to become available 
to target tissues. Overall, bioavailability in human health fields deals with how much of the 
compound of interest or its metabolites appear in systemic circulation and/or target tissues.  
Ingestion of nutrients in food does not guarantee complete absorbance of nutrients for 
bodily utilization, fuel, or storage.  Generally, only a portion of total nutrients ingested from 
foods become bioavailable.  Some nutrients have more availability than others, while in whole 
food interactions can influence the rate or extent of bioavailability.  Other factors that can hinder 
nutritional bioavailability are the form of nutrient and enzymatic activity.   
In humans, the digestion of starch starts on a small scale immediately in the mouth with 
salivary " –amylase.  As the food bolus moves through the digestive tract, pancreatic " -
amylases (1,4-" -D-glucan glucanohydrolase, EC 3.2.1.1) continues to break down 
polysaccharides of starch to oligosaccharides and dextrins for release into the lumen of the small 
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intestine.  The small intestine is the last location for native enzymatic digestion of food. Here in 
the brush border region of the small intestine, glucose and other sugars are hydrolyzed by 
glucoamylase, " –glucosidase, maltase-glucoamylase, and sucrose-isomaltase for absorption and 
release into the bloodstream.  The undigested portion passes from the small to the large intestine 
where it becomes available to resident microbes for enzymatic fermentation. The colon is where 
RS has the most effect because this is the site of fermentation and where fermentation products, 
such as short-chain fatty acids (SCFA) and gases (carbon dioxide, methane and hydrogen) are 
formed. 
Bioavailability of RS to lower intestinal microbiota for fermentation can be considered a 
desirable outcome with health implications.   However, the bioavailability of glucose from any 
carbohydrate can be both desirable and undesirable.  Another classification of carbohydrates 
with respect to glucose bioavailability is glycemic2 vs. non-glycemic carbohydrates.  Glycemic 
carbohydrates are free sugars, maltodextrins, and simple starches while non-glycemic 
carbohydrates are non-starch polysaccharides (NSP), resistant short-chain carbohydrates, sugar 
alcohols, and resistant starches (Englyst and Englyst, 2005).   
Glycemic carbohydrates are bioavailable in the small intestine where glucose can be 
absorbed into the bloodstream.  Resistant starch, on the other hand as a non-glycemic 
carbohydrate provides limited glucose bioavailability.  
This classification of carbohydrates as glycemic and non-glycemic is infrequently used, 
although quantifying how much sugar becomes available after carbohydrate digestion is the key 
question in many carbohydrate human feeding studies (Hoebler et al., 1999; Holm and Björck, 
1992) and animal studies (Granfeldt et al., 1993; Hildebrandt and Marlett, 1991).  Availability of 
                                                
2 The term glycemic refers to glucose present in the blood; the usage of glycemic carbohydrates 
refers carbohydrates that rapidly release glucose into the blood in the same manner as RDS. 
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RS for fermentation is also a key research question, to such a degree that significant research 
effort has gone into producing starches modified to reduce glycemic bioavailability and enhance 
fermentation bioavailability. 
 
A.5   Interactions of RS with dietary components 
Previously brief mention has been made of factors that affect bioavailability or digestion 
of starch, one of which is dietary interactions.  Food components can interact with starch to alter 
in vivo bioavailability or alter the formation of RS in preparation (Escarpa et al., 1997).   Sajilata 
and associates (2006) reviewed in vitro interactions of starch and other dietary compounds.  To 
summarize: protein, calcium and potassium ions, soluble sugars (glucose, sucrose, lactose, 
maltose, ribose), and defatting lowered RS formation; other dietary fibers such as cellulose and 
lignin had minimal effect on RS formation; polyphenols, phytic acid, lectins and tannic acid 
acted as enzyme inhibitors decreasing RS digestion; and amylose-lipid complexes formed during 
cooking and/or processing reduced RS formation or contradictory were forms of RS (Sajilata et 
al., 2006).  
In addition, Sajilata’s review also cited an in vitro starch digestibility study that observed 
enzyme inhibition of trypsin and pancreatic "-amylase activity on insoluble indigestible residues 
from black beans, green beans, carrots, and rice bran. Though the use of the term ‘indigestible 
residue’ was poorly defined, the inhibitory effect on amylase of black bean residues was 
attributed to tannin content (Moron et al., 1989).   Another amylose inhibitor is the bacterial-
derived oligosaccharide, acarbose, which restricts starch digestion in the small intestine (Wolin 
et al., 1999). 
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The lipid starch relationship is a notable interaction because starch-lipid complexes have 
been used to make novel types of RS (Jane et al., 2009).  Interaction of fat and starch in vivo 
lends inconsistent results.  As implied by Sajilata and company (2006), amylose-lipid complexes 
can lower or increase RS.  However, overall fat content whether complexed with starch granules 
or present in the food matrix can lower postprandial glucose response. Hasjim et al (2010) 
studied a complexed lipid with a high amylose starch in a human (20 males) feeding study and 
found a decrease in postprandial glucose and insulin response. A starch interaction study was 
conducted where 9 women were fed 75 g glucose equivalent of in the form of pasta with 0 g (low 
fat; LF), 15 g (medium fat; MF), or 40g (high fat; HF) of sunflower oil to measure glucose and 
insulin response among other variable over a 7-hour period (Normand et al., 2001). Postprandial 
glucose AUC was initially decreased in HF and MF diet within the first 3 hours although no 
significant difference was observed in total glucose AUC between meals. Insulin and 
insulin:glucose AUC was found to be highest in HF diet.  These results lead to the conclusion 
that there is an important need for further investigation on the mechanism in which fat modifies 
carbohydrate metabolism. 
 
 
B.  Beneficial health effects 
As a dietary fiber, RS has been implicated in the improvement of digestive health as well 
as aiding in other positive biological effects. Research has associated RS with beneficial health 
effects such as increased mineral uptake (such as calcium and magnesium in rats and apparent 
retention of iron and zinc in humans), increased fermentation and other gastrointestinal events 
such as fecal bulking, modulated gut microbiota towards beneficial bacterial species, increased 
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lipid oxidation and satiety for possibly improved weight loss and/or weight maintenance, 
lowered thermogenesis, and decreased blood glucose and insulin response (see Table 2). 
 
 
 
Table 2. Potential health effects of RS 
 
Gut health  Reference 
Prebiotic and synbiotic  Topping et al. 2003 
Brown et al. 1998 
Fermentation  
Total SCFA production Cummings et al. 1996 
Butyrate production van Munster et al. 1994 
Breath H2 Muir et al. 1994 
Li et al. 2010 
Fecal bulking  Jenkins et al. 1998 
Modulate gut microbes Abell et al. 2008 
Martínez et al. 2010 
  
Improves  
Glucose and insulin response Achour et al. 1997 
Hasjim et al. 2010 
Lipid oxidization/fat accumulation Higgins et al. 2004  
Satiety and reduced energy intake Willis et al. 2009 
Thermogenesis Heijnen et al. 1995 
Mineral absorption Behall et al. 2002 
Younes et al. 2001 
  
Protective  
Colon/rectal cancer Cassidy et al. 1994 
Topping et al. 2003 
Cardiovascular diseases (inhibitor) or  
Improves cardiovascular health 
Martínez-Flores et al.  2004 
Inflammatory bowel diseases  Bassaganya-Riera et al. 2011 
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B.1   Resistant starch as a dietary fiber 
On average, Americans are consuming less dietary fiber than the recommended 25-38 g 
per day. In order to meet the dietary fiber recommendations, the 2010 Dietary Guidelines for 
Americans suggested increasing consumption of foods with naturally occurring fiber that can be 
found in legumes, vegetables, fruits, whole grains (U.S. Department of Agricuture and U.S. 
Department of Health and Services Human, 2010).  The benefits of increased dietary fiber 
consumption have been substantiated by various scientific publications as well as approved 
health claims by the U.S Food Drug Administration (FDA). The FDA health claim outlines the 
benefits for the consumption of dietary fiber in fruit, vegetables, and grains for the reduction of 
some types of cancer (§ 101.76).  Scientific publications provide evidence that increased dietary 
fiber consumption assists in hypertension and cancer prevention, constipation, diverticulitis, and 
reducing risk of cardiovascular disease, diabetes, and other metabolic syndromes (American 
Dietetic Association, 2008; Carlson et al., 2011; Keenan et al., 2002; Wolk et al., 1999).  
Sources of dietary fibers are numerous, but refining of grain flours has depleted dietary 
fiber content of some food products.  In efforts to increase nutritious qualities, foods are being 
enriched with dietary fibers such as fructans, resistant maltodextrins, polydextrose, and RS.  In 
general, RS conveys many of the same health effects as the broader class of dietary fibers and 
possibly for some outcomes with more efficacy than dietary fiber.  The health benefits of RS 
have been outlined in table 2.  However, all known benefits of RS as a dietary fiber are still 
being investigated as researchers continue to analyze this fermentable fiber in various forms and 
sources. Studies of the range of health effects of RS have not always generated consistent results 
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(Nugent 2005), but such studies have generated enough evidence of benefit to warrant further 
investigation.  
Resistant starch has been compared with other dietary fibers, such as wheat bran, for 
well-established health endpoints.  Jenkins et al. (1998) compared four treatments for their 
effects on colonic function (fecal bulking, fecal SCFA production), glycemic control, and serum 
lipid metabolism.  Twenty-four healthy human participants were randomly assigned a low-fiber 
control, high- fiber wheat bran, RS2 or RS3 supplemented foods for two weeks, with a two-week 
wash out period between each treatment.  Parameters such as serum lipids, urea, and creatinine, 
breath hydrogen and methane, and glycemic index had no significant differences between 
treatments.  RS supplement products produced a greater satiety score than the low-fiber control, 
while the high-fiber supplement satiety score was not statistically different from any treatment.  
Overall, the wheat bran supplement significantly increased fecal bulking more than any other 
treatment; however, RS treatments also increased fecal mass more than the low-fiber control.  
Fecal butyrate was found to be the highest after RS3 treatment among all the treatments. The 
study concluded RS could be used to gain potential benefits of improve colonic health by 
increasing fecal bulking and SCFA production.  This study also passively addresses the concept 
that all dietary fibers are not physiologically equal and some dietary fibers may have advantages 
over others.  
 
B.2   Resistant starch as a prebiotic 
Good gastrointestinal health seems to depend, at least in part, on a healthy composition of 
gut microbiota.  Functional dietary components, such as probiotics and prebiotics, can be added 
to foods to improve gastrointestinal health.  Probiotics are live microbes incorporated into food 
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products or administered in pill or other supplemented form that when ingested in adequate 
amounts can provide a benefit to the host (e.g., Lactobacillus acidophilus, a common probiotic 
found in yogurt).  Prebiotics have been defined as ‘nondigestible food ingredients that 
beneficially affect the host by selectively stimulating the growth and/or activity of one or a 
limited number of bacterial species resident in the colon in attempt to improve host health’ 
(Gibson and Roberfroid, 1995).  Simply, prebiotics are substrates that promote the growth of 
beneficial microbes, whereas probiotics are the viable beneficial microbes and synbiotics are a 
combination of prebiotics and probiotics resulting in a synergistic interaction between the two. 
Examples of prebiotics are hemicellulose, pectins, gums, inulin, lactulose, 
fructooligosaccharides (FOS), and other non-digestible oligosaccharides. Resistant starches can 
be classified as prebiotics, but the question still remains can all types of RS prebiotics.  A strong 
case has been made for the use of RS as a prebiotic that considers three fundamental facts:  
1) The GI tract is colonized by 1013-14 organism (Hao and Lee, 2004). The large intestine 
particularly has the largest population of microbes in the GI tract with about 1011-12 
CFU/ml (Pandeya et al., 2012).  
 2) The definition of RS is the sum of starch and starch degradation products not absorbed 
in the healthy small intestine and therefore passed to the large intestine.   
3) As previously defined, prebiotics are substrates that promote microbial growth and 
activity but are non-digestible implying that prebiotic target organisms within the large 
bowel alone.  
Considering these facts, inferences from experimental research in human and animal models 
have been made for the use of RS as a prebiotic and moreover as components of synbiotics 
(Topping et al., 2003).  The degree of microbial utilization of RS as a prebiotic might vary by 
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type of RS and type of autochthonous3 organisms of host. Efficacy of different types of 
prebiotics such as lactulose, lacitol, inulin, soybean oligosaccharides, FOS, galacto-
oligosaccharides (GOS), and isomalto-, gluco-, and xylo-oligosaccharides have been evaluated 
(Cani et al., 2009; Gibson and Fuller, 2000); however, RS is not as common a prebiotic as other 
prebiotics like FOS and GOS.  However, RS has been used as an effective prebiotic and is being 
established in scientific literature as a prebiotic.   
Prebiotics are used to increase the growth of beneficial bacterial, such as Bifidobacterium 
and Lactobacillus, but more over to enhance the growth and activity of any beneficially bacterial 
in the gastrointestinal tract.  The efficacy of RS has been reviewed and shown to promote the 
growth of Bifidobacterium and Lactobacillus; elevate colonic butyrate concentrations; act as a 
synergist with other oligosaccharides; reduce intestinal pathogens (Conway, 2001).  In a long-
term in vivo randomized study, 96 inbred rats were fed a low-fiber control diet (CD), starch free 
wheat bran (WB), resistant starch (RS3), or FOS diet to evaluate fermentation and induction of 
induction of aberrant crypt foci (ACF).  After a 44-day diet stabilization period 36 rats were 
injected with azoxymethane  (AOM) and ACF was evaluated 30 days later (Perrin et al., 2001).  
Perrin and associates (2001) found that RS3 and FOS diets induced the production of large 
amounts of butyrate and rats on those diets had a significant reduction in ACF formation 
(p=0.022 and p=0.043 respectively) when compared with CD. This study compared the prebiotic 
effects of RS and FOS and found them comparable in producing potential anti-carcinogenic 
metabolites (i.e., butyrate). 
                                                
3 Used in this context for microbiota considered indigenous, resident, or permanent members that 
colonizes [parts of] the gastrointestinal (GI) tract in contrast to allochthonous organisms which 
are transient members “passing through” and only colonize GI tract under abnormal or contrived 
conditions as described by Savage (1977) and Wu and Gordon (2003) 
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 In a randomized, double-blind, placebo-controlled, crossover human trial, RS was found 
to have stronger effects on induction of microbial shifts as a synbiotic than as a prebiotic or when 
compared with probiotic Bifidobacterium lactis alone (Worthley et al., 2009).   The study was 
conducted as a 4-week intervention of 25 g high amylose maize starch (~12.5 g RS), 5 g B. lactis 
(LAFTI B94 at 109 colony-forming units/g), or both for a total of 16 weeks (n=17).  When 
participants were on prebiotic intervention, they were given a placebo probiotic and given a 
placebo prebiotic when on the probiotic intervention.  Overall, any beneficial outcomes in 
microbiota of the gastrointestinal tract due to RS, builds stronger evidence of RS as an effective 
prebiotic. 
 
B.3   Postprandial glucose and insulin  
Discussions and recommended strategies on controlling glucose and insulin responses 
through diet are commonly associated with metabolic syndromes such as diabetes mellitus.  
Extensive study has been conducted implicating RS as a dietary agent that can be used to control 
postprandial glucose and insulin.  Furthermore, because RS has shown to reduce glycemic 
response by impaired glucose bioavailability, it can also lower the insulin surge.  Postprandial 
glucose and insulin response after a carbohydrate dietary intervention are conventionally studied 
within a 2 to 8 hour period. Likewise with experimental feeding of RS, however, RS feeding 
studies can have prolonged study periods to assess if RS has a second meal effect4 or other 
overlapping interactions.   
                                                
4 A physiological phenomenon in which a carry over effect, normal of decreased glucose is 
observed at the second meal in conjunction to the prior meal.  However, the term can also be 
used when the effect of decreased insulin is observed,  
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The topic of RS on postprandial glucose and insulin is rather controversial.  In response 
to RS some studies have observed significant decrease in glucose and insulin, other have 
observed no change due to treatment, while a few studies have observed an increase glucose or 
insulin response.  Although it is generally thought that RS lowers postprandial response, careful 
attention should be given to experimental conditions.  Due to the breadth of this research area 
and our specific research interest in humans, further discussion on RS and postprandial glucose 
and insulin have been narrowed to glucose and insulin response in humans (see section D.2). 
 
B.4   Satiety and Obesity  
In United States of America and other developed countries, the rate of obesity has risen to 
historic and epidemic proportions. People who are overweight and obese increase their risk for 
metabolic diseases and other adverse health effects (Ma et al., 2013).  Maintaining healthy 
weights or reducing body fat composition within a body mass index (BMI) of 18-25 is a health 
goal for some.  Through diet and exercise, BMI can be controlled.  With strict regard to diet and 
obesity, appetite control is essential.  Feeling satiated plays an enormous role in appetite control.  
If RS can affect satiety, it can exert a beneficial role in weight regulation. In turn, weight 
regulation influenced by diet may play a role in lower gut microbial population and 
gastrointestinal functions.  
While RS does share a lot of the same properties of dietary fiber, the mechanism of 
weight management through the use of RS is unclear.  Some of the proposed ways dietary fiber 
can aid in weight management is by slowing gastric emptying promoting longer feelings of 
fullness, while lowering food energy density (Slavin, 2005).   The mechanisms for effects of RS 
on satiety and weight management have not been well established.   
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 One can assume all dietary fiber is not equal, but what effect might different fibers have on 
satiety? This question was addressed in a human study (7 men, 13 women) in which investigators 
evaluated effects of different fibers on satiety after a single meal, quantified by AUC taken from 
100 mm visual analog scale (VAS) measuring hunger, satisfaction, fullness, and prospective 
food intake at 15, 30, 45, 60, 120, and 180 minutes after muffin meal (Willis et al., 2009).  Four 
types of high-fiber muffins (corn bran, barley !-glucan + oat fiber, RS, and polydextrose) were 
tested against a low-fiber muffin.  In this study, RS and corn bran muffins reduced AUC for 
desire of food intake (p= 0.009 and p = 0.025 respectively) and were overall more satiating than 
the other types of muffins tested. 
A human study providing 48 g of type II RS to 20 healthy adult males investigated ad 
libitum energy intake after test meals (Bodinham et al., 2010).  The 48 g of RS was divided into 
2 portions incorporated in mousse products and eaten as part of a meal, one at breakfast and one 
at lunch.  The same meals were given for the placebo treatment except the mousse products were 
supplemented with 32 g RDS.  At dinner, participants were given an ad libitum meal and energy 
intake was calculated.  Other parameters were measured but with respect to energy intake, 
Bodinham et al. (2010) observed after the RS treatment energy intake of 5241 ± 313kJ was lower 
when compared to placebo at 5606 ± 345 kJ (p =0·033). These results infer that increased RS 
consumption might suppress the urge to overeat facilitating weight manage or reduce weight 
gain.  
There is not sufficient evidence that RS promotes weight loss, especially in humans.  
However, there are implications that RS could decrease long-term fat accumulation by 
significantly increasing lipid oxidation (Higgins et al., 2004).  In this study, Higgins and 
company spiked bread with 50 µCi [1-14C]-triolein (glycerol tri [1-14C] oleate) suspended in 
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olive oil and added it to each test meal containing a total of either 0%, 5.4%, or 10.7% RS. 
Through indirect calorimetry, they measured fat oxidation by conversion of [14C]-triolein to 
14CO2.  Postprandial oxidation of radiolabeled triolein was 23% greater with RS meal at 5.4% 
resistance than 0% resistance (p = 0.0062).  Unexpectedly, fat oxidation at the 5.4% RS dose was 
also higher than for a 10.7% RS dose (p < 0.0001) but researchers could not explain the non-
linear dose response. Higgins and others did not report fluctuations in weight of the 12 healthy 
participants, BMI 24.7±2.4, nor was it part of the experimental design provided that each 
participant was fed a RS diet for only one day.   Fat storage, however, was assessed by gluteal 
biopsies and appeared lower for 5.4% RS meal, but was not statistically significant.    
 In a parallel arm design, two overweight groups were supplemented in their normal diets 
with 24 g of either resistant starch (RS) or control starch (CS) for 21 days (Park et al., 2004). 
Group 1 (n=13, initial BMI of 27.9 ± 0.5) received CS and group 2 (n=12, initial BMI of 26.6 ± 
0.7) received RS.  After 21 days, there was no significant change in BMI.  This study directly 
assessed weight fluctuations among other variables due to ingestion of RS, however the 
experimental design to assess RS impacts on BMI might have been flawed.  For a parallel 
design, it is possible the cohort was too small to observed significant weight reduction and could 
have benefited from a larger cohort.  
 
B.5   Gastrointestinal Health  
Hippocrates is credited for the sweeping generalization ‘all disease begins in the gut’.  
Though this statement may not always be true, more and more correlations between overall 
health and gastrointestinal health are being made. While Hippocrates established a link between 
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the gut and disease, gut health is now linked with the health of other periphery symptoms (e.g., 
cardiac, immune, and neural).  
At the most basic level of gut health, proper bowel function is vital for waste elimination 
but also for adequate nutrition absorption.  Conditions like constipation and diarrhea can 
interfere with proper bowel function. As isolated incidences, they are only moderately harmful 
and can be corrected.  However, other conditions like Crohn’s disease and cancers of the lower 
gut are harder to manage and can be lethal.  Yet, the use of RS for all these conditions might be 
advantageous.   
Mammalian cells contribute largely to digestion in the gastrointestinal (GI) tract but other 
key contributors are resident microbes.  The microbe facilitated fermentative property of RS is 
key, and because of this aspect, it is hypothesized that the main target organ of RS is the lower 
gut.  Regional diseases and ailments like colorectal cancer, inflammatory bowel diseases (IBD), 
diverticulitis, and constipation are conditions for which RS putatively will protect against or 
improve GI health.  The fermentative properties of RS in the lower gut can act as a weak 
laxative, which is suggested to aid in constipation and diverticular disease (Topping et al., 2003).   
An inverse association was found between starch, non-starch polysaccharides (NSP), and 
RS and incidence of colorectal cancer in a correlative study of 12 countries (Cassidy et al., 
1994).   Significant inverse association between ingestion of RS and incidence of colon, rectal, 
and large bowel cancer were not obtained even after adjusting for fat and protein interactions. 
However, associations were found for a combination of NSP and RS.  
Better transit time, fecal bulking, and frequency of bowel movements are attributes of 
dietary fiber. Bowel health can be improved as well as absorption of nutrients, such as 
microminerals zinc and iron.  Though bioavailability of glucose in RS is lower than rapidly 
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digestible and slowly digestible starches, bioavailability of micronutrients such as mineral 
absorption seems to be improved with RS.  Increased absorption of mineral after ingestion of RS 
has been observed more consistently in animal models than in humans.   However, there is 
evidence that RS will increase zinc mineral uptake in humans (Behall et al., 2002). 
Behall and associates (2002) in a long-term crossover human study fed 10 healthy and 14 
hyperinsulinemic men 5 food products formulated with standard (70% amylopectin, 30% 
amylose; AP) or high amylose (70% amylose, 30% amylopectin; AM) cornstarch.  Food 
products bread, muffins, cookies, corn flakes and cheese puffs RS content ranged from 3.3-12.7 
g/day for AM and 0.4-1.0 g/day for AP food products were test products as part of controlled 
meals.  The duration of each diet intervention was 14 week, at 2 weeks participants collected all 
urine and feces and mineral content was measured by flame atomic absorption 
spectrophotometry.  In this study, though Behall and associates did observe an apparent mineral 
uptake in zinc and iron on the AM diet.  In addition they observed after AM diets fecal starch 
excretion and transit time was greater though fecal weights did not differ by diets. Little 
differences form study variables were observed between the two types of study participants, but 
the healthy controls had greater transit time compared to hyperinsulinemic.  This is one of the 
few studies, by comparison, that reports an increase in transit time on a RS diet. 
Overall RS supplementation can assist in: normalizing bowel function and improving a 
host of ailments such as diarrhea (Raghupathy et al., 2006), antibiotic-associated diarrhea, 
traveler's diarrhea, gastroenteritis and colitis, reducing irritable bowel problems /IBD, 
prevention/protection from colon or colorectal cancer, boosting immune function, infant health 
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and nutrition, prebiotic promoted growth of beneficial microorganisms such as Bifidobacterium 
and culture protagonist5, and modulating gut microbes. 
 
B.6   Lower intestinal microbiota and fermentation  
The gastrointestinal tract is colonized with microbiota from birth.  Microbial 
communities and populations become more dense and diverse as the GI tract progresses from the 
stomach to the rectum.  Maintaining human health for many centuries has been related to GI 
health, which could be accomplished through a simplistic perspective of good nutrition and 
avoiding toxins or harmful organisms.  Now, it is further understood that maintaining health 
should also be considered from the perspective of symbiotic relationships (Nicholson et al., 
2005; Pandeya et al., 2012; Rooks and Garrett, 2011; Xu and Gordon, 2003).  Symbiotic 
relationships between a host and another organism can be parasitic, commensalistic, or 
mutualistic. Microbes, especially bacteria, as a whole have rather a poor public reputation as 
valuable health agents, however, emerging public perception is accepting that not only are the 
vast majority of bacteria harmless in relative amounts but rather ingestion of live bacteria 
(probiotics) might be propitious to health.    
Lower intestinal microbiota are fed by the indigestible part of the diet that host cells were 
unable to break down.  The predominate anaerobic bacterial genera of the lower gut are 
Bifidobacterium, Ruminococcus, Clostridium, Bacteroides, and Eubacterium (Moore and 
Holdeman, 1974).  Bifidobacterium contribute to substrate production of lactate and succinate, 
which can then be converted to butyrate and propionate, two of the three principal gut microbial 
SCFA fermentation products. The production of butyrate, a chief metabolically active 
                                                
5 Used to enhance the survival of probiotic cultures 
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fermentation product, comes mainly from bacterial classes Clostridia and Fusobacteria. The 
microbial utilization of food that host cannot metabolize would appear to be a commensal 
relationship.  However, the perception of a commensal relationship is slowly being revamped 
because microbes and microbial activity can be to the benefit or detriment of host.  Xu and 
Gibson (2003) captured the gravity of the host-microbiota relationship with a review article 
entitled ‘Honor thy symbionts’ in which they emphasized contributions towards understanding 
the human microbiota and beneficial symbiotic host–bacterial relationships through genome-
based techniques.  The complexity of the gut microbiome and an inclusive range of its function 
would profit from even greater insight, specifically concerning biological mechanism (such as 
how intestinal microbiota affect intestinal and immune homeostasis; elucidating microbiota-
related host tolerance; understanding intestinal uptake of polysaccharide; and others discussed in 
Xu et al, 2013) and microbial species associations in gastrointestinal health and disease.  
Although a great deal of work in this area has already begun a full grasp of gut microbiota is still 
in its infancy.  
 
B.6.1   Overview of Gut Microbiota and implications for health and disease  
The subject of gut microbiota is an extensive area that surpasses digestive health and 
affects many different biological systems.   Because of the number of microbes in comparison to 
host eukaryotic cells and their specialized function, gut microbiota may loosely be termed an 
organ.  As an exogenous organ, they work to influence host systems (e.g., digestive, 
cardiovascular, immune, integumentary, and nervous) through fermentation, energy salvage, 
production of micronutrients, epithelial regulation, and microbial competition.  Fermentation is 
an important specialized function of gut microbiota, but understanding microbial communities 
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has also become a main interest.   Gut microbiota fingerprints or distinct changes in gut 
microbiota have been implicated in:  
 
! Increased energy harvesting and obesity (Ley et al., 2005; Turnbaugh et al., 2006) due to 
shift in Bacteroidetes and Firmicutes ratios 
! Diabetes type II (Cani et al., 2008) reduced Lactobacillus spp., Bifidobacterium spp., and 
Bacteroides-Prevotella spp. 
! GI inflammation (Lupp et al., 2007) reduces total colonic bacteria, increase in 
Enterococcus faecalis and Enterobacteriaceae 
! Inflammatory bowel diseases (Frank et al., 2007) depletion of bacterial groups in 
Firmicutes, Bacteroidetes, Lachnospiraceae, and  Bacteroidales; enrichment of 
Actinobacteria, Bacilli, Alphaproteobacteria, Betaproteobacteria Gammaproteobacteria, 
and smaller group of Firmicutes 
! Colitis, colon and colorectal cancer (Uronis et al., 2009) potentially attenuated in 
presence of Bacteroides vulgatus 
 
The exact role of microbiota in the progression of diseases is still being clarified.  What is known 
is that gut microbiota have dichotomous effects with the potential, for instance, to exert both pro- 
and/or anti-inflammatory responses and be protective against and/or associated with gastric 
cancers or other GI cancers.  In the case of carcinogenesis, the link between gut microbiota and 
GI cancers has been associated but no strong mechanisms of causation, especially for cancers of 
the lower gut, has been proposed.  Mechanistic hypotheses of how certain gut microbiota initiate 
cancer are diverse with one general postulation that the host immune system has not fully 
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recognized the symbionts and induce host-signaling pathways that effect cancer growth and 
development.  
 
B.6.2   Effects of Microbial fermentation products 
The indigestible portion of starch is fermented in the large intestine, which results in the 
production of products like carbon dioxide, methane, hydrogen, organic acids (e.g., lactic acid) 
and short chain fatty acids (SCFA). Fermentation by-products from protein metabolism are also a 
likely event; however, it occurs at a lesser rate in comparison to carbohydrate fermentation 
(Macfarlane and Macfarlane, 2011).  Furthermore, favored fermentation end products for protein 
metabolism are not the same as for carbohydrate fermentation. A more detailed description of 
carbohydrate fermentation products in response to RS in human studies will be discussed in a 
subsequent section.  
The principal products of carbohydrate fermentation are SCFA.  Breath gases are 
products of overall carbohydrate fermentation but are not strongly correlated with any beneficial 
health effects.  Breath gases have been used as diagnostic tools for carbohydrate malabsorption 
and cancer but are more widely used as indicators of fermentation. In the case of hydrogen, it is 
an indicator for fermentation while playing a role in microbial redox reactions. Naturally SCFA 
are also used as indicators of microbial fermentation because the majority of physiological 
production of SCFA is from gut microbes.   
Attention to adverse effects due to carbohydrate fermentation is more obscure and less 
reported in comparison to advantageous health effects of fermentation and its implications. 
Furthermore, toxic effects are more commonly referenced in concurrence with protein 
fermentation rather than carbohydrate fermentation.  MacFarlane and MacFarlane (2012) 
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reviewed physiological effects indicative of improved health from acetate, propionate, and 
butyrate in various studies (see Table 3).  These are the main SCFA produced and recognized for 
their role in maintaining health.  
 
 
 
Table 3. Physiological effects of principal SCFA in colonic fermentation  
 
Summarized adaption from MacFarlane and MacFarlane, 2012 review of in vivo animal and human and 
in vitro studies, improved lipogenesis from Hosseini et al., 2011.  
 
 
The MacFarlane and MacFarlane (2012) review of physiological effects of SCFA acetate, 
propionate, and butyrate resulted in categories that highlight a range of detailed effects 
(categories seen in table above).  Out of eleven categories immune responses, carcinogenesis, 
and colonic function were the three physiological categories that were affected by each of the 
principal SCFA. Though specific physiological responses in the three categories were not the 
same, similarities did arise. In the immune system lipopolysaccharide (LPS) stimulated tumor 
necrosis factor (TNF") release was decreased by acetate but inhibited by propionate and butyrate 
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suppressed production of TNF".  For carcinogenesis propionate and butyrate induce apoptosis in 
colonic cancer cells. MacFarlane and MacFarlane (2012) did not review any article in which 
acetate was shown to influence apoptosis, although they did highlight a study in which acetate 
administered intravenous to cancer patients increased polyclonal antibody secretion in the blood 
and natural killer cell activity.  Lastly for colonic function, like the other categories SCFA effects 
were not the same.  In a dose-dependent manner, propionate increased but acetate decreased rat 
smooth muscle contractions in vitro, whereas in large bowel of rats, butyrate concentration 
decreased smooth muscle contractions.  Overall, the MacFarlane and MacFarlane (2012) review 
was fairly extensive and invaluable to understanding the impact of principal SCFA to health. 
 
B.6.3   Gut microbial interactions with RS as substrate 
The human microbiome in the lower gut contains approximately 500 or more microbial 
species, mostly anaerobes, in the magnitude of 1011 -1013.  The human intestinal tract is 
colonized in large part by facultative anaerobic microbiota, such as members of the family 
Enterobacteriacea (Finegold et al., 1978). The genus Bacteroides belonging to the 
Bacteroidaceae family are also predominant microorganisms in normal feces.   Gut microbiota 
obtain carbon sources from the host diet and in the case of the colon, fermentable fibers are their 
food.  Which raises the research question: how and what microbiota can be modulated by diet or 
more specifically can diet preferentially influence microbiota for targeted health effects?  
There is evidence that microbiota can be modulated by dietary RS.  Intricacies of the 
human gut microbiota were observed in human flora-associated (HFA) rats colonized with fecal 
microbiota from either UK or Italian donors (Silvi et al., 1999).  In both UK and Italian HFA 
rats, 4 out of 7 main bacterial groups were affect by RS for 4 weeks in which bacterial counts for 
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Lactobacilli and Bifidobacteria increased while Enterobacteria counts decreased.  As for 
Staphlococci, the 4 bacterial groups that were affected in both UK and Italian HFA rats, UK 
HFA had an increase in bacterial counts while Italian HFA rats had a decrease.  Other bacterial 
difference between HFA rat groups were observed, Italian HFA rats also had no change in total 
aerobes whereas UK rats did.  Also shifts in 6 out of the 7 bacterial groups were observed in UK 
HFA rats while only 4 out of 7 significant shits in bacterial groups was observed in Italian HFA 
rats.  
In humans, colonic microbial changes in response to RS diets have also been observed.  
Two studies with human fecal specimens contributed after RS feeding found bacteria related to 
Ruminococcus bromii increased on RS diets when compared to NSP and other diets (Abell et al., 
2008; Walker et al., 2011).  In a double-blind crossover design, 10 (5 female, 5 male) healthy 
participants consumed crackers containing either RS2, RS4, or control starch for 3 weeks with a 2 
week washout (Martínez et al., 2010) human fecal bacterial shifts were comparable to that found 
by Silvi and associates (1999) in HFA rats. Silvi and associates (1999) noticed increases in 
Bifidobacterium of the Phylum Actinobacteria and Bacteroides from the phylum Bacteroidetes.  
With human fecal microbiota16S rRNA multiplex sequencing, Martínez and associates (2010) 
showed both types of RS induced significant microbial shifts even on a species-level.  At the 
phylum-level RS2 and RS4 show different effects on bacterial community structure, where 
Bacteroidetes and Actinobacteria had the highest proportions after consumption of RS4. From 
their study Martínez and associates inferred that specific microbial populations could be targeted 
with RS functional foods. 
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C.  In vitro Fermentation for metabolic analysis of RS 
Assessing fermentation using in vitro systems is valuable for understanding metabolites 
and microbial communities in a well-controlled environment.  Research conducted using in vitro 
methods lead to the discovery of RS and its classification via digestion rates.  Afterward, in vitro 
fermentation studies of RS led to the elucidation of fermentation mechanisms and pathways, 
although substantial investigation is still ongoing.  In vitro fermentation models are also useful 
for understanding chemical events occurring during starch degradation and SCFA production by 
tracing carbon conversion. 
 
C.1.   Defining In vitro Fermentation Systems   
Methods for fermentation in vitro studies fall under one of two motifs: batch or 
continuous fermentation. Following the ideology that a system is either 1) contained with a set 
mixture of microbes, nutrients, and substrates for a short period of time or 2) a continuous 
system with replenishment of nutrients, substrate, or other environmental inputs (e.g., sustained 
pH).  
Batch fermentation typically spans from 24 to 96 hours, while continuous fermentations 
have been recorded to go as long as 8 weeks.  Both fermentation systems are used to quantify 
microbial shifts, microbial growth, pH changes, fermentation patterns, and RS degradation.  
Fermentations can be done with pure cultures, a mix of strains, or with crude environmental 
samples such as feces.  Fecal matter is used to make inocula with media and other nutrients.  In 
some cases, incoula from ileal digest is used although it requires a more effort for researchers to 
acquire than fecal specimens.  When addressing research questions pertaining to bacterial species 
and bacterial pathways, pure cultures or co-cultures can be used. When addressing research 
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questions about bacterial communities and fermentation patterns, ileal or fecal inoculum are 
used.  For outcomes of in vitro RS fermentation research, see section C.4 (In vitro RS 
fermentation studies).  
Similarly, batch and continuous in vitro systems can also be used to simulate digestion as 
well. When the digestibility of RS2 and RS3 was compared using batch and dynamic in vitro 
system (TIM-1), Fässler et al. (2006) found similar amounts of RS3 escaping digestion in both 
models but RS2 produced more indigestible starch fraction for batch digestions than dynamic 
TIM-1 digestion (P < 0.05).  Interestingly, RS2 digestion in TIM-1, which is a sophisticated 
compartmentalized system created to simulate conditions in human stomach, duodenum, 
jejunum, and ileum was not significantly different from RS2 digestion using a Megazyme kit, 
which is a much simpler in vitro digestion method (Fässler et al., 2006b). 
 
C.2   Media Selection 
In order to do fecal incubations, it would seem to be beneficial to mimic the gut 
environment as closely as possible; however, simulating the gut environment is very complex.  A 
major challenge for a survey of the complete microbiome is how to stimulate the growth of 
microbes without creating a selective milieu.   
Media can be solid or liquid (broth).  Either form can be synthetic in which the exact 
chemical composition is known, or non-synthetic in which the amounts but not the exact 
composition of major constituents is known.  Selection of appropriate media for research 
purposes requires much consideration, expertise, and above all should not be trivialized.  In the 
book Bailey and Scott’s Diagnostic Microbiology, Finegold et al. (1978) suggest several general 
guidelines for selecting a good culture medium: consistent quality control, adequate 
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concentrations of essential nutrients and salt, adequate amount of water, appropriate pH for 
required metabolic function, lack of inhibitory substances of interest, and sterile environment.  
Other factors worth considering for a maintaining a successful culture are temperature and 
oxygen requirements. 
Carbohydrates, such as glucose, are often included in media, which is known to enhance 
the growth of microorganisms in plate (solid) or broth cultures.  Finegold et al (1978) state when 
selecting a standard medium, a glucose free medium tends to give more consistent and reliable 
results because of the elimination of enhanced growth due to small amounts of carbohydrate. 
Also, they describe that the fermentation of glucose can alter the pH and be harmful to acid-
sensitive organisms 
After the appropriate broth is chosen the method chosen to sterilize is also critical.  Media 
is commonly sterilized through autoclaving, however certain media due to particular constituents 
cannot withstand high temperature.  After choosing a media, especially if it has been tailored to 
specific needs of an experiment, proper sterilization is necessary. Finegold et al (1978) suggest 
sterilization methods that include autoclaving (moist heat), flowing steam, inspissation, filtration, 
and chemical methods. 
Often when investigating intestinal microbiota, even when comparing media, selective 
media is used to target specific bacterial genera (Mundy et al., 1995; Vael et al., 2011).  In some 
media comparison studies, liquid and solid media have been evaluated in addition to different 
anaerobic culture methods to analysis clinical specimens (Rosenblatt et al., 1973). However, 
media comparisons with total fecal populations have been done.  When 10 different media were 
compared to evaluate floral enumeration in mice feces some proved to be more selective for 
specific bacteria although each media was chosen for comparisons were considered to be similar 
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to each other (Nelson and George, 1995).   Nelson and George (1995) found all media to be 
comparable for enumeration of total anaerobes.  However, when identified colonies in media was 
compared, Mannitol salt agar was more selective than Baird-Parker agar for staphylococci; 
Brucella blood agar + vancomycin and kanamycin (VK) agar was more selective than Wilkins-
Chalgren blood agar + nalidixic acid and vancomycin (NAV) agar for obligate anaerobic Gram 
negative bacilli; Rogosa agar more selective than LBS agar for Gram positive rods; and KF 
(Kenner Fecal) Streptococcus agar was found to be most appropriate for fecal enterococci and 
streptococci. 
Similarly an earlier study compared “non” selective media for anaerobic fecal bacteria in 
mice, some media proved to be more selective than others (Itoh and Mitsuoka, 1985).  These 
studies both suggest that choosing a non-selective media is still limited to what organisms it can 
actually grow.  This notion is well established considering culture methods have never been able 
to grow all bacteria present in biological specimens.   
Very few articles compare media for use of total microbiota in healthy human fecal 
samples.  Notwithstanding, Hartemink and Rombouts (1999) compared total anaerobes in human 
fecal samples by evaluating plate counts.  They were able to rank nine different media.  In the 
end they reported no significant difference between the non-chosen selective media.  Though 
they also evaluated selective media for the detection of Bifidobateria and Lactobacilli.  Plate 
counts, colony morphology, and colony size were used to determine if the none-selective media 
performed the same (Hartemink and Rombouts, 1999).  Though the actual diversity of colonies 
grown via each media is unknown.  
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C.3.   Preparation of fecal samples for microbial analysis 
Fecal samples are used to evaluate microbial community and metabolites in the intestinal 
tract.  Waiting for feces to pass and taking an effluent sample or biopsy are the methods by 
which fecal samples are obtained for analysis.  Biopsies are far more invasive than fecal 
elimination though and fecal samples from biopsies are a “cleaner” sample since these generally 
contain very few epithelial cells.  During elimination, food solidifies in the large intestines and 
moves through the colon picking up resident cells (i.e., sloughed off intestinal epithelial cells and 
microbes).  Indubitably, the easiest way to sample the gut microbial population is through fecal 
passing.  Assessing microbial metabolic activity through fecal samples though not completely 
accurate might be the best type of sample or sample preparation for representation of the large 
intestinal environment.  Currently, no other specimen or method of specimen collection 
producing more accurate results has been defined.  
Genomic methods are used to analyze microbial composition. However, analysis of 
microbial metabolites and microbial activity in fecal samples are commonly evaluated through 
fecal incubations. Fecal incubations can also be used to evaluate microbial shifts in controlled 
environments, generally followed by molecular methods.  Regardless of what method of analysis 
is chosen, the way in which samples are handled and prepared is critical to appropriately 
interpreting results.  Factors that will influence analysis and results of fecal microbial activity are 
collection time, form of substrate, type of incubations (batch or continuous), media selection, 
inocula/substrate ratio, and anaerobic conditions (Li, 2010a). 
The time interval between fecal excretion and analysis or start of incubations is 
sometimes not reported. Some articles will report working with freshly prepared samples without 
citing a specific time frame (hours).  This might introduce significant variability in results of in 
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vitro fecal incubations making comparison between studies difficult.  The underlying targets 
when conducting fecal incubations are the microbiota; whether there is a direct measurement of 
microbiota through molecular fingerprinting or indirect measurements through production of 
SCFA’s.   Roesch et al. (2009) investigated if time affects fecal microbial communities when 
they compared bacterial communities from human donors immediately after defecation from 
time points 0h, 12, 24, 48, and 72 hours.  All time points except for 0h, which was immediately 
frozen, were permitted to sit at room temperature before frozen at -80 C.  Samples were kept 
frozen until DNA was isolated.  Through 16S rRNA gene amplification and 454 pyrosequencing 
a gradual change in bacterial diversity over time was observed, reporting the least change, 
3.06%, at 12 hours (Roesch et al., 2009).   
In the Roesch et al. (2009) study, the most diversity change was 10.14% at 72 hours. The 
maximal time period over which a fecal sample is considered viable is 72 hrs. In light of their 
results, an important research question is raised: is ~10% change too high of a background to 
accurately interpret results?  This question is also applicable for fecal incubations where samples 
cannot be frozen immediately.  If samples cannot be processed immediately (within 0-1 hr), no 
more than 12 hours should be permitted before microbial diversity shifts become different from 
the original samples.   
Depending on the method of analysis, samples must be handled differently.  For 
microbial activity assays such as measuring SCFA, viable samples are needed. Therefore, 
freezing and thawing samples or prolonged exposure of samples to aerobic conditions would 
produce questionable estimates. Thus, timing around sample collection if important for assessing 
viable microbial activity.  For molecular methods, immediate anaerobic conditions are not as 
crucial but immediate freezing of the samples is preferred.   
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C.4   In vitro RS fermentation Studies 
In vitro fermentation models are also useful in assessing fermentability of RS and 
understanding chemical events occurred during starch degradation and SCFA production by 
indirectly or directly tracing carbon conversion. For an overview of RS metabolism and 
microbial fermentation end products, see figure 2 in Section D.3. 
Many of the functions of the most metabolically active SCFA, butyrate, has been 
evaluated through in vitro studies.  An in vitro study showed that butyrate had synergistic effects 
by improving probiotic viability in conjunction with RS (Brown et al., 1998).  Another in vitro 
study also showed synergistic effects in the production of butyrate and propionate when 
incubating RS with one or two bacterial strains in human fecal extracts (Zhao and Zhu, 2013).  In 
addition, in vitro studies have been used to postulate mechanistically the fermentation of RS in 
vivo and fermentation by-products.  Duncan and associates (2004) suggested in an in vitro study 
that a cross-feeding between Bifidobacterium adolescentis and species related to Eubacterium 
hallii and Anaerostipes caccae isolated from human feces may be the contributing reason to a 
butyrogenic effect to dietary substrates like RS (Duncan et al., 2004).   
Measuring SCFA production from in vitro fermentation is a good way to screen starches 
or predict in vivo fermentation response.  Pyrodextrinized starches from potato, lentil and 
cocoyam made resistant due to acid treatment were fermented anaerobically using human fecal 
inocula for 24 h (Laurentin and Edwards, 2004).  The native starches were compared with 
pyrodextrinized starches from the same sources.  Net total SCFA production for each RS source 
was significantly higher when compared with native starch.  For all RS sources, acetate 
production decreased while propionate production increased.  Laurentin and Edwards (2004) 
found that pyrodextrinized RS was fermentable in vitro by the colonic bacteria of healthy adults, 
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indicating pyrodextrinised starches may be fermentable in vivo but the mechanism of increased 
SCFA production by these RS forms remains to be elucidated. 
During in vitro fermentation substrates can be added to assess fermentation or substrates 
can be administrated in vivo.  Langkilde and associates (2002) provided 30 g of RS2 in raw 
banana flour (RBF) or cooked green banana flour (CBF) mixed into yogurt to 10 ileostomy 
volunteers in addition to their ordinary diet for a period of four days.  After each of the two 
periods, ileal effluents were collected from 6 of the patients and incubated for a total of 24h with 
samples analyzed at 0, 4, 8, and 24 hours. The study found lower pH and percent molar 
propionate ratios but higher total SCFA concentrations and percent molar ratios for butyrate for 
RBF when compared to CBF (Langkilde et al., 2002).  The results suggest that fermentation after 
in vivo digestion of RS fermentation continues in vitro.  This study was complicated by the use 
of yogurt, which contains probiotics, as the food vehicle for the prebiotic RS.  Investigators did 
not address additive effects of yogurt and RS on fermentation and SCFA production.  
  
 
D.  Human Studies with RS 
D. 1   Methodology of Human Feeding Studies  
To further the knowledge of human health, data have been used from in vitro and animal 
studies.  Where applicable, inferences and extrapolations can be made from these experimental 
findings to humans; however, inferring in vitro results to humans can lead to misapplied 
interpretations.  In addition, though in vivo studies are more dynamic than in vitro studies, 
extrapolations of in vivo studies across species can also pose problems. Notwithstanding that 
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both in vivo and in vitro methods are invaluable, understanding appropriate conditions in which 
to use each method is necessary.  
Data obtained from in vivo studies of species of interest are a more direct approach for 
measuring and understanding physical phenomena where ethically applicable and financially 
feasible. Human nutritional in vivo studies are a common tool, designed to be innocuous and 
easily reproducible. When humans are the species of interest, human feeding studies tend to be a 
more powerful tool in nutritional research than animal studies since intra-species extrapolation 
generates less confounding variables than interspecies extrapolations.  
However, human studies come with their own set of drawbacks.  When answering 
research questions, controlled human feeding trials can be a useful tool if sources of variation are 
properly controlled.  Designing experiments to reduce plausible sources of variation is critical.  
The subsequent three sections (D1.1-D1.3) provided general information addressing some of the 
basic issues to consider when conducting experimental human feeding studies: careful screening 
of participants, careful selection of food treatments, and sound experimental setup. 
 
D.1.1   Experimental Setup 
Planning human studies starts with a sound experimental design and should be the first 
order of business after a research question is generated.  The experimental set up should be well 
thought out and employ appropriate methods. Ways to reduce sources of variability should 
strategically be incorporated into experimental setup. 
Possible sources of variability are: human (researchers and participants/experimental 
unit) and experimental error, food formulations (varying concentrations, different cooking 
parameters or days), time, and non-compliance.  Variation will always exist and some sources of 
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variation cannot be controlled, however, streamlining experiments for what can be controlled 
(e.g., consistent time points and collection methods) helps to reduce high variation.  
 The design of an experiment can also be constructed to reduce unwanted variation 
slightly harder to control.  For instance, if there are systematic characteristics that are of no 
interest to the researcher, one could ‘block’ for those factors to increase accuracy of 
characteristics or factors of interest. Blocking, randomization, and nesting are design techniques 
that help reduce unwanted variation.  Popular design terms to be familiar with when evaluating 
or constructing human studies are as follows: 
Block  
Case series 
Case study 
Clinical ¥ 
Cohort study 
Controlled trials 
Crossover 
Intervention 
Latin-square 
Nested 
Observational 
Parallel or parallel-arm 
Prospective 
Randomized 
Retrospective 
Stratified 
¥ can be an example of an intervention study 
 
 
Experimental designs are normally a combination of above terms.  For example, 
randomized studies can be crossover and parallel.  Other example designs are case-controlled 
study, nested case control, or a controlled observational cohort study.   
Use of a control, or placebo, is common in human studies.  However, it is well known in 
human studies investigating a physiological response can sometime be affected by a 
psychological adjustment, which is termed placebo effect.  Because of the placebo effect, human 
studies can be blinded or double blinded to avoid this phenomenon and reduce bias.   Terms like 
run in and washout are part of experimental design, and setup that should also be carefully 
considered to reduce interactions or carry over effect. 
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Randomization of participants and treatments is important to remove unintentional bias.  
In experimental designs such as crossovers, balance of randomized treatment order among 
participants also limits treatment interactions/carryover effect. When a balanced randomization is 
not conducted in crossover designs, it is impossible to partition effects of time from effects of 
test products.  For example, a crossover study conducted in Japan stratified participants into two 
groups; on the first experimental day group one (n=10) was fed test product of bread containing 
6g RS per two slices and group two (n=10) was fed placebo (Yamada et al., 2005).  After a two-
week washout, treatments were switched, group one was fed placebo and group two was fed test 
product. Though initially this experimental setup might seemed balanced and assurance was 
given by researchers that the two test days were same, there is no certainty that after analysis 
with paired t-test observed differences in experimental variables of blood and insulin profiles and 
characterization of participants vitals (blood pressure, pulse rate, body weight, BMI) was solely 
from treatment differences. This study could have benefited from randomization of treatments 
and participants, which was not described in study outline. 
 
D.1.2   Selection and Design of RS Food Treatments  
Controlled human feeding studies are designed around punctiliously crafted food 
products.  Careful thought should be given to dose, dietary interactions, physicochemical 
properties, and food preparation to insure a reliable vehicle for dietary components of interest. 
Using high precision research foods allows for 1) the biological response of interest to be more 
accurately estimated, 2) a shorter experimental period (as short as 1 day) to establish biological 
response, 3) the use of a smaller cohort (5-25 participants), and 4) a maximal physiological 
response due to diet (Most et al., 2003).  Factors such as minimizing experimental period can 
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remove confounding variables that can occur over long periods of time (e.g., weight change).  
Feeding studies can also be designed in which weight change is specifically investigated as a 
desirable variable to be altered due to treatment, although typically weight is maintained 
throughout short-term human feeding study.  
To address specific research question(s), the appropriate selection and preparation of RS 
must be employed especially when the aim is to increase the RS content of foods.  Thus food 
product formulation and preparation is critical.  Not only are food products the vehicle of 
delivery for test material but also formulation and preparation can affect test material.  It is 
known that different types of RS can elicit different response to the same variable, such as 
glucose response (Haub et al., 2010), which could be due to physicochemical nature of specific 
starch types.  Furthermore, the source of RS  (e.g. beans, bananas, corn, or potatoes) can also 
have different physicochemical properties that can influence physiological responses such as 
digestion and glucose and insulin responses.  Thus, the first step in product formulation should 
be selection of what type of RS is to be used and in what products can it be incorporated.  Some 
types of RS are water-soluble that can easily be incorporated into beverages, while others are not 
readily dissolved in water and different test products must be used.  
Once the type of starch and ideal food product has been chosen, formulation and 
preparation can begin with careful consideration avoiding potential confounding variables. 
Ideally, studies with multiple treatments should have a food formulation with minimal to no 
variation due to food components other than the test material.  Not only should food formulations 
should be congruent with other test treatments in experiment, but preferably simple and 
palatable.   When researchers strictly consider food formulations without regard to palatability, 
participant compliance and moreover retention can drastically decrease.  
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RS stability can be altered by food preparation with different food matrices and cooking 
conditions.  High temperature heating and cooling of high moisture starch (such as potatoes) can 
form RS3 due to retrogradation after gelatinization and subsequently lower glycemic response 
(Najjar et al., 2004); however, in other starches gelatinization can occur during boiling or 
cooking inducing a more digestible starch. Boiling and pressure cooking have been reported to 
increase RS while roasting, extrusion cooking, frying, and drum drying decreased RS when food 
processing methods were compared (Parchure and Kulkarni, 1997). 
After test product is completed even storage and post-handling (heating and freezing) of 
final food product can alter RS content.  Long-term storage can not only affect sensory 
outcomes, but also make foods stale.  Whether a food product is stale or not stale can alter RS 
content, where stale starches are higher in RS content than fresh starches (Ahmed et al., 2000).  
 
D.1.3   Screening of Participants 
Though inter-human variability is a natural source of variation, it can potentially be too 
high occluding evidence of significant results.  Ways to address and control for this inevitable 
variation is through proper screening criteria and obtaining the desired level of statistical power.  
Parameters that naturally vary among individuals like genetics and environmental 
conditions may also increase experimental variability.  Though most researchers try to streamline 
parameters by tailoring recruitment requirements (weight, diet, energy expenditure, disease, etc.), 
influential variations that are harder to streamline, such as metabolic differences, can still exist.  
For instance, McOrist et al (2011) found different entry fecal butyrate levels varied among 46 
healthy adults. Change in fecal butyrate concentration after RS test meals subsequently varied, 
though in general they observed that RS consumption increased butyrate.  Some inter-individual 
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butyrate variation was attributed to BMI (low butyrate entry levels corresponded with lower 
BMI) and nutrient intake of protein, starch, carbohydrate, fiber, and fat in normal diets. 
Variation is certain even in the simplest experiment.  The goal in dynamic experiments 
such as human studies is to reduce as many sources of variation to glean a better understanding 
of what is being tested. Differences in experimental conditions and experimental design can alter 
the results of a study, which can make comparisons between studies difficult, but eve in human 
studies when experimental designs and setup are kept the same, great variability can exist.  
Moreover, keeping participants in the study until completion is important to maintain balance of 
design.  Coercion of participants of any sort (ex. excessive monetary reimbursement) is not 
ethical or allowed, therefore strategic methods to increase retention and compliance can be 
employed in the experimental setup (examples: palatable food treatment).  The human palate is 
largely variable; therefore, screening participants via questionnaires for palatable of test products 
is of great value for the purposes of study retention and compliance.  Though this practice has 
been employed before commencement of human feeding studies, author did not find a published 
example of a human research study where they reported prescreening of test food product. 
 
D.1.4 Dissertation methodology employed 
 Three research experiments were included the dissertation research, two human in vivo 
studies and one in vitro study.  Both human studies were conducted as randomized blind 
crossover design.  This design was chosen so each participant could act as their own control 
instead of having a control group as seen in parallel designs and some intervention studies.  In 
addition, one study was had 15 participants and benefited from crossover design due to a smaller 
cohort.  For both studies careful consideration was given to test food product.  Simple recipes 
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were used (i.e., pudding and crackers) in which the same recipe was used for all products only 
differing by test starches and in some cases addition of water.  However, despite consideration to 
food products, in the first human feeding study, three participants dropped out after the first 
experimental day two expressing inability to finish test meal. By the second human study, rating 
of palatability for test product was implemented and only participants who rated test product 
above a 6 on a scale of 1-10 (1 meant participant liked the product ‘not at all’ and 10 meant they 
liked the product ‘very much’) were entered into the study.  Resulting in one participant who 
dropped the study for unspecified reason. 
 
!"#$!!!%&'()*+(!,-.!/-01&+-!2)034-0)!45!26!
The main dietary source of blood glucose comes from carbohydrates (e.g., starch), which 
according to the Department of Agriculture’s 2010 Dietary Guidelines for Americans, should be 
45 to 65 percent of daily calories. Therefore, deductively starches are a major contributor to the 
glycemic response and thus are categorized by their digestibility with respect to glycemic 
response: rapidly digestible starch (RDS), slowly digestible starch (SDS) or low-digestible 
carbohydrates (LDC), and resistant starch (RS) - see table 4.  
 
Table 4.  Categorization of carbohydrates by digestion rates. 
 Rapidly Digestible Starch (RDS) 
Slowly Digestible 
Starch (SDS) Resistant Starch (RS) 
In vitro  
digestion time Within 20 min 20-120 min >120 min 
Location of digestion  Mouth and small intestine Small intestine 
Escapes small intestine, 
main action in colon 
Example Freshly cooked foods, pregelatinized starch 
Uncooked cereal 
starches maize, waxy 
maize, barley, wheat, 
and rice --- change 
Cooked and cooled 
potatoes, bread, 
cornflakes 
Adapted from Englyst et al. 1992; Lehmann and Robin 2007 
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RDS is not known for physiological benefits other than when quick release of glucose is 
needed, such as in cases of hypoglycemia.  Otherwise, large doses of rapidly available glucose 
can have drawbacks, especially for prolonged periods of time. Diets with low glycemic foods 
have established their benefit in reducing the risk of developing diabetes (Salmerón et al., 1997a, 
1997b) and cardiovascular disease (Liu et al., 2000) in long-term perspective cohort studies.   
Such observations have led to the sustained investigation of foods and dietary components with 
lower glycemic index.   
SDS and RS are being investigated for physiological benefits akin to dietary fiber. 
Though SDS and RS are dietary fibers, each with specific physiochemical properties that 
respond differently to enzymatic hydrolysis of glucose into the bloodstream.  With respect to RS 
digestion and absorption of glucose the source, structure, preparation, and concentration of 
starches are important variables to consider.  
Ratios of amylose and amylopectin influence digestive resistance and thus alter glycemic 
response. Depending on the amylose:amylopectin structure, hydrolysis to monomeric glucose in 
digestion can be enzymatically hindered. Starches with higher amylose content have a higher 
digestion resistant than starches high in amylopectin. This is the induction for the ideology that 
RS lowers postprandial glucose as well as insulimic response, which has been shown in select 
human studies.  
Behall et al. (1988) fed 25 people (12 women, 13 men) 2 cracker meals in a crossover 
design.  The two meals were comprised of either a cracker with 70% amylose and 30% 
amylopectin or 30% amylose and 70% amylopectin. The cracker recipe was the same for each 
type of cracker only varying by the different type of starch. Crackers were administered to give a 
dose of 1-gram carbohydrate and 0.33gram fat/kg body weight. The goal was to observe if 
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different chemical structure of starch due to different amylopectin and amylose ratios had an 
effect on glycemic responses.   Insulin was also measured.  Six blood samples over a period of 
180 minutes were used for evaluation.  The sum insulin response above fasting measurements 
was significantly different between test meals but the same was not true for glucose 
measurements above fasting.  However, the high amylose cracker obtained a lower glucose peak 
at 30 min and lower insulin responses at 30 and 60 minutes when compared with the high 
amylopectin cracker (Behall et al., 1988). When glucose response was summed, there was no 
difference between treatments.  This study noticed a stable glucose response and lower insulin 
response after a high amylose meal.  Being one of the earlier RS human feeding studies they 
surmised that these results suggested a benefit to carbohydrate sensitive or diabetic individuals. 
Bodinham et al. (2010) conducted a study where they incorporated RS supplements into a 
flavored mousse fed to 20 healthy males.  The study was an acute randomized, single-blind 
crossover design where the subjects participated in two separate test days scheduled a week 
apart.  The supplements were either a RS product comprised of 60% RS and 40% RDS or a 
placebo comprised of 100% RDS.  The supplemented mousse was administered to the subjects 
with a standardized breakfast and lunch. This study also tested satiety by separately consuming 
an ad libitum pasta dinner at the end of the dietary intervention until subjects felt full. The results 
from this study were similar to Behall et al (1988) with respect to glucose and insulin response.  
They observed no change overall in postprandial glucose concentrations between treatments, but 
a significantly lower insulin response was observed with the RS supplemented meal when 
compared to the placebo-supplemented meal (Bodinham et al., 2010).   
The Bodinham et al. (2010) study differed from the Behall et al (1988) study because 
instead of one test meal per day, Bodinham et al. (2010)served two test meals per day.  
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Bodinham et al. also supplemented standard meals with their test product, instead of only the test 
product being served as a meal.  Generally, it is believed RS lowers postprandial glucose as well 
as insulinemic response; however, overall both studies reported no change in glucose response. 
Nonetheless, other human feeding studies have reported a lower glucose coupled with a lower 
insulin response (Hoebler et al., 1999; Raben et al., 1994).  
There is a wealth of publications on the effects of RS on glycemic and insulin responses. 
These studies assess glucose and insulin response with food products composed mainly of starch 
and/or where portions of food constituents have been substituted with RS (Hoebler et al., 1999).  
Observed differences in glucose or insulin response after ingestion of RS have led to conflicting 
reports. Many researchers have reported a decrease in postprandial glycemic or insulin response 
while others have reported no observed difference (see table 5(a-d)). Major differences have 
been found in glucose response when consumption of a RS meal was only compared with 
control. For example the use of raw potato starch against pregelatinized potato starch (Raben et 
al., 1994) and a RS bread against a white bread (Hasjim et al., 2010) expressed noticeable 
differences between treatment and control.  
The use of RS for lowering blood glucose has promising implications for people with 
diabetes since, for this subpopulation, controlling blood glucose concentrations is a beneficial 
trait.  However, in comparison to healthy individuals little research is available for people with 
diabetes (Table 5(a) and (b)) probably in part due to ethical issues since no true control can be 
administered. 
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Table 5(a). Human studies evaluating glucose and insulin response to RS feeding in healthy participants  
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Design and Duration! Main Effect of RS Comments! Study!
!"#$%!&' ! ! !  ! !
n= 10 
 
6M, 4F 
Age: 19-27 
BMI: 22.4±0.8 
Type II*, 
19.5g  
Trt1.  RS supp 
meal 
Trt2. Non-RS supp. 
meal 
 
Meals low in fiber 
and RS, 30 gram 
raw potato starch 
(19.5g RS and 6.5g 
DS) supp. to trt1 
1 day  
Total visits: 2 
within 15 days 
 
DESIGN: 
randomized 
crossover* 
! Glucose AUC 
 
NS for insulin AUC 
Trt 1 and trt 2 differed in energy 
2385kJ and 2282kJ respectively; 
and CHO 61g and 54.5g 
respectively.  Though small, 
could account some for 
unsuspecting increase in glucose 
from trt1 the RS supp. meal, 
though research assume potato 
starch was more digestible than 
presumed.  
Marchini 
et al. 1998 
 
n= 8 
 
6M, 2F 
Age: 21-28 
Weight: 55-70kg 
Type II, 
16.5g 
Trt 1: white bread, 
1.3g RS 
Trt2: wheat 
spaghetti, 2.5g RS 
Trt3: Supp. bread, 
16.5g RS 
 
RS only added to 
trt3 was high 
amylose maize 
starch 
1 day with 
~4day washout 
period  
Total visits: 3 
 
DESIGN: 
crossover* 
" glucose and insulin 
trend with 16.5g RS 
when compared to 
other treatments 
 
" glycemic and 
insulinemic indexes of 
RS bread was different 
from white bread 
reference index  
(p<0.05) 
Trt 3 lowered glucose 
concentration though not all TP 
reached a significant level.  Trt 
3 at TP 90 and 1034 from trt 1 
(p<0.05).   Insulin also showed 
a lower curve however trt3 
produced sig. lower insulin 
response from trt1 TP 90- 200 
min. and was sig. lower than 
trt2 at 170min. 
Hoebler et 
al. 1999 
 
n=  7 
 
Gender: NR 
Age: 20-26 
BMI: NR 
Type II 
and Type 
III, 40g 
of starch 
 
 
Trt1: RDS, GI 98 
Trt2: RS2, GI 22 
Trt3: RS3, GI 48 
 
40 g dissolved in 
low fat milk and 
non caloric flavors 
and sweeteners 
added for 
palatability 
1 day, 48 hour 
washout period  
 
DESIGN: 
parallel group 
" GI 48 and 22 from 
98, 43± 15%, 44±16%, 
and 82±23% 
respectively after 2hr. 
 
No evaluation of 
insulin 
All treatments were corn 
starches.  Researchers used 13C 
marker naturally enriched in 
corn to asses plasma glucose 
and ultimate oxidization of 
glucose to 13CO2 during 
digestion.  Subjects were given 
a list of 13C foods not to ingest 
2days before test day 
Vonk et al. 
2000  
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Table 5(a). Continued 
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Design and Duration! Main Effect of RS Comments! Study!
n=  30  
 
12M, 18F 
Age: 20-74 
BMI: 24.1 ± 0.6 
Type IV, 
25g 
Trt1: glucose 
Trt2: OSA  
 
25 g of either trt 
was incorporated 
into test beverage 
1 day, washout 
5-14 days  
 
DESIGN: 
double blind 
randomized 
crossover 
! glucose at TP 15 and 
30 min (p<0.05)  
!mean glucose peak 
reduced by 19% 
(p<0.01) 
 
NO evaluation of 
insulin 
Trt 2 is an octenyl succinic 
anhydride (OSA) modified 
starch.  Each test beverage was 
made to a viscosity < 5 mPa"s.  
Diets were controlled 3 days 
leading into test day. 
Wolf et al. 
2001 
n=  25 
 
13M, 12F 
Age: 23-53 
BMI: 21.3 - 32.8 
Type II,  
2-13.4g 
RS 
Trt1: glucose sol. 
Trt2: 30%, 2g RS 
Trt3: 40%, 3.8g RS 
Trt4: 50%, 8.2g RS 
Trt5: 60%, 11.5g 
RS 
Trt6: 70%, 13.4g 
RS 
 
Bread products 
with varying 
amounts (by %) of 
amylose 
1 day 
Total visits: 6 
 
DESIGN: Latin 
square 
! glucose AUC for all 
trt were lower than 
glucose (p<0.0001), trt 
5 and 6 lowest AUC 
 
! insulin AUC for trt 5 
with 11.5g RS and 6 
with 13.4 RS than all 
MTT (p<0.0001) 
Trt 2-6 were given as test corn 
starches in bread, trt1 was not a 
bread.  Subjects consumed 1g 
CHO/kg body weight based on 
the mean of weights 2 days 
before MTT.  Men and women 
were paired for age and BMI, 
but there were no sig. gender 
differences in glucose or insulin 
response.  
Behall and 
Hallfrisch 
2002 56 
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Table 5(a). Continued 
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Design and Duration! Main Effect of RS Comments! Study!
 n=  10 
 
4M, 6F  
Age: 23-65 yrs 
BMI: 20.3-35.9 
Type II, 
60g 
Trt 1.  RS: 60g and 
40g RDS=100g 
Trt 2. Placebo: 40g 
RDS 
 
Given basal meals 
with Trt 1 divided 
into 4 15g doses in 
jelly, or trt 2 of 4 
jelly products with 
0g RS over 24hrs 
24hrs: diets 
implemented for 
24hrs next 
morning MTT 
 
DESIGN: 
single-blind, 
crossover 
(acute) 
! Insulin sensitivity 
(p=0.03) 
 
" Hepatic insulin 
clearance (p=0.02) 
 
" postprandial glucose 
(p=0.04) and insulin 
(p=0.04) 
Identical background ready-to-
eat diets where used to evaluate 
the effects of inulin solely on 
the addition of RS to diet. 
Measurements taken after RS 
ingestion and evaluated with 
MTT. Also measured plasma C-
peptide, GLP-1, NEFAs, 
breathe H2  
Other effects: fermentation 
byproducts SCFA and H2 were 
slightly elevated with RS 
though NS 
Robertson 
et al. 2003 
 
 
n= 12 
 
7M, 5F 
Age: 33±5 yrs 
BMI: 24.7±2.4  
Type II;  
2.5, 5, 
and 10g 
 
 
Trt 1. Meal 0% RS 
Trt 2. Meal 2.7% 
RS  
Trt 3. Meal 5.4% 
RS  
Trt 4. Meal 10% 
RS 
 
isocaloric meals 
adjusted to be 30% 
individual daily 
energy needs.  
1 d, 4 w washout 
period  
 
DESIGN: 
crossover*  
NS in postprandial 
glucose or insulin 
response for AUC or at 
specific tp 
Mainly a lipid oxidation 
experiment. Important to note 
glucose and insulin response was 
measured in response to a mixed 
meal. Gluteal fat biopsies and 
breath samples were collected.  
Also measured blood TAG, FFA, 
RQ, and urine N content.  
Significant differences were 
found in RQ 
Higgins et 
al. 2004 
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Table 5(a). Continued 
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Design and Duration! Main Effect of RS Comments! Study!
n= 10 
 
4M, 6F 
Age: 24-61 
BMI: 18.4-32.3 
Type II, 
30g/d 
 
Trt 1. RS: 30 RS and 
20 RDS=50g 
Trt 2. Placebo: 20g 
RDS 
 
 Supp. prepackaged 
sachets into normal 
diet 
4 w over 12 w 
period 
 
DESIGN: 
single-blind, 
crossover 
dietary 
intervention 
! insulin sensitivity 
with clamp (p=0.03) 
and meal tolerance 
(p=0.5) 
 
! mean glucose 
clearance (p= 0.01) 
 
" postprandial insulin  
(p=0.02) 
Hyperinsulinemic-euglycemic 
clamp used to maintain glucose 
plasma at 5 mmol/L (2 visits) 
and arteriovenous MTT to asses 
metabolism of adipose tissue 
and skeletal muscles (2 visits) 
also measured NEFAs, C-
peptide, and ghrelin     
Minor effects: found 1.1 kg 
increase in lean body mass 
(p=0.003) 
Robertson 
et al. 2005 
 
n= 12 
(healthy lean) 
 
7 M, 5 F 
 
Age: NR 
BMI: NR 
Type III, 
~30g  
Trt1: glucose control  
Trt2: tapioca-based 
retrograded 
maltodextrin 59.7% 
RS 
 
50g of CHO dissolved 
in water 
1 day  
 
DESIGN:  
randomized 
single-blind 
crossover 
study 
" glucose AUC (p < 
0.05) 58.52 ± 7.33% 
compared to trt1 
 
" insulin AUC (p < 
0.01) 24.81 ± 10.12% 
compared to trt 1  
Blood samples via an 
intravenous catheter were 
collected from participants after 
a 10 hour overnight fast  
Brouns et 
al 2007 
STUDY 2 
n= 24 
11 M, 13 F 
 
Age: 22–59  
BMI:  23.2 ± 0.6 
 
 
Type IV, 
RS dose 
NR but 
7.2g DF 
for DSF 
(Group 
2, trt 1) 
Group 1 (n=10) 
Trt 1:CHO 
constituent product 
(0g DF) 
Trt 2: control glucose  
--- 50g of trt 
dissolved in 400 ml 
water 
Group 2 (n = 14) 
Trt 1: DSF (T-Diet 
PlusÒ Diabet NP)  
Trt 2: control product 
--- 400 ml of each trt 
1 day, 2 days 
total, 1 week 
washout  
 
DESIGN: 
randomized 
parallel arm* 
 
" glycaemic index  
and glycaemic load 
both trt 
 
NS glucose AUC 
 
" insulin AUC after 
CHO constituent as 
well as after the new 
DSF (p < 0.001) when 
compared to controls 
 
The new DSF consisted of 
slowly digestible CHO mainly 
RS type IV.  No comparison of 
between treatments in different 
groups.  
García-
Rodríguez 
et al. 2012  
STUDY 1 
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Table 5(b). Human studies evaluating glucose and insulin response to RS feeding in people with diabetes 
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Duration! Main Effect of RS! Comments! Study 
!"#$%&'(!)*+,()"")!"#-(*".! ! ! ! !  
n = 90 - see 
comments 
 
Control group 
(n=44) 
26 M, 18 F 
Age: 49.4 ± 1.74 
BMI: 24.5 ± 0.37 
 
RS group (n=41) 
21 M, 20 F 
Age: 51.7 ± 2.03 
BMI:  25.0 ± 0.49 
Type 
NR, 6.51 
g RS 
Trt 1: cooked 
refined rice 
(control) 
Trt 2: test rice with 
corn derived RS 
 
 
Rice trts were   pre-
packaged as 210g 
serving to be  
consumed for one 
meal a day on top 
of normal diets 
 
 
4-week 
2-week run-in 
 
 
DESIGN: 
randomized 
double-blind, 
placebo-
controlled 
parallel arm  
 
! fasting insulin  
 
! insulin resistance 
 
!  postprandial insulin 
at tp 30 min 
 
! postprandial glucose 
(P= 0.010) 
Participants (n=90) had either 
impaired fasting glucose (IFG) 
or glucose tolerance (IGT) or 
newly diagnosed diabetes. 
Diabetes was assessed as 
fasting plasma glucose !126 
mg/dL, prediabetes was 
defined as having IFG levels 
of 100-125 mg/dL, and IGT 
was described as after 2-hr in 
oral glucose tolerance test 
having 140-199 
mg/dLglucose.  Before and 
after 4-wk intervention, 
subjects received a standard 
meal tolerance test after an 
overnight fast 
Kwak et al. 
2012 
 
n= 10 
4 M, 6 F 
 
Age: 37–64  
BMI: 35.5 ± 3.6 
Type IV, 
RS dose 
NR but 
3.04 - 8g 
DF 
Trt 1: new DSF T-
Diet Plus® Diabet 
NP (8g DF) 
Trt 2: DSF  
Glucerna® SR 
(3.04g DF) 
Trt 3: 
Novasource® 
Diabet (6g DF) 
--- 400 mL of each 
trt 
1 day, 3 days 
total, 1 week 
washout  
  
DESIGN: 
crossover* 
 
! glucose AUC was 
lower after new DSF, 
trt 1, (P = 0.037) 
compared with the 
other trts. 
 
NS insulin AUC among 
trt 
The new DSF consists of 
slowly digestible CHO, mainly 
RS type IV 
García-
Rodríguez et 
al. 2012  
STUDY 2 
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Table 5(c). Human studies evaluating glucose and insulin response to RS feeding in overweight participants. 
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Duration! Main Effect of RS Comments! Study!
!"#$%&'()*#+' ! ! ! ! !  
Overweight 
hypertriglyceride
mic n= 29 
 
10F, 13 M 
 
Age: 44-64  
BMI: 29 ± 2 
 Type 
II*, 17g 
for W, 
25g for 
M only 
in trt1 
Trt1: high-amylose  
Trt2: oat bran 
Trt3: low-amylose 
 
Test products 
(muffins, bread, 
breakfast cereal, and 
pasta) were given as 
supplements to 
background diet 
12 wks, 
3wks/trt 
 
no washout 
 
DESIGN: 
randomized 
crossover 
! postprandial glucose 
after trt1 (RS) when 
compared to trt 3 
 
! postprandial plasma 
insulin, total 
 
NS fasting insulin and 
glucose for all trt 
Diets had 55%< CHO and 
30%> fat.  Background diets 
were self-selected within 
researchers constraints and 
treatments were given as test 
products. 
Other effects:  RS, trt 1, had 
no effect on plasma lipids but 
increase fecal butyrate.  Trt 1 
and 2 increased stool 
frequency and lowered pH 
Noakes et 
al. 1996 
Healthy 
overweight 
female 
 
n= 25 
 
Age: 26-57 
iBMI: 27.9±0.5 
(CS); 26.6±0.7 
(RS) 
Type 
III*, 
24g/d 
Trt1. Resistant Corn 
starch group, RS 
Trt2. Regular corn 
starch group, CS 
 
Supp. into regular 
diet  
21 days  
 
DESIGN: 
double-blind 
parallel 
! fasting glucose 
(p<0.05) 
 
 
NS fasting insulin 
Fasting baseline measurements 
were taken before the 21day 
and fasting measurements 
were taken after.  Change in 
fasting glucose was observed 
but not in insulin.   
 Other effects: lowered 
cholesterol  (total and LDL) 
Park et al. 
2004 
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Table 5(c). Continued 
Participants 
Characterization! Type, RS Dose! Treatments/ Products! Duration! Main Effect of RS Comments! Study!
Normal (NW) 
and overweight 
(OW) women 
 
n= 20 F 
 
NW (n=10) 
Age: 43.4 
BMI: 22.0  
 
OW (n=10) 
Age: 43.3 
BMI: 30.4 
Type II, 
0.71, 
2.57, 
or 5.06 g 
RS/100 g 
muffin, 
Trt 1: glucose control 
Trt 2: 0.26 !: 0.71 RS 
Trt 3: 0.26 !: 2.57 RS 
Trt 4: 0.26 !: 5.06 RS 
Trt 5: 0.68 !: 0.71 RS 
Trt 6: 0.68 !: 2.57 RS 
Trt 7: 0.68 !: 5.06 RS 
Trt 8: 2.3 !: 0.71 RS 
Trt 9: 2.3 !: 2.57 RS 
Trt 10: 2.3 !: 5.06 RS 
 
Trt levels are written 
as grams of !- glucan 
(!) to grams of RS 
per 100 g muffin, 
except for trt 1 which 
is not a muffin  
1 test day, 
total 10 visits 
 
DESIGN:  
Latin Square 
! overall AUC for 
insulin trt 10, high !- 
glucan and high RS  
 
 
! overall AUC for 
glucose in trt 9 and 10, 
high  !- glucan and 
medium and high RS 
Investigating interactions with 
three levels of resistant starch 
and three levels of ! -glucan. 
Ten subjects in each group.  
OW paired for age with NW as 
a control.  Subjects consumed 
1g CHO/kg body weight.  
Standard equilibration diets 
were given for 2 days before 
and test day, but between 
meals/trt normal diet was 
consumed.  OW had plasma 
insulin concentrations higher 
and were marginally more 
insulin resistant than NW but 
maintained similar plasma 
glucose concentrations. 
Behall et al. 
2006  
 
Overweight, 
n=33 
11 M, 22 F 
 
Age:  (18-69y) 
49.5 ±1.6 y 
BMI: 30.6 ± 0.5 
Type II, 
2 levels 
of ~60% 
RS 
 
 
Trt1: 0g/d Amioca 
Trt2: 15g/d Hi-maize 
260 
Trt3: 30g/d Hi-maize 
260 
 
trts individually 
packaged in ready-to-
use sachets to be 
mixed with cold or 
room-temperature 
beverages or foods 2 
times per day 
4 wk, 3wk 
washout  
 
DESIGN:  
double blind 
randomized  
crossover 
" insulin sensitivity for 
men in both levels of 
RS (trt2 and 3) when 
compared to control 
(trt1)  
 
NS change between RS 
levels in men and 
women 
 
NS insulin sensitivity in 
women among 
treatments 
Participants’ waist 
circumference " 89 cm for F 
or " 102.0 cm for M to 
increase insulin-resistant 
probability, but   individuals 
with BMI " 35 were excluded. 
Mean fasting glucose was 5.29 
± 0.08 mmol/L, which is 
within normal range.  Insulin 
sensitivity was measured using 
insulin-modified i.v. glucose 
tolerance test. There was a 
treatment and sex interaction 
(P = 0.033) but no proposed 
mechanism.  
Maki et al. 
2012  
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Table 5(d). Human studies evaluating glucose and insulin response to RS feeding in healthy participant 
 
 
Participants 
Characterization!
Type, RS 
Dose! Treatments/ Products! Duration! Main Effect of RS! Comments! Study 
"#$%&! ! ! ! ! !  
insulin resistance 
(IR) and 
normoinsulinemic 
(NI),  "#$!% !
4 IR, 5 NI &'()!20.9 * 0.7!+%,)! 30.6 * 3.4!
-./(!,,,0!12!3'4!51!678!9:;!'!<=(8>?.!@=6(?!@A?!8?8!B!>"<!C!!
-?8!B)!hot potato 
(HP)  at 83.6 * 
2.0° F 
Trt 2: cooled 
potato (CP) at 
26.0 *!0.6° F 
Trt 3: white bread 
B!<>.0!8A8>D!9!<>.E!F=8G!BHI!F((J!F>EGA78!!KL2,M5)!?>"<AN=O(<!P?AEEAQ(?!R!
! glucose in trt2 the 
cooled potato 
 
NS insulin !
Insulin sensitivity was 
calculated based on fasting 
insulin:glucose concentration.  
No diabetics were entered into 
the study. To avoid second-
meal effect no legumes in the 
meal preceding overnight fast. 
Najjar et al. 
2004  
 
+A?<(?D="(!37"8?(>8(<4!<=>6(8(E!N(DD=87E0!CS!!$%0!BBT!&'()!IS:I*U:I!.!+%,!51!
-./(!,,,0!V'!! !"#$%:!6?(><!27//:!F=8G!8>/=AP>!12!
!"#$&:!WD>P(6A!PA"8?AD!6?(><!!BXS'YC!ED=P(EY8?8!
B!<>.0!CF((J!F>EGA78!8A8>D!Q=E=8E)!C!!KL2,M5)!<A76D(!6D="<0!E="'D(H="'(E8=A"!P?AEEAQ(?!
52!="!'D7PAE(!&Z[!!
!!,"E7D="!&Z[!="!>DD!E76\(P8E!3/#S:SI4!!
!!'D7PAE(!PA"P("8?>8=A"!="!6A?<(?D="(!'?A7/!BG?!>@8(?!="'(E8=A"!A@!8?8B!!
W>?8=P=/>"8E!EP?(("(<!@A?!@>E8="'!6DAA<!'D7PAE(!A@!BSSHBXS!N'Y<D!8G("!E8?>8=@=(<!="8A!6A?<(?D="(!'?A7/!3'D7PAE(]BBBN'Y<D4!A?!"A?N>D!3'D7PAE(!^!BBSN'Y<D4:!!28>8(<!8A!6(!P?AEEAQ(?!678!PA7D<!G>Q(!6("(@=8(<!@?AN!6(="'!>!?>"<AN=O(<!P?AEEAQ(?!
Yamada et 
al. 2005 
 
Insulin resistant 
12 M, 8 F 
 
Group 1 (n=10) 
Age: 45.2 ±3.55  
BMI: 31.3 ± 1.70 
 
Group 2 (n=10) 
Age: 50.1 ± 4.05  
BMI: 30.4 ± 1.15 
Type II, 
40 g⁄day 
RS 
 
 
Trt 1: Hi-Maize 
260 (RS- group 
1) 
Trt 2: Amioca 
(placebo- group2) 
 
starch in ready-
to-use sachets  
12 weeks 
 
DESIGN: 
randomized, 
single-blind, 
placebo- 
controlled, 
parallel  
intervention 
" insulin sensitivity (p 
= 0.023) 
 
NS fasting insulin 
sensitivity 
Insulin resistant qualified as 
fasting plasma insulin value > 
60 pmol ⁄L in healthy 
participants. For intervention 2 
sachets/day incorporated into 
participants diet, 2-test days 
before and after 12 weeks for 
measurements. Total of 4 test 
days.  Insulin sensitivity was 
measured by euglycaemic–
hyperinsulinaemic clamp. 
Johnston et 
al. 2010  
 
! ! ! ! ! ! !
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Table 5(a-d). Continued 
 
 
Abbreviation used in Table 5:  
BMI or iBMI: (initial-i) Body Mass Index, measured as kg/m2 
CHO- carbohydrate 
DSF – diabetes-specific formula  
F- Female 
FFA – free fatty acids 
GI- Glycemic Index 
M- Male 
MTT- Meal Tolerance Test 
NEFA- Non-esterified fatty acids 
NR – not reported 
NS- Not Significant 
Supp. – supplemented 
RDS – Rapidly Digestible Starch 
RQ- Respiratory quotient 
RS- Resistant Starch 
SCFA- Short chain fatty acids  
sol.- solution 
TAG – triacylglyceride 
tp- time point 
trt – treatment 
wk - week  
 
--- Age and BMI were reported as mean (± SE were applicable) not unless written as a range.  
*- Not reported but assessed to be as indicated by description of procedures 
a – 40g of total starch grams of RS was NR only GI  
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D.3   Fermentation Studies  
Currently, considerable public attention is given to dietary fiber and colon health, but 
perhaps the most underrated aspect of colon health in public perception is resident microbiota 
and their fermentative ability.  Gut microbiota play a very active role in host interactions, one of 
which is fermentation. Fermentation of the gastrointestinal tract is the sum of metabolic 
processes and reactions from the decomposition of organic substances by anaerobic microbiota. 
RS, like other dietary fibers, can be fermented in the colon by microbiota. The portion of RS that 
is not absorbed in the small intestine enters the large intestine where it is utilized as a substrate 
by colonic bacteria resulting in the release of fermentation by-products carbon dioxide, methane, 
hydrogen, energy, organic acids (e.g. lactic acid) and SCFA.   
Anaerobic metabolism of starch does induce physiological changes, which can offer 
benefit to the host. Once glucose from starches enters the glycolytic pathway, it is broken down 
to pyruvate, from which ultimately all fermentation products can be produced (Figure 2).  In 
humans, the large bowel is the main site of fermentation and SCFA production, specifically the 
large proximal bowel where fermentation and absorption of fermentation products is the greatest.  
Fermentation, as a whole, can increases colonic blood flow (Scheppach, 1994), reduce 
fecal/colon luminal pH (Ahmed et al., 2000)  and secondary bile acids, improve colon epithelial 
cell function, stimulate fluid and electrolyte absorption, and has implications in colon cancer 
protection (Topping and Clifton, 2001). Other implicated physiological benefits of fermentation 
from dietary fibers are decreased growth/binding of pathogenic bacteria, increased mineral 
absorption, and sources of energy for the colon epithelium.  Thus, fermentation not only plays a 
large role in colon health but also in colonic function (e.g., nutrient absorption) and plausibly as 
an aid in the immune system’s first line of defense not only by decreasing pathogenic bacteria 
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adhesion but also by eliciting anti-inflammatory effects (Meijer et al., 2010).  Moreover, specific 
fermentation by-products can elicit different physiological responses, which can aid in improving 
human health (refer to table 3).  
 
 
 
 
(Figure 2).  Fermentation schematic of major carbohydrate fermentation by-products. Dotted 
arrows are not direct production of metabolite but do contribute to overall production, like in the 
case of lactate to butyrate.  
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A carbohydrate-rich diet has been shown to increase fermentation, although gender 
differences are thought to decrease fermentation due to menstruation.  There have been 
fermentation studies, which have excluded women.  One of which (van Munster et al., 1994b) 
explained that fermentation and starch absorption was influenced by menstruation, citing an 
article that observed the effects of the menstrual cycle on GI changes in starch malabsorption, 
stool bulking, stool mucinase, and beta-glucuronidase activities when on a low-fiber diet were 
investigated (McBurney, 1991).  There are GI differences of women versus men, but 
fermentation studies have been conducted with both genders in which no gender differences 
were reported.  Conversely, fermentation studies have reported significant gender differences in 
response to dietary fibers and RS (McOrist et al., 2011).   
Fermentation studies in humans are practical and can provided constructive information 
towards the improvement of colon health especially for people suffering from GI disorders.  The 
study of microbial fermentation by-products of RS in human studies, though useful, does not 
always lend clear or predictable results.   However, as for postprandial glucose and insulin 
response, there are notable trends or hypothesis driven generalizations that RS increases 
fermentation.  Human fermentation has provided varied results as to the efficacy of RS (see table 
6), although there is evidence for the use of RS as a fermentable fiber, results are not consistent. 
 
D.3.1   Quantification of Fermentation 
The most common variables used for fermentation quantification are breath gases and 
SCFA production.  SCFA are readily absorbed and metabolized in the liver and muscle tissues to 
produce energy.  What is not absorbed or utilized is excreted in the feces.  Gases produced in 
fermentation, on the other hand, have to be absorbed in the colon before pulmonary excretion.  
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The two variables, breath gases and SCFA production, can be used to survey fermentation 
activity but is not always a direct measurement of gut fermentation.  Sample analysis to measure 
fermentation by-products in the colon can be taken from blood, breath, and/or feces.  Use of 
excreted samples are the more common methods for human in vivo models, yet ileostomy 
effluent and intestinal intubations are also in vivo methods used in fermentation studies though 
the latter methods require more care due to their evasive nature by comparison.  Sampling from 
feces is not invasive and can be used in vitro and in vivo models and are considered the ‘gold 
standard’ for overall digestion and fermentation studies (Salminen et al., 1998).  
Gas chromatography (GC) is the most common techniques for analysis of SCFA.  
Quantification of SCFA by GC can be done with free fatty acids; however, due to the volatile 
nature of acetate and other SCFA, normally derivatization or esterification techniques are 
employed.  Blood samples have been measured by automated head space GC methods with 
esterified SCFA (Achour et al., 1997). SCFA quantification in blood samples is a useful method 
but not as widely used as quantification of SCFA in fecal samples since concentrations of SCFA 
in the periphery are low and are believed to be difficult to measure accurately because an 
increase in SCFA production might not be proportionally detected in peripheral circulation.   
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Table 6.  Summary of in vivo human studies examining effects of RS on change in colonic fermentation  
 
       SCFA Breath gases 
Reference  RS Dose Type No. trt Duration N Acetate Propionate Butyrate Total H2 CH4 CO2 
Achour et al. 1997 50 g starch RS3 2 Acute 8 +, Blood ! ! ", blood +* + (5) +*, 13CO2 
Muir et al. 1994 59.1g ¥ RS2, RS1 2 Acute 8 +*, Blood " " ! + ! ! 
Vonk et al. 2000 40g starch RS2, RS3 3 Acute 7 ! ! ! ! " ! +*, 13CO2 
van Munster et al.  1994 28g RS2 2 1 w 19 ! ! ! ! + + (11) ! 
Ahmed et al. 2000 50 g CHO RS3 2 8 d 14 + NS + + + " ! ! 
Cummings et al. 1996 Various RS2, RS3 7 15 d 12 -1 -1 " +1 ! ! ! 
Phillips et al. 1995 26-50g ¥ RS2, RS1 2 3 w 11 + " + " ! ! ! 
McOrist et al.  2011 22g RS2 2 4 w 46 + + + + ! ! ! 
              
Acute, 2 < test days, 1 RS treatment meal  
+ (green), increase p<0.05 unless otherwise specified 
- (pink), decrease p<0.05 unless otherwise specified 
" (blue), no effect   
!, not measured/not reported 
NS, non-significant trend  
*, p < 0.01 
1 , highest or lowest in some forms of RS 
¥, highest of two RS doses  
Note: Studies Muir et al. 1994, Ahmed et al. 2000, Phillips et al. 1995, and McOrist et al. 2011, did not clearly define what type of RS was used, 
therefore, type information used in table was interpreted from description of meals in text of respective article. 
!
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D.3.2   Short Chain Fatty Acids (SCFA) 
SCFA are anionic organic fatty acids with a chain length 1-6 carbon long.  The 
production of SCFA by gut fermentation of RS has already been reviewed to be beneficial to 
health.  Fermentation of RS produces SCFA that are active metabolites utilized by the colonic 
epithelium and enter the portal circulation. If fermentation of dietary fibers such as RS is 
sufficient, SCFA produced in the large intestine will increase epithelial and portal 
concentrations. Thus, SCFA can be used as biochemical markers of gut microbiota fermentation.  
The most abundant SCFA of microbial fermentation in the human large bowel in order of 
proportion are acetate, propionate, and butyrate, though the order of metabolic significance is 
reversed (butyrate>propionate>acetate). However, all of these SCFA are of interest in 
maintaining human health and have an implicated role in gut health.  Valerate (C5) and 
hexanoate (C6) are also observed but at lower concentrations and furthermore with little interest 
to carbohydrate fermentation health effects.  Branched SCFA are predominantly proteolytic 
bacteria fermentation products of proteins and amino acids.  
With substrates like RS and other fermentable dietary fiber substrates, saccharolytic 
bacteria produce SCFA.  These fermentable fibers are targeted for their putative ability to 
increase SCFA; but, in some human studies, no change in SCFA in response to RS has been 
observed (Heijnen et al., 1998; Hylla et al., 1998). However, generally RS on some level 
increases SCFA production.  With an increase in SCFA production, a decrease in fecal pH from 
colon effluent has also been observed (Ahmed et al., 2000).  Overall, SCFA are useful in colonic 
health as nutrients or regulators of proliferation, differentiation, and gene expression for the 
colonic epithelium; and modulators of colonic pH (Cook and Sellin, 1998). 
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D.3.2.a   Acetate 
Acetate is the most abundant SCFA in the gut. It is formed through the reduction of CO2 
by acetogenic bacteria, its production is also described as oxidative decarboxylation of pyruvate 
(Cummings, 1981).  Initial substrates for the production of acetate can either come from hepatic 
or peripheral glucose or fatty acid metabolism.  Once formed, acetate is readily absorbed and 
taken up by colonic epithelium to eventually enter peripheral circulation where it can be 
metabolized by peripheral tissues. As the liver absorbs acetate as it appears in portal blood from 
the intestines, it can then be used in hepatic de novo lipogenesis via acetyl-coA synthetase/fatty 
acid synthase and hepatic cholesterol synthesis (Bergman, 1990). 
Colonic fermentation provides microbial production of acetate allowing the body to 
utilize indigestible carbohydrates for energy. Most of acetate from the gut is taken up by the 
liver, which makes it less likely to be metabolized in the colon than by other tissues (e.g., 
muscle).  Acetate, however is utilized by colonic bacteria, mainly for the production of butyrate 
as shown in bacterial culture and human microbiota fermentation (Duncan et al., 2002).  
Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, Fusobacteria, and Lentisphaerae are 
some of the human gut phyla that contribute to acetate as a fermentation end product (Jacobs et 
al., 2009) as reviewed from 16S rRNA methods in the human gut microbiota.  
The mechanistic study of the production and utilization of acetate in gut is conducted 
mostly in vitro. Measurements of concentrations of acetate with other SCFA and fermentation 
products as a function of fermentation are conducted in human studies.  Acetate concentrations 
in plasma after an RS intervention were found to be greater in women than in men.  This study 
examined 11 men and 22 women who were overweight or obese in a crossover intervention with 
4-week test periods on either control (0 g/d RS2), 15 g/d RS2, or 30 g/d RS2 (Maki et al., 2012).  
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Plasma acetate had a treatment effect (P = 0.0007), but no treatment and gender interaction.  
Acetate concentration of 4.4 ± 0.1 µmol/L was greater in the highest RS level (30-g/d RS2) than 
in the control (P = 0.047).  Gender differences in RS fermentation were attributed to generally 
different gut transit time between genders influencing the rate of fermentation events, although 
gut transit time in this study was not a direct measurement.   There was no change in any other 
SCFA.  This study is of interest because generally butyrate is the SCFA in vivo that is reported 
to change due to RS treatments.  
 
D.3.2.b   Propionate  
The formation of propionate is by two main pathways: the dicarboxylic acid pathway and 
the acrylate pathway (Cummings, 1981). Like acetate, the liver also takes up propionate.  But 
unlike acetate, it is implicated for its effect on glucose as well as lipid metabolism and thereby 
attributed with the reduction blood lipid profile and insulin resistance. 
The role of propionate in carbohydrate metabolism is species specific and its effect on 
glucose metabolism across and within species seems to vary.  An example of species variation is 
in ruminants propionate is thought to be a glucose precursor but not in hindgut fermenters. 
Though more species differences exist, within species (like in humans) effects of propionate also 
differ.  
Propionate, like acetate, tends not to be proportionally affected by percent in total SCFA 
production due RS consumption.  Contrarily, RS consumption is thought to induce higher 
propionate and butyrate production, but research studies have shown the spread of propionate 
concentration to have all-inclusive results. A few human studies have shown specific increase of 
fecal propionate, like in a study when 12 healthy participants were feed different forms of RS 
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and found RS3 increased propionate concentrations over RS2 (Cummings et al., 1996). Generally, 
RS diets have increased total SCFA production but one study showed that not only was there no 
effect on total fecal SCFA concentration but over a 4 week period in 12 healthy participants 
propionate concentration after a in high RS treatment decreased when compared to low RS 
treatment; 10.8 ± 0.6 and 14.6 ± 1.3 µmol/g wet weight respectively (Hylla et al., 1998).  Also, in 
vitro studies have shown that overweight and obese individuals have higher amounts of 
propionate (Schwiertz et al., 2010), though there is little human in vivo evidence that propionate 
changes due to RS treatment when considering metabolic factors such as weight.  
 In a study where propionate improved postprandial glucose response, it was in 
carbohydrate products supplemented with propionate and not from gut fermented propionate 
(Todesco et al., 1991). Here propionate appeared to have an inhibitory effect on amylolytic 
activity. More effort can be spent expanding the knowledge of propionate from RS fermentation 
in humans and specifically in overweight and/or obese individuals.  
 
D.3.2.c   Butyrate 
Butyrate seems to be the SCFA of interest when considering colonic health.   
Acetate feeds into the production of butyrate when it is reduced to acetoacetate. However, lactate 
is also a major contributor of butyrate (Bourriaud et al., 2005).  Butyrate is a preferred substrate 
for colonocytes (Schwiertz et al., 2002) providing a major source of energy.  In addition, 
butyrate is also attributed with playing a role in maintaining a normal colonocyte phenotype and 
population. 
The main SCFA acetate, propionate and butyrate are all taken up by the colonic mucosa, 
but butyrate is preferentially transported by colonocytes (Ritzhaupt et al., 1998).  It is estimated 
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that the majority of butyrate (95%) produced by microbes is transported across the epithelium 
and utilized, making butyrate hard to detect in portal blood.  Common ways to examine butyrate 
production are through fecal samples, colon cell lines, or luminal effluent mostly likely because 
it is believed butyrate exerts its main effects in the lower gut.  
Butyrate production can be sensitive to some forms of RS consumption (Jenkins et al., 
1998), and when compared with a low fiber diet RS might be the dietary component most 
influential on butyrate production.  In a 3-week dietary trial of 19 healthy participant consuming 
45g of RS approximately 32% resistant or 20g natural fiber low in RS showed an increase in 
butyrate (van Munster et al., 1994b).  This study also showed an association between high fecal 
butyrate and lower colonocyte proliferation. Overall, RS is thought to increase butyrate 
production and which can bear beneficial colonic health effects such as inflammation inhibition 
by influence on NF-kB expression and activity (Segain et al., 2000) and potentiating protection 
at various stages of colorectal cancer by suppressing growth of tumor cells and enhancing 
differentiation (Scheppach et al., 1995). 
  Starch as a substrate has lead to increased butyrate fermentation over other substrates 
(Weaver et al., 1992), and RS specifically has shown to increase fecal butyrate production over 
other dietary fibers (Noakes et al., 1996). Though inter-individual and gender differences to 
SCFA concentrations, particularly butyrate, has been reported (McOrist et al., 2011).  McOrist 
and associates (2011) conducted a randomized crossover study were 46 participants (16 males, 
30 female) were feed 25 g of NSP or 25 g of NSP plus 22 g of RS per day for 4 weeks.  Entry 
fecal butyrate concentrations varied from 3.5–32.6 mmol/kg where 27% of inter-individual 
variability was explained by BMI. From butyrate entry levels, participants were ranked into 
quintiles.   Participants in the quintile with low butyrate entry levels tended to have an increase 
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butyrate in response to RS treatment, but those with high entry levels often decreased in butyrate 
concentration.  Total SCFA concentrations overall did increase due to treatment with RS and 
gender differences were observed. Men had higher SCFA concentration than women for acetate, 
propionate, and total SCFA, which is plausible since it is believed men have greater fermentation 
than women.  What was interesting in this study was there were no gender differences in only 
butyrate concentrations (p=0.08).  
Butyrate is oxidized in the colonic mucosa, which can lead to production in CO2.  
Compromised populations, such as people with inflammatory bowel disease (ulcerative colitis), 
have been shown have lower levels of butyrate oxidation in the lower gut than population with 
healthy digestive tract(Chapman et al., 1994).   Due to the symptomatology of IBD, it is 
postulated that lower levels of butyrate exist in this group.  Thus, esterified starches have been 
studied to supplement SCFA of interest in food engineered to be delivered to the colon.  In a 
randomized crossover trial 16 participants (4 men, 12 women) in good health supplemented their 
diets with a treatment of low RS with 20 or 40 g of high amylose corn starch (HAMS) or 
butyrylated HAMS, HAMS20, HAMS40, HAMSB20, or HAMSB40 respectively, each for 2 
weeks (Clarke et al., 2011).  Fecal samples were collected for 4 days out of a two-week period 
(day 2, 3, 12, and 13). Esterified butyrate concentrations on days 12 and 30 and free fecal 
butyrate were highest for HAMSB40.  The esterified starches, HAMSB40 and HAMSB20 
excreted more (g/100g feces) than non-esterified starches, HAMS20 and HAMS40; which leads 
to the inferences that the HASB starches are not bioavailable and would lead to more lower gut 
microbial fermentation.  Microbial analysis showed an increase in abundance of Parabacteroides 
distasonis after HAMSB40 on days 12 and 13, concluding that this bacteria probably facilitated 
butyrate production.  
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D.3.3   Breath Gases  
Intestinal gases N2, O2, CO2, H2, and CH4 come from ingestion, diffusion from 
bloodstream, or colonic bacterial activity. Gases from colonic bacterial fermentation (H2, CO2, 
and CH4) can diffuse into the blood and be excreted in the breath, though only H2 and CH4 are 
exclusively from bacterial fermentation.  This premise, through the measurement of breath 
samples, has been used to estimate gastrointestinal conditions and as a non-invasive 
gastroenterological diagnostic tool.  
 
D3.3.a   Hydrogen 
Breath hydrogen is an indicator of intestinal fermentation.  When H2 is produced, it is 
rapidly absorbed into the bloodstream and excreted by the lungs where it can be measured.  
Formate, a product of anaerobic metabolism, can be converted into carbon dioxide and hydrogen.  
In turn, H2 can either be converted into methane if appropriate bacteria are present or excreted. 
 In 1970 Levitt and Donaldson wrote a popular article “Use of respiratory hydrogen (H2) 
excretion to detect carbohydrate malabsoprtion” in the Journal of Laboratory and Clinical 
Medicine.  From this article and other works (Bond and Levitt, 1972), excretion of H2 was linked 
to the malabsorption of carbohydrates. Carbohydrate malabsorption, where a carbohydrate 
cannot be absorbed in the small intestines, is usually seen in people with abnormal GI functions. 
When breath hydrogen and carbohydrate malabsorption studies were being conducted in the 
early 1970s, it was before the discovery of what is known as resistant starches today. Strictly 
speaking, since RS is not fully digested in the small intestine it is malabsorbed.  However, the 
incomplete digestion of RS is not considered carbohydrate malabsoption though the ingestion of 
RS can also cause an increase in breath hydrogen just like carbohydrate malabsorption (Bond 
76 
 
and Levitt, 1972; Born, 2007). Though unlike in carbohydrate malabsorption, fermentative 
properties of RS does not have to be associated with GI disorders.  In addition, RS is suspected 
to preferentially increase the concentration of colonic bacteria involved in fermentation.  
Ingestion of RS has shown signs of increased fermentation by increased breath H2. When 
8 subjects were feed a 3 meal diet of high and low RS (type I and II) there was a comparative 
increase in breath hydrogen production 34.1 ± 4.7 and 23.9 ± 3.9 ppm (P < 0.001) respectively 
(Muir et al., 1994).  Likewise, after 16 hrs test period, a genetically modified rice for enriched 
RS was found to increase (p<0.05) peak breath H2 at 38.9± 17.6 ppm over its wild type 10·5 ± 
3.7 ppm (Li et al., 2010).    There is also evidence of no change to breath hydrogen in response to 
RS or other fermentable fibers (Jenkins et al., 1998).  
There are drawbacks to measuring H2 as a metabolite of fermentation.  Although H2 can 
be excreted in the lungs it can also be used in other colonic bacterial pathways such as sulphate 
reduction, acetogenesis, and methanogenesis.  Consumption of H2 is essential for the formation 
of by products such as methane. Thus, though fermentation of RS represented as hydrogen 
production might be occurring, it is utilized before it can be excreted in the breath.  Bacterial use 
of H2 is one factor that influence excretion of H2 but colonic environment plays a role in H2 
production.  Gas production is directly proportional to colonic pH, as fecal pH is lowered so is 
the production of H2.    Notwithstanding since there is evidence that H2 is influenced in response 
to RS it is a good indicator to survey fermentation.   
D.3.3.b   Methane  
The production of methane is dependent on whether the host has resident colonic 
methanogenic microbiota. Methanogens consume large quantities of hydrogen to produce 
methane. Euryarchaeota and Firmicutes are examples of human gut microbotic phyla that 
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produce methane as fermentation end products (Jacobs et al., 2009). Some people do not have 
the appropriate microbiota to produce methane and considering the production of methane has 
not been shown to be a function of eukaryotic cells, measurements and inferences of methane 
production are only applicable for a sub-population of humans.  
Methane is normally a breath gas that rarely reaches significance when assessing the 
effect of RS, in diets even when divided into producers and non-producers (Hallfrisch and 
Behall, 1999).  Although studies have shown an increase in methane fermentation (van Munster 
et al., 1994b).   It is estimated that 30% of the adult population are methane producers 
(Gasbarrini et al., 2009), but experimental data stratified for production of methane have varied. 
An in vitro study quantified 23 out of 30 of human fecal samples to produced methane as the 
primary method of hydrogen consumption (Gibson et al., 1990).  Though the research question 
of Gibson and associates (1990) was to identify the main method of hydrogen disposal, it also 
showed that 77% of their sampled size had methane-producing bacteria.  Other human feeding 
studies have found 58% (11 of 19) (van Munster et al., 1994b), and 63% (5 of 8) (Achour et al., 
1997) of participants to be methane producers.  A more stable estimation of methane producers is 
30-60% of adult population on westernized diets though in other countries where a carbohydrate 
rich diet is more prevalent, higher incidents upwards of 70- 85% of methane producers can be 
observed (Cummings, 1981; Segal et al., 1988). 
The criteria for categorizing CH4 producer are also inconsistent.  When pulmonary 
methane excretion rate was measured in 22 adults, participants with methane > 1 ppm were 
considered producers while all participants < 1 ppm where non-producers (Bond et al., 1971), 
but this same study is accredited elsewhere as defining methane producers as having methane 
concentrations >2 ppm higher than ambient air. Other studies have cited cut off of corrected 
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fasting methane to be as high as 10ppm to be considered as a methane producer (Hallfrisch and 
Behall, 1999). 
Methane production can also decrease overall fermentation. Substantial reduction in 
SCFA production has been observed in methane producers when compared with non-methane 
producers, where producers were defined as ! 5 µmol methane in 24 hours and non-producers 
<0.3 µmol methane in 24 hours (Weaver et al., 1992).  This study used methane measurements 
from feces and not breath samples and the definition of producers verse non-producers was based 
off of gram per feces per unit time instead of conventional (breath) ppm for fermentation gases. 
To date, no studies could be found with long-term measurements of methane in only methane 
producers.  An increased sample size with only methane producers might strengthen evidence 
and correlations between methane production and RS consumption.  
 
D.3.3.c   Carbon dioxide 
Like breath hydrogen, carbon dioxide (CO2) can be absorbed in the gut to be excreted by 
the lungs. In the human body, CO2 can be produced from a number of reactions.  Formate is 
produced from anaerobic metabolism and can be converted into carbon dioxide and hydrogen.  
In the small intestine carbonic anhydrase will rapidly convert hydrogen ions and bicarbonate to 
CO2. It can also be oxidized from butyrate in the colon. However, when considering lower gut 
fermentation, carbon dioxide is the lesser reported breath gas.  
Studying CO2 as a gut bacterial fermentation product from carbohydrates has been 
commonly evaluated though the use of labeled carbon.  Corn has a natural carbon isotope, 13C.  
Oxidation of this 13C to CO2 generates a stable labeled fermentation by-product, which allows the 
quantification of the production of CO2 strictly from a corn RS source, since CO2 is a product of 
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the citric acid cycle fed by all glycolysis.   Excretion of 13CO2, when measured in response to 
naturally 13C- enriched corn starches, was found to be higher after a corn derived RS 
(retrograded) meal than after a digestible corn starch meal fed to humans (Achour et al., 1997), 
indicative of higher fermentative ability of RS than RDS.  Although CO2 is used as an indicator 
of bacterial fermentation; no reports of change due to RS consumption can be found if not assed 
by 13CO2.  Furthermore, CO2 is a ubiquitous metabolic product in humans and may not be a 
strong measurement for bacterial fermentation.  
 
D.3.4   RS Comparisons in fermentation Studies 
Resistant starches have been compared to other dietary fibers for its health benefits. RS 
might be more useful for lower gut fermentation than some other dietary fibers. However, 
research by Jenkins et al. (1998) did not support this hypothesis when they compared four dietary 
fibers for their effects on colonic function (fecal bulking, fecal SCFA production), glycemic 
control, and serum lipid metabolism.  Healthy human participants were randomly assigned low-
fiber control (LF), high- fiber wheat bran, RS2 or RS3 enriched foods for two weeks, with a two-
week wash out period between treatments. Out of all the treatments, fecal butyrate was found to 
increase 45±17% after RS2 and 66± 26% after RS3 treatment (p=0.015 and p=0.02 respectively) 
when compared to LF, whereas wheat bran increased 48± 21% (p=0.030) when compared to 
LF.  Yet these results still supports that some types of RS might improve colonic health by 
increasing SCFA production particularly butyrate.   
Similarly, another study was conducted comparing diets containing no starch (SF), wheat 
starch fully digested in the small intestine (R+SDS), wheat bran (Bran-NSP), potato RS (Potato-
RS2), banana RS  (Banana-RS2), processed wheat starch (Wheat-RS3) and processed maize 
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starch (Maize- RS3) in 12 healthy adults over a 15 day period (Cummings et al., 1996). Two 
diets, Potato-RS2 and R + SDS, showed the highest total SCFA concentrations excreted in feces. 
Lower fecal acetate molar ratios were observed for diets with RS3 and lower propionate molar 
ratios were observed for diets with RS2.  Differences in fecal acetate concentrations reached 
significance (p<0.05) when RS3 diets were compared to bran-NSP and banana-RS2 diets and for 
propionate when RS2 diets were compared to R +SDS and wheat-RS3 diets.  Changes in fecal 
butyrate were only observed in potato-RS2 diet, which was found to be significantly greater than 
R+SDS, bran-NSP and wheat-RS3 diets.  To summarize results of this study, RS2 shows promise 
in increasing total SCFA production and increasing butyrate production over RS3; while RS2 and 
RS3 might be used lower propionate and acetate concentrations respectively.  
Evidence of comparative fermentation studies point to different types of starches 
generating different fermentation profiles. Not all RS increases butyrate production.  Some 
studies have found additive effects when dietary fibers were mixed.  Muir and associates (1994) 
found that a combination of wheat bran and RS reduced transit time and fecal pH, but increased 
fecal output and excretion of SCFA. As for glycemic response there seems to be no observable 
trend as to which dietary fibers preforms best. 
 
 D.4   Gastrointestinal Symptoms 
The health and gastrointestinal benefits of dietary fibers and RS have previously been 
discussed (see section B.1).  But as for all substances there is an upper and lower tolerance.  
Therefore, at some dose we know RS will cause adverse GI effects.  Effective and recommended 
doses have been made for RS by different researchers to improve various physiological 
endpoints; however, defining an adverse dose has been challenging.  Adverse GI effects of low-
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digestible carbohydrates are influenced by characterization of carbohydrate (e.g., type, degree of 
polymerization), dose, and human host interaction and variability (Grabitske and Slavin, 2009); 
which makes blanket recommendations for tolerance of RS hard to quantify.   
With the growing interest in the use of RS there is yet little research on possible adverse 
effects, which is not alarming because dietary fibers in general seem to pose little risk of adverse 
effects.  According the Dietary Reference Intake by the Institute of Medicine, no tolerable upper 
intake level (UL) has been set for dietary fibers since consumption of dietary fibers are normally 
self-limiting.   
Furthermore, adverse GI symptoms are normally not primary end points in RS or dietary 
fiber studies. There are some RS feeding studies that have reported GI symptoms, although RS 
dose and type along with observed GI symptoms are underreported.  Gastrointestinal symptoms 
such as bloating, abdominal discomfort and diarrhea have been anecdotally associated with an 
increase in dietary fiber.  However, the dose of dietary fiber loosely correlated with adverse GI 
symptoms has not been well defined.  As increased consumption of dietary fiber can have minor 
adverse side effects, one can postulate that theoretically the increased consumption of RS will do 
the same.   
RS as well as other forms of dietary fiber can have a laxative effect and increase the ease 
and/or frequency of laxation (Heijnen et al., 1996; Noakes et al., 1996). Increased or excess 
intakes may cause acid reflux and heartburn, diarrhea, flatulence, bloating, and/or abdominal 
discomfort (See table 7). Such GI symptom though normally transient can negatively alter the 
perceptions of consumers that may cause conscious reductions in the amount of RS/dietary fiber 
foods consumed.  
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Table 7. Tolerance terms used to assess symptoms of RS consumption. Adapted from Livesey 2007 
Acid reflux Flatulence  Rumbling in stomach 
Belching (eructation) Gripes Stomachache 
Borborygmi – rumbling in intestines  Heartburn Toilet visits 
Burping Laxation Undergarment staining 
Colic Loss of appetite Vomiting  
Diarrhea Meteorism Watery feces 
Distension Nausea  
Fecal incontinence Rumbling in gut  
 
Gastrointestinal symptoms and discomforts, such as flatulence, bloating, and abdominal 
pain are unpleasant but normally not harmful.  Likewise flatulence, burping and stomach 
rumbling are possibly embarrassing but not harmful.  Notwithstanding, GI distress such as 
diarrhea can become problematic.   Excessive diarrhea can lead to dehydration and loss of fluids, 
sodium, chloride, and potassium, which can lead to serious health issues for children, elderly, 
and immune-compromised people.  Besides GI symptoms and discomforts, other serious side 
affects can occur with dietary fiber consumption:  interfere with absorption of nutrients, inhibit 
efficacy of medication, and GI blockages normally occurring with supplemented dietary fibers.  
Gastrointestinal symptoms can occur for a number of reasons; however, adverse GI 
symptoms are a concern with any increases in fiber that putatively intensify with dose.  
Conversely, minimal GI symptoms were observed by symptoms survey in a human study where 
four dietary fibers, one of which was resistant starch, were used to increase fiber consumption by 
12g a day for 2 weeks (Stewart et al., 2010).  Stewart and associates (2010) supplemented dietary 
fibers to increase consumption of fiber above what was naturally present in participants’ habitual 
diets.  A daily 12g increase of dietary fiber was well tolerated even though plausibly any increase 
in fiber could cause GI distress, since dietary fiber tolerance is individually variable. Specifically 
for RS, no adverse effects were reported by bowel habit diaries in an acute study where 20 males 
were given 80g of a 60% resistant Hi-Maize® 260 product (48g of type II RS) in a day 
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(Bodinham et al., 2010). The dose of 48g would be considered a high dose of dietary fiber since 
recommended values of dietary fiber are 25-38 g per day.  
In the human feeding studies conducted as part of this dissertation, moderate doses of RS 
were fed as a one-meal replacement in normal diet and few GI symptoms were reported. Most 
human feeding studies of RS also report minimal or no adverse effects to RS even at high does of 
60 g (Karalus et al., 2012; Klosterbuer et al., 2013; Li et al., 2010; Storey et al., 2007; Tomlin 
and Read, 1990; Wolf et al., 2001).   Therefore, there is sufficient evidence to support shifting 
the percentage of RDS to SDS or RS might prove to be advantages to lowering postprandial 
glucose response and improving health with little to no adverse gastrointestinal events.  
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ABSTRACT 
Resistant starches (RS) are complex partly indigestible carbohydrates that have shown 
promise in improving digestive health and glycemic response.  The use of RS is gaining 
popularity in commercial products, generating interest in practical agronomic production for 
variable RS sources.  In the present study, cornstarch derived from conventional maize (AR), 
high RS maize (Guat), and maize crossbred to enhance yield of high RS maize (AR/Guat) were 
used to evaluate the change in blood glucose compared with standard commercial cornstarch 
(CCS). A four-week randomized blinded crossover study was conducted using AR, Guat, 
AR/Guat, and CCS in a pudding fed to 11 participants (6 men and 5 women).  Blood samples 
were collected -15, 0, 15, 30, 45, 60, 75, 90, 120, 180, and 240 min after ingesting the pudding 
starches.  There was no significant treatment effect on plasma glucose Area Under the Curve 
(AUC).  Guat, the treatment with the highest digestion resistance at 26.2% of total starch, 
showed the lowest change from baseline with a 30 min postprandial glucose peak of 6.87 ± 0.27 
mmol/L, indicating that Guat had a lower glycemic increase after a RS meal at 30 min, 
significantly different from Guat/AR (7.48 ± 0.26, p= 0.03) and AR (7.57 ± 0.26, p=0.01).  
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Participants reported no adverse gastrointestinal effects in response to resistant starch meals.  
Lower glucose responses with minimal to no adverse gastrointestinal effects supports the role of 
RS in novel corn lines potentially improving postprandial blood glucose with promise to aiding 
in preventing diabetic complications. 
Key Words: resistant starch, glycemic response, humans, dietary fiber, crossover 
 
 
INTRODUCTION 
Various scientific publications have substantiated the health benefits and implications of 
increased dietary fiber (DF) consumption to aid in hypertension, risk of cardiovascular disease, 
and metabolic syndrome lowering risk of diabetes mellitus (Carlson et al., 2011; Keenan et al., 
2002; Marlett et al., 2002; Wolk et al., 1999).  In addition, the benefits of DF have been 
supported by approved U.S Food and Drug Administration (FDA) health claims outlining the 
consumption of DF in fruit, vegetables, and grains for the reduction of some types of cancer (21 
CFR 101.76).  Resistant starch (RS), as a source of DF, has some of the same health benefits as 
other DFs and can be used to aid in improvement of digestive health and further favorable 
biological effects (Jenkins et al., 1998; Nugent, 2005).  Research has associated RS with 
increased mineral uptake of zinc in humans (Behall et al., 2002), modulation of gut microbiota 
presumably for enhanced fermentation (Abell et al., 2008; Walker et al., 2011), colorectal cancer 
protection (Cassidy et al., 1994), and improved blood glucose and insulin response(Behall and 
Hallfrisch, 2002).  
RS is defined as the portion of starch that undergoes incomplete digestion in the small 
intestine (Asp, 1992) and is largely fermentable in the lower gut (Cummings and Englyst, 1991; 
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Cummings et al., 1996). Due to low glucose bioavailability of RS in the small intestines, the 
glycemic load for RS containing foods is lower than rapidly digestible (RDS) or slowly 
digestible (SDS) starches (Englyst et al., 1996, 1999), as the names (SDS and RDS) imply.  
Maintaining stable blood glucose concentrations has positive implications especially for the 
improvement of metabolic syndrome where controlling blood glucose within normal 
concentrations is ideal.  There is emerging evidence that the use of RS in the diet beneficially 
modulates blood glucose, insulin and C-peptide; improves blood lipid profile; reduces oxidative 
stress and energy to aid in management of diabetes and obesity (Bodinham et al., 2010; García-
Rodríguez et al., 2012; Kwak et al., 2012; Park et al., 2004).   For people with diabetes and 
people with high risk factors for diabetes mellitus, like obesity, controlling blood glucose 
through diet is advantageous.  Increasing RS concentration in food products fed to healthy 
individuals has shown to reduce blood glucose area under the curve (AUC) by over half (57%) 
when compared to a control (Granfeldt et al., 1995).  Although RS meals have been shown to 
significantly decrease postprandial glucose when compared to a control (Raben et al., 1994), 
contrary results were reported with RS (type 2 and 3) had no effect on glucose response when 
compared to a low-fiber control (Jenkins et al., 1998).  However, overall replacing portions of a 
rapidly digestible starch with slowly digestible or digestion resistant starch generally reduces 
glucose concentrations (Achour et al., 1997; Behall and Hallfrisch, 2002; Behall et al., 2006; 
Vonk et al., 2000) people with diabetes mellitus (García-Rodríguez et al., 2012) and even in 
borderline diabetics (Yamada et al., 2005). 
On average Americans are consuming less DF than the recommended 25-38 grams per 
day.  Though hard to truly estimate, based on combined data from the US Department of Health, 
Human Services and National Health and Nutrition Examination Surveys (NHANES), and 
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literature-based RS database, Americans are consuming approximately 3 to 8 grams of RS per 
person per day (Murphy et al., 2008).  In order to meet the DF recommendations, the 2010 
Dietary Guidelines for Americans suggested increasing consumption of foods with naturally 
occurring fiber (U.S. Department of Agricuture and U.S. Department of Health and Services 
Human, 2010). There are many naturally occurring sources of RS, such as bananas, potatoes, 
certain legumes, whole grains, and corn, although RS content can be altered by chemical (Al-
Tamimi et al., 2010) and genetic modification (Li et al., 2010).  Providing natural sources of RS 
that have not been chemically or genetically modified might be a consumer conscious approach 
to increasing recommended DF consumption while promoting lower postprandial glycemic 
response for subpopulations of interest. 
Producing RS sources or products with physiologically relevant doses is a concept of 
considerable scientific interest. When formulating a RS product, various food preparation 
conditions (e.g., cooking, baking) can cause alteration of RS concentrations (Eggum et al., 1993; 
Siljestriim and Asp, 1985). However, subsequent to any product preparation, RS concentrations 
also vary by source. Several commercial products are available which use RS maize as a DF 
substitute. Maize is an abundant, popular, and variable source of RS since its amylose content 
can be genetically manipulated.  Although genetic modification has produced viable RS, which 
can be classified as type IV, manipulation of amylose content can be done through conventional 
crossbreeding of maize.  Investigation to produce novel and stable corn line with increased 
amylose is still ongoing.  
In this study we used resistant starches from a novel crossbred corn lines in a pudding-
like product to evaluate their influence on blood glucose response. We hypothesized that starches 
from parent corn lines and starches from corn conventional crossbred to vary in RS concentration 
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will provide naturally occurring resistant starches that lower postprandial blood glucose response 
when compared to commercially available a corn starch with low RS content.   
 
MATERIALS AND METHODS 
Participants and Study Design  
Healthy non-smoking adults between 18-45 years of age were recruited from Iowa State 
University and surrounding community. Recruited volunteers were assessed by a health 
questionnaire for inclusion.  Participants were selected based on the following inclusion criteria: 
not taking any drugs or medications, no use of antibiotics within the last six months, non-
smokers, and not allergic to corn.  Individuals with diabetes (type I or II) and/or gastrointestinal 
diseases were excluded. 
Out of 49 volunteers who screened for the study, 15 eligible participants were entered, 
and 11 (6 men, 5 women) completed.  Characteristics for the 11 participants were 25 ± 4.3 years 
of age, 67.8 ± 4.11 height (in), 162.4 ± 31.5 pounds, and 24.8 ± 3.6 BMI. The experiment was 
conducted in a randomized blinded crossover design. Participants were scheduled for a total of 
four days one week apart to consume the pudding product. After a 12-hour overnight fast, 
participants consumed one of four lemon-flavored puddings made from corn starch.  Thereafter, 
finger pricks for blood glucose samples were obtained at time points 0, 15, 30, 45, 60, 75, 90, 
120, 180, and 240 minutes. Gastrointestinal symptoms where assessed 24-hours after consuming 
pudding product by a gastrointestinal questionnaire. The Institutional Review Board of Iowa 
State University approved the study design and recruitment procedures. Informed consent was 
obtained from all participants prior to entry into the study. 
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Assessment of Gastrointestinal Distress 
Participants were asked to fill out a gastrointestinal questionnaire for 24 hours after 
ingestion of test pudding describing individual events of gastrointestinal distress and rating 
overall intensity of gastrointestinal symptoms.  Overall occurrences of gastrointestinal bloating, 
gastrointestinal pain, and diarrhea were rated on a 0 -10 scale where 0 = none; 1 to 5 = mild; 6 to 
7 = moderate; 8 to 9 = severe, 10 = worst possible.  Individual events of gastrointestinal distress 
(such as discomfort, feeling bloated, gas, pain, burping, flatulence, diarrhea, or loose stools) 
experienced over the 24-hour period were record by symptom time of onset and cessation, and 
level of discomfort.  Level of discomfort was expressed numerically 1 = lowest, 10 = most 
severe possible; or number of flatulence where applicable.  
 
Corn lines and corn starches  
Three corn starches were tested against a commercially available cornstarch for 
postprandial glucose response. Of the three starches of interest, two were parent lines, Normal 
yellow dent corn (AR) and high-amylose corn (Guat), and the third conventionally crossbred line 
Guat/AR high amylose hybrid (Guat/AR).  Guat was an exotic corn accession from Guatemala 
with pedigree Guat209:S13/Oh43ae/H99ae-1-2-1-B-B-02-B.  AR pedigree 
AR011050:S01:1081-1-2-B  was an exotic non-mutant breeding corn line from Argentina.  
Guat/AR pedigree 209/S13 OH43aeH99ae had an amylose extender recessive gene expressed in 
the presence of both alleles. Guat and AR were planted in 200 rows, Guat/AR was planted in 267 
rows.  Corn was grown in 2009 at Iowa State University Agronomy Farms. The plants were self-
pollinated, hand harvested, force-air dried at room temperature, and mechanically shelled.  The 
seeds were bulked, ground into meal, and found to be negative for the presence mycotoxins 
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(deoxynivalenol and related trrichothecenes, aflatoxin B1, fumonisin BI) by the North Dakota 
State University Veterinary Diagnostic laboratory.  Bulk seeds were processed via wet milling at 
Iowa State University for corn starch.  The resulting three corn starches were tested against Argo 
corn starch (ACH Food Companies Inc. Cordova, TN), a commercially available corn starch 
(CCS) that contains very little RS. 
 
Mycotoxin analysis of corn lines 
Corn meal from each of the corn lines showed no detectable contamination for any 
mycotoxin (deoxynivalenol and related trrichothecenes, aflatoxin B1, fumonisin BI), tests 
performed at Veterinary Diagnostic laboratory, North Dakota State University.  Therefore, 
starches derived from wet milling of corn meal would contain no detectable levels of 
mycotoxins. 
 
Test Meal: Pudding recipe 
 The corn starches were mixed in three parts water.  Splenda® Sucralose micronized 
powder (200 mg/serving, Tate & Lyle Sucralose, Inc. Decatur, IL, USA) was added for a sweet 
taste and lemon extract (5g/serving, McCormick Corporation, Sparks MD) was added for flavor. 
Under continual stirring the puddings were made by bringing the corn starch and water mixture 
to a medium boil.  Yellow food coloring (McCormick Corporation, Sparks MD) was added for 
aesthetics (1-5 drops were added to achieve pale yellow coloring) and puddings were portioned 
and allowed to cool at room temperature before stored at 4 °C until consumption (less than 48 
hours after preparation).  Each pudding portion contained 50 g of cornstarch.  
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Analysis: Resistant Starch, Moisture, and Blood Glucose 
The determination of resistant starch content in puddings and in raw starch samples was 
conducted by AOAC method 2002.02 using Megazyme Kit (Megazyme International Ireland 
Limited, Bray Business Park, Bray, Co. Wicklow, Ireland).  RS concentrations were determined 
from wet weight. Moisture content was measured gravimetrically for each sample by drying 
pudding samples overnight at 110°C.  
Blood samples were collected by finger pricks in heparinzed capillary tubes (Fisher 
Scientific Inc. Hampton, NH).  To obtain plasma, whole blood samples were centrifuged at 3000 
rpm for 7 minutes.  All plasma was frozen at – 80° C until analysis. Plasma glucose 
concentrations were analyzed using a Biochemistry Analyzer 2700 Select (YSI Incorporated, 
Yellow Springs, OH).  An Area Under the Curve for plasma glucose concentration was 
calculated using the trapezoidal rule, omitting negative measurements.  
 
Statistical Analysis 
Data were analyzed using SAS 9.2 (SAS Institute, Cary, N.C., USA).  AUC data were 
analyzed using an ANOVA linear model with treatment and week as fixed effects.  Random 
effect terms were used for participant difference to consider dependency among observations 
from the same participants and variability between participants.  Analysis of glucose response 
treatment differences by time point followed the same model as AUC data, except time point 0 
was included as a baseline in the fixed effect in which the difference from baseline was analyzed.  
Data was pooled for male and female. Statistical significance was set at p < 0.05. 
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RESULTS 
Resistant Starch Content 
Corn starches used to make test meals were Guat, Guat/AR, AR, and CCS. The RS 
content of the raw starch was 28.8, 11.7, 3.1, and 0.6 percent, respectively (Table 1). 
Crossbreeding of Guat and AR corn lines resulted in the production of a cornstarch, Guat/AR, 
with an intermediate resistance.  Therefore, the parent line Guat was the test starch with the 
highest RS content, followed by Guat/AR, AR, and CCS.  Moisture content for all puddings was 
between 85-90 percent. Resistant starch analysis of pudding products provided similar 
characterization of RS content as did the raw starch except for AR and CCS values were closer 
in pudding products than raw starches.  Guat, Guat/AR, AR, and CCS had 13.1, 5.3, 2.4, and 2.7 
grams of RS per serving size, respectively.   
 
Blood Glucose Response  
Although Guat had the lowest AUC of all starches, there was no significant difference in 
AUC between pudding types.  Total AUC values were 194.38 ± 30.51, 211.08 ±30.51, 159.55 ± 
30.41, 183.61 ± 32.43 for Guat/AR, Guat, AR, and CCS, respectively (Fig 1).   General trends of 
glucose response due to treatment; however, can been observed at the time point level.  Glucose 
concentrations in plasma reached maximum between 30-45 minutes after ingestion of pudding 
for all treatments.  Plasma samples from individuals that consumed Guat pudding had the lowest 
glucose values at 30 minutes, but the change from baseline for Guat was only significantly 
different from Guat/AR (7.48 ± 0.26, p= 0.03), AR (7.57 ± 0.26, p=0.01).  Despite their 
difference in RS content (Table 1) and difference in glucose concentration at 30 min, Guat 
difference from baseline was the same as CCS.  Mean AUC values across treatments were not 
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significant though trends can be observed.  Inter-individual variability for time points of all 
treatments was evident, specifically during elevation of postprandial peak. 
 
Gastrointestinal symptoms 
No gastrointestinal symptoms differences were observed due to resistant starch puddings.  
Overall, few gastrointestinal symptoms were reported. Throughout the duration of four weeks 5 
events of bloating, 2 events of pain, and 1 event of diarrhea were reported for all treatments.  No 
symptoms were reported with intensity above 7 (moderate score could be reported as 6 or 7). 
 
DISCUSSION 
We expected to see a lower postprandial peak from puddings formulated from starches 
with the higher RS contents.  Although a trend was observed with Guat at postprandial peak, 
total glucose AUC did not reach significance.  However, this outcome is not uncommon.  
Glycemic responses to a RS meal have shown divergent results.  In a glucose tolerance test 
where 25 healthy participants were fed cornstarch in a bread product with 30, 40, 50, 60, or 70 % 
amylose (2, 3.8, 8.2, 11.5, and 13.4 g of RS respectively), a lower AUC in glucose response was 
observed when participants were fed 60 or 70% amylose thus estimating the recommended 
amounts of RS (presumably type II) to lower blood glucose response to be between 11.5 and 
13.4 g (Behall and Hallfrisch, 2002).  Another study used 5, 15, and 25g of type III RS in cereal 
bars and beverages and observed no difference between RS doses in postprandial blood glucose 
AUC of 22 healthy participants (Kendall et al., 2010).  Likewise, other studies have investigated 
consumption of RS and glucose response resulting in variable outcomes, which have raised the 
question- what is a biologically relevant type and dose of RS?  
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In our study 13.1 g of RS in the Guat pudding was fed to participants, which 
encompasses the range that Behall and associates recommended for lower glucose AUC.  Yet, 
overall we found no significant reduction in postprandial glucose AUC, although, an apparent 
reduction in postprandial peak from consumption of Guat was evident.  Differences have been 
found in glucose response after consumption of one RS meal compared only to a control. The 
following studies fed healthy humans 50g/treatment/person of raw potato starch and 
pregelatinized potato starch in a syrup to 10 males (Raben et al., 1994); retrograded cornstarch 
and pregelatinized cornstarch in a porridge-like gel to 8 participants (Achour et al., 1997); RS 
bread against a white bread to 20 males (Hasjim et al., 2010) in order to evaluate the change in 
glucose response from the control.   
Glycemic response studies ideally generate an AUC from 5 or more time points and 
where overall AUC has failed to provide evidence of a difference, investigation of specific time 
points has given insightful results.  Numerous studies have seen no difference in treatments with 
AUC, however, describe notable differences when comparing treatments across time points 
(Behall et al., 1988; Kendall et al., 2010; Yamada et al., 2005).   A postprandial glucose peak is 
typically observed between 30-45 minutes.  This time frame is a good indication of the amount 
of glucose absorbed from the small intestine and released into the blood stream.  During this time 
frame bioavailability of glucose from meal due to treatment might be easier to observe. As in our 
study, significant difference between treatments have been observed during this peak when AUC 
failed to show evidence of a differences (Behall et al., 1988).   
Glucose concentration will begin to return to baseline values between 90 and 240 
minutes. By 240 minutes, glucose concentrations should return to concentrations (3.9 - 5.6 
mmol/L) similar to fasting baseline measurements.   The quick return of glucose after a meal is 
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presumed as healthy for prevention of type II diabetes in which is implicated to lower the risk of 
cardiovascular disease. For people who suffer from type II diabetes, maintaining glucose 
concentrations below 7.8 mmol/L after meals is advantageous. Thus, starches that show promise 
of lower glycemic response at 30-45 and 90-240 minutes are ideal. 
When accounting for the change from baseline after 30 minutes and despite their 
differences in RS content, the rise in postprandial plasma glucose concentration as a result of 
consuming the Guat pudding was comparable to that of CCS though different from Guat/AR and 
AR (Fig 1).  Although no explanation can be given for baseline differences since participants 
were entered into the study based on fasting glucose ! 100 mg/dL, in addition to overnight 
fasting before each experimental day.  
Crossbred corn lines to improve amylose content have been shown to resist enzymatic 
digestion in vitro (Li et al., 2008) making them plausible candidates to use in the reduction of 
glucose response.  However, composition of starches, crystallinity and RS classification (Type I-
IV), food product, matrix, and processing are all critical components to consider in digestion of 
starches.   For instance, in the present study, raw starches showed different RS content for each 
starch (Table 1). When cooked, AR and CCS had similar RS content per gram even though they 
were derived from different corn lines (CCS. Argo #10 Dent) and processed on a different scale.  
The process of pudding preparation altered RS contents from raw starches resulting in the same 
RS content in AR and CCS puddings.  
Shifting the percentage of rapidly digestible starch to slowly digestible or resistant starch 
might prove to be advantageous to people with diabetes and obesity.  An increase in dietary fiber 
anecdotally can be associated with gastrointestinal distress, although very few studies report 
strong evidence of gastrointestinal distress with increased RS consumption.  In studies in which 
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an increase of 35-60g/day of RS increased gastrointestinal distress (Hylla et al., 1998; Muir et 
al., 1994; Phillips et al., 1995),  reports were  only a mild to moderate.  Mild to moderate 
gastrointestinal symptoms have been observed at lower doses (12g of RS) (Stewart et al., 2010), 
but a larger number of studies in which gastrointestinal events were reported report minimal to 
no evidence of adverse responses due to RS consumption (Karalus et al., 2012; Klosterbuer et 
al., 2013; Li et al., 2010; van Munster et al., 1994b; Storey et al., 2007; Tomlin and Read, 1990).  
Overall, gastrointestinal symptoms are easy to assess though tricky to define meaningful 
application since most measurements of gastrointestinal distress (e.g., bloating, pain, increased 
flatulence, stool consistency) through questionnaires, bowel diaries, or interviews are subjective.  
In this study gastrointestinal distress was self-reported. Participants were encouraged to 
be detailed and record symptoms as they occurred, because this was an acute feeding study in 
which total food intake of the day was likely to be greater than food intake from one treatment 
meal, symptoms of gastrointestinal distress could be from other sources.   In present study, prior 
diets and subsequent meals after puddings were not controlled, although other researchers have 
controlled the diet of participants via interventions of planned diets (Noakes et al., 1996); 
however, those tend to be for long-term studies with multiple variables and might not be 
necessary for acute feeding studies to assessing postprandial glucose response and 
gastrointestinal stress from RS meal.  
Overall, participants reported no adverse gastrointestinal effects due to resistant starch 
meals.  In our study, participants were fed at most 13 g of RS per serving size. Minimal 
gastrointestinal symptoms were also reported in a human study in which four DFs, one of which 
was resistant starch, were used to increase fiber consumption by 12 g a day for 2 weeks (Stewart 
et al., 2010).  No adverse effects were found in an acute study in which 20 males ingested 48 g of 
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RS in a day (Bodinham et al., 2010).  Our study is similar to Bodinham et al. (2010) with respect 
to duration; therefore, the acute feeding of 13 g RS in a day showing a lack of adverse 
gastrointestinal effects is not surprising.  
Lower glucose responses with minimal to no adverse gastrointestinal effects supports the 
role of resistant starches in potentially improving postprandial blood glucose and maintaining 
health. This research showed the pudding with the highest resistance starch played a biological 
role in reducing peak blood glucose concentrations compared to two of the more digestion 
resistant treatments. However, differences between starch sources of 8-10g of RS, with the 
greatest content fed of 13 g in a meal, did not result in significant differences in glucose AUC.  A 
more palatable product might facilitate volunteer participation since in present study a quarter of 
original participants did not complete the pudding study.    
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Table 1. Plasma glucose mean ± SE mmol/L by time points. 
minutes Guat/AR AR Guat CCS p value 
-15 4.45 ± 0.28 4.44 ± 0.29 4.61 ± 0.29 4.61 ± 0.31 0.92 
0 4.65 ± 0.26 4.59 ± 0.26 4.59 ± 0.27 4.73 ± 0.28 0.96 
15 5.72 ± 0.26 5.72 ± 0.26 5.57 ± 0.27 5.92 ± 0.28 0.69 
30 7.48 ± 0.26b 7.57 ± 0.26b 6.87 ± 0.27a 7.41 ± 0.28ab 0.05 
45 7.07 ± 0.26a 7.39 ± 0.26ab 6.43 ± 0.27ac 6.92 ± 0.28a 0.01 
60 6.07 ± 0.26 6.53 ± 0.26 5.84 ± 0.27 6.30 ± 0.28 0.08 
75 5.41 ± 0.26 5.68 ± 0.26 5.48 ± 0.27 5.76 ± 0.28 0.57 
90 5.11 ± 0.27 5.18 ± 0.26 5.18 ± 0.27 5.17 ± 0.28 0.99 
120 4.94 ± 0.26 4.86 ± 0.26 4.95 ± 0.27 5.01 ± 0.28 0.96 
180 4.92 ± 0.26 4.47 ± 0.26 4.76 ± 0.27 4.82 ± 0.28 0.41 
240 4.49 ± 0.27 4.37 ± 0.26 4.54 ± 0.267 4.68 ± 0.28 0.76 
Means sharing the same superscript within a row are not significantly different.  P 
values are a main time point effect and superscripts within rows are treatment 
within time point comparisons.  Time point -15 is baseline measurements before 
pudding consumption; time point 0 (zero) was glucose measurements taken 
immediately after. 
 
 
 
 
Table 1.1. Least Square differences of pudding treatments by time point 
 p value 
 30 minutes 45 minutes 
Differences of LSM   
Guat/AR vs 2 0.70 0.48 
Guat/AR vs Guat 0.03 0.19 
Guat/AR vs CS 0.54 0.93 
AR vs Guat 0.01 0.05 
AR vs CS 0.35 0.46 
AR vs CS 0.15 0.26 
Main treatment effect 0.05 0.01 
 !
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CHAPTER 4.   INFLUENCE OF CRACKERS CONTAINING RESISTANT STARCH V ON 
POSTPRANDIAL GLUCOSE, INSULIN, AND FERMENTATION RESPONSE IN 
HEALTHY HUMANS 
 
A paper to be submitted to Journal of Nutrition 
 
Esther Haugabrooks, Yongfeng Ai, Jay-lin Jane, Suzanne Hendrich 
 
ABSTRACT 
Stearic acid-modified resistant starch was compared with its parent high amylose starch 
for physiological effects on healthy humans.  In a randomized blinded crossover study, after a 
10-h fast, 30 participants ate crackers providing 50 g carbohydrate approximately 6 % (control 
starch crackers, CS), 24% (high amylose crackers, HA) and 58% (stearic acid-high amylose 
crackers, RS5) resistant starch as measured by AOAC method 991.43.  Cracker types were given 
solely as a test meal once a week over a period of 3 weeks.  Glucose, insulin, and fermentation 
responses were evaluated. Area under the curve (AUC) for blood glucose, was not different 
between HA and RS5; both produced lesser AUC responses than CS (p < 0.001).  Reduced 
insulin AUC was found only in HA when compared to CS (p < 0.01). In vitro digestion of 
crackers was also evaluated by AOAC method 2002.02 showing different RS content than 
991.43 method.  In vivo postprandial glucose (PPG) response corresponded with AOAC 2002.02 
in vitro digestion for each starch.  Fermentation, assessed by breath hydrogen, was greater after 
ingestion of RS5 than after eating HA or CS (p < 0.05).  Fermentation assessed by short chain 
fatty acid (SCFA) production was not different between cracker types. Gastrointestinal 
symptoms assessed from a questionnaire were minimal and not statistically different between 
cracker types.  This study indicates that further study of health effects of the fermentability of 
RS5 should be feasible in humans.   
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INTRODUCTION 
The portion of starch not digested in the small intestine is passed to the colon where 
fermentation can ensue is termed resistant starch (RS).  These types of starches (I-V) have been 
implicated for reduction of glucose and insulinemic response (Behall and Hallfrisch, 2002; 
Brouns et al., 2007; Noakes et al., 1996; Wolf et al., 2001) and for their fermentative ability 
(Ahmed et al., 2000; Cummings et al., 1996; McOrist et al., 2011).  Fermentation by colonic 
microbiota which has been associated with a bevy of beneficial physiological responses 
(Fuentes-Zaragoza et al., 2010; Nugent, 2005; Topping et al., 2003) mainly thorough the 
production of acetate (C2), propionate (C3), and butyrate (C4); however, valerate (C5) and 
caproate (C6) can also be produced.  In addition, consumption of RS has been implicated for 
potential amelioration in gastrointestinal ailments (Higgins and Brown, 2013) and metabolic 
syndrome (Johnston et al., 2010).  Though accumulated evidence for the use dietary RS for the 
modulation of human health is not always consistent, unequivocally RS has been used as a 
dietary fiber.  
RS starches have evolved from mere scientific intrigue to incorporation into commercial 
products. Interest in RS as a dietary fiber has become so prodigious new starches are being 
modified and tested to quantify efficacy to influence physiological responses such as 
postprandial glucose (PPG), insulin (PPI), and fermentation.  RS types I-V are commonly cited 
in literature. However, a novel type of RS is emerging, typed RSV, which has been modified by 
lipid starch interactions. RSV has shown evidence to improve PPG and PPI responses (Hasjim et 
al., 2010) with far-reaching implications for management of diabetes mellitus and obesity.  The 
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goal of this study was to evaluate the effect of RSV and RSII incorporated into a practical food 
on glucose, insulin, and fermentation response with humans in vivo.  
 
MATERIALS AND METHODS 
Participants 
Healthy participants, assessed by health questionnaire, were recruited from Iowa State 
University and surrounding community.  Participants were chosen based on inclusion criteria of 
not taking any drugs, medications, or antibiotics within the last six months, non-smokers, not 
allergic to corn, no gluten sensitivity, and within 18-45 years of age. Exclusion criteria were 
volunteers with diabetes (type I or II), gastrointestinal diseases, fasting plasma glucose 
concentration ! 100 mg/dL, body mass index (BMI) > 30, and pregnant.  While entered in the 
study, use of oral contraceptives was permissible. 
A total of 58 volunteers were screened for the study, 30 participants who met all 
inclusion and exclusion criteria were entered into the study.  In total, 29 participants completed 
the study (14 female, 15 male).  Participant characteristics for male and female participants were 
25 ± 5.4 (19-42) years of age, 23 ±3.5 (17-29) BMI, 89 ± 6.2 (79-98) mg/dL fasting glucose.  
Where gender differences were present, males and females were represented separately in 
results. Therefore, participant characteristics by gender are as follows: females 24 ± 3.6 (19-30) 
years of age, 23 ± 3.5 (17-29) BMI, 90 ± 5.9 (81-98) mg/dL fasting glucose; males 26 ± 6.6 (19-
42) years of age, 24 ± 3.6 (18-29) BMI, 88 ± 6.9 (79-97) mg/dL fasting glucose.  Participant 
characteristics are reported as mean ± SD (range). Ethnicities of participants were 12 White, 9 
Asian/Asian American, 5 African/African American, 3 Other, and 1 Latino/Hispanic. 
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The Institutional Review Board at the Iowa State University approved the study design 
and recruitment procedures.  Oral and writing explanations for the design and purpose of the 
study was given to each participant prior to entry into the study.  The experimental design and 
possible gastrointestinal discomforts were explained to the participants before written informed 
consent was obtained. All participants who entered the study signed an informed consent before 
first experimental day.   
 
Cracker preparation 
Three test starches were used to formulate experimental crackers: 1) commercial corn 
starch, product name Argo (ACH Food Companies Inc. Cordova, TN), obtained from a local 
grocery store; 2) a native high-amylose maize starch, commercial product name AmyloGel 
03003, courtesy of Cargill (Hammond, IN); 3) a stearic acid lipid-modified corn starch 
developed at Iowa State University.  Crackers prepared from these starches are termed CC, HA, 
and RS5, respectively.  
Crackers were formulated to have 50 grams of starch per serving. For RS5, 10 % of the 
volume was attributed to stearic acid complex; therefore, 55 g of raw starch was used per serving 
to account for total starch differences. For all of other ingredients, each test cracker contained 8 g 
gluten, 7 g vegetable shortening, 1 g whey, 1 g salt, and 0.7 g baking powder per serving size.  
Varying amounts of water per cracker type was added to kneed ingredients together.  Due to 
different water binding capacity, 33 ml, 45 ml, and 68ml per serving size was used to obtain 
workable doughs for CC for HA, for RS5 crackers, respectively.  CC, HA, and RS5 crackers 
were baked at 400 °C until light to golden brown which was approximately 9, 12, and 17 
minutes, respectively.  The crackers were prepared each week and frozen until consumption.  
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Total serving size of crackers/day was served in a sealed bag at breakfast with a glass of water.  
Participants were required to consume the entire bag within 10 minutes.  
 
Experimental Design  
Study was conducted as a randomized blind crossover design.  The duration of the study 
was 3 weeks with one-week washouts between test crackers.   Each participant was randomly 
assigned to 1 of 6 treatment sequences to avoid treatment carryover interactions. Before 
consuming test crackers as a breakfast meal, participants were asked to undergo at least a 10-
hour overnight fast.  Participants were asked to stay at Nutrition and Wellness Center (NWRC) 
for an 8-hour experimental day.  Upon arrival, participants were given a bag of crackers designed 
to be similar in appearance for their first meal of the day.  The study design intended for each 
participant to receive all three treatments at the end of the three-week period; however, eight 
participants during the second week of the study were accidently feed the wrong treatment.  
Therefore, 8 out of 29 participants that completed the study were not randomized and treatment 
order was corrected where applicable. Of the eight participants, three had already been fed the 
same treatment previously.  
Before consuming cracker products, baseline breath and blood samples were obtained.  In 
total 4 breath samples and 10 blood samples collected at time points 0 (baseline), 2, 4, 8 hours 
and -15 (baseline), 0, 15, 30, 45, 60, 75, 90, 120, and 240 minutes, respectively.  Participants 
were given a gastrointestinal symptoms questionnaire in which they were asked to list all 
symptoms and rate gastrointestinal distress symptoms bloating, pain, and diarrhea on a scale of 0 
(none) to 10 (most severe) over the 24-hour period after the consumption of cracker meal.    
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Participants were served lunch four hours into their eight-hour experimental day. A 
standardized lunch of turkey or cheese sandwich (supplied by local Jimmy Johns, nutritional 
facts at https://www.jimmyjohns.com/menu/#/), 16 potato chips (Pringles, Kellogg Company, 
Battle Creek, MI), 3 small cookies (Oreo, Nabisco, East Hanover, NJ) was served immediately 
after their 240-minute blood time point.  All fecal samples were collected from cracker 
consumption until 72 h after.   
 
Chemical Analysis 
Physiological variables 
Blood from finger pricks were centrifuged to retrieve plasma.  Plasma was analyzed with 
YSI Model 2700 Select Biochemistry Analyzer (YSI Inc., Yellow springs, OH) for glucose 
concentration and Ultrasensitive Insulin ELISA 80-INSHUU-E01.1 kits (APLCO diagnostics, 
Salem NH) were used to measure plasma insulin. 
Breath samples were collected with Quintron EasySampler Collection Device and 
Vacuum tubes (QuinTron Instrument Company, Inc, Milwaukee, WI) and analyzed less than two 
hours after collection by the Quintron Gas Analyzer (MicroLyzer Model SC).  The Quintron Gas 
Analyzer was calibrated every hour with a linearity check using QuinGas™-3 (QT07031-G – 
100 ppm H2, 50 ppm CH4 and 5 % CO2) error established to be no greater than ±0.05 % absolute 
or ± 2 parts per million (ppm) for calibration gas.  Participants were divided into non-producers 
and producers by quantification of methane productions, producers were defined as  > 7 ppm of 
methane at one or more time points.   
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Fecal and SCFA analysis 
Fecal weight, frequency, and pH were evaluated. Fecal frequency was determined by 
number of bowel movements obtained in 72 hours after cracker consumption.  Fecal weight of 
the total sample was determined on wet weight basis by weighing the sample in the collection 
bag and subtracting the weight of an average collection bag. Samples were homogenized by 
kneading the fecal sample in the collection bag, and then a subsample was obtained for a 1:3 
dilution of fecal sample to sterile water.  Diluted fecal mixtures were centrifuged, and 
supernatant was frozen at 80°C until SCFA analysis. Remaining supernatant was analyzed to 
determine fecal pH. 
Supernatant from fecal dilutions were subjected to silyl derivatization before GC analysis 
on Agilent 7890A GC system model (Agilent Technologies, Inc, USA). Silylation outlined as 
follows: 100 µL of 2-ethylbutyric acid (internal standard) added to 1 ml supernatant, protonated 
with concentrated hydrochloric acid, silylated with N-(tert-butyldimethylsilyl)-N-
methyltrifluoro- acetamide (MTBSTFA), SCFA extracted with diethyl ether.  Derivatives 
incubated for 20 min at 80°C stood at room temperature for 24 hours.  After derivatization was 
competed, samples were injected on a HP-5MSI column (30 m x 0.25 mm x 0.25 !m, Agilent 
Technologies).  Helium was used as a carrier gas flow rate 1 mL/min, with split mode (5:1) 1!L 
injection volume.  Injector (inlet) temperature was 250°C and MS detector temperatures were 
and 230°C and 150 for source and quad, respectively. Ion source was EI with voltage at 70 eV.  
The column temperature was held at 40°C for 4 minutes the programed to rise to 240 °C at 25 
°C/min, then to 320 °C at 30 °C/min.  SCFA C2-C6 and isomers of C4 and C5 were present in 
detection.  However, due to recognized physiological relevance of SCFA C2-C4 only acetate, 
propionate, and butyrate concentration are reported.  Likewise, where SCFA total is reported, it 
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is only for the 3 SCFA of interest.  The ratio of peak area of a SCFA to internal standard (2-ethyl 
butyric acid) versus the SCFA concentration was used as a standard calibration curve to estimate 
the concentration of SCFA in in vitro fecal fermentations. 
 
Other parameters 
Resistant starch content of finely ground crackers was measured using method AOAC 
991.43 and AOAC 2002 using Megazyme kit (!"#$%&'"()*+",*$+-.*$/(),"/$*0(1-'-+"02. 
Gastrointestinal symptoms were also assessed using a gastrointestinal questionnaire.  Participants 
were asked to list any gastrointestinal distress 34(3*+-/(56(7.3,8($9+",(-*#"8+-.*(.9(+"8+(:,$:;",8(<7","(+7"&(<.3/0(record the time, duration, and severity of individual symptoms. =8+-'$+"0(-*+"*8-+&(.9(.>",$//(.::3,,"*:"8(.9(#$8+,.-*+"8+-*$/(?/.$+-*#@(#$8+,.-*+"8+-*$/(4$-*@($*0(0-$,,7"$(<$8(8:.,"0(.*($(A(BCA(8:$/"(<7","(A(D(*.*"E(C(+.(F(D('-/0E(G(+.(H(D('.0",$+"E(I(+.(J(D(8">","@(CA(D(<.,8+(4.88-?/"K( 
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!"#$"%"&'()*$!+,-$"$.+/)*$&+%)"0$.1*)&$2+/)*$)22)3,#$4)%*)05$,0)",.)%,5$4)%*)0$,0)",.)%,$+%,)0"3,+1%5$"%*$.),-"%)$1%$0)#61%#)$7"0+"8&)#$"3),",)5$6016+1%",)5$89,'0",)$"%*$:;<=$,1,"&$!+,-$#98>)3,$"#$"$0"%*1.$)22)3,?$@"#,01+%,)#,+%"&$#'.6,1.#$9#)*$"$.+/)*$.1*)&$!+,-$,0)",.)%,$"#$,-)$."+%$)22)3,?$$:ignificance level was set at p < 0.05.$
 
RESULTS  
Resistant starch content  
Two methods of analysis were used to estimate RS content.  For AOAC 991.43 Insoluble 
Fiber method RS content for crackers and raw starch was significantly different from each other 
(p < 0.001). Megazyme analysis (AOAC 200.12) of raw starch and crackers showed that CS was 
different from RS5 and HA; however, RS5 and HA were not different from each other.  The 
cooking processes seemed to reduce RS content of RS5 and HA7 almost by half but had little 
effect on CS RS content.  The difference in RS content by method analysis estimates the average 
intake of RS differently (Table 1). Moisture content for all cracker treatments was measure to be 
9.03 + 2.09 % (mean + SD) but not accounted for in RS calculations 
  
Postprandial Glucose and Insulin  
For all participants, there was strong evidence that PPG AUC was lower for HA and RS5 
when compared to CS (p<0.001).  PPG peak reached maximum at 15 minutes for CS and HA but 
reached maximum peak at 30 minutes for RS5. By time point PPG with CS was higher than with 
HA and RS5 from 0-45 minutes.  CS for PPI AUC was only different from HA (p<0.01) and 
there was borderline evidence HA and RS5 were different from each other (p=0.0529). RS5 was 
not different from CS.  Gender differences were found in AUC for PPG and PPI (Figure 2).  For 
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every cracker type females had higher PPG and PPI than males. There was evidence in PPI AUC 
of treatment and gender interaction in males (p=0.0394) but not females, however the opposite 
was found in PPG AUC where treatment gender interaction was observed for females (p=0.0107) 
but not in males.   
By time point PPG for CS was significantly different from HA and RS5 from 0-45 
minutes (Figure 2.). There were no gender differences when PPG was analyzed by time point, 
however gender differences were found when PPI was analyzed by time point (p = 0.035).  PPI 
analyzed by time point for RS5 showed an oscillating trend in concentration after 45 minutes. 
RS5 trend differed from CS and HA which both showed a slightly more stable glucose response 
with a postprandial peak at 15 min and subsequent decline  (Figure 2).  Similar to PPG, PPI time 
point differences were found between 0-45 minutes; however, results were not as consistent.  CS 
was different from HA and RS5 at 0 (p<0.01), 15 (p<0.001), and 30 minutes (p<0.05). At 45 
min, HA was different CS and RS5, but HA was only different from RS5 at 75 min and CS at 90 
min (p<0.05).  Due to the complexity of PPI time point response by gender, gender differences 
were only discussed in PPI AUC. 
 
Breath Samples for gases H2, CO2, CH4 
Fermentation, assessed by breath hydrogen, was greater after ingestion of RS5 than after 
eating HA or CS. For all participants, there was no evidence of treatment differences until 4 and 
8 hours after ingestion of crackers, where H2 was highest in RS5 at 10.22 ± 2.06 and 11.25 ± 
2.08 ppm respectively (Figure 3).  Gender differences were observed in breath hydrogen 
production, in which females produces more than males (p=0.0485). However, there was no 
change in CO2 by treatment or gender.   
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Participants were divided into two groups: non-producers and producers.  Producers were 
defined as participant with breath methane measurement ! 7 ppm at any time point.  With the 
methane cut-off 15 participants were found to be producers. When methane was analyzed for all 
participants (producers and non-producers) there was still evidence of treatment differences and 
gender treatment interactions. Overall, methane production for all participants was the same to 
the results for just methane producers alone for both genders except with lower means.  
Time point differences were analyzed among producers and non-producers.  However, 
because there was no gender difference at the time point level, results are expressed for as one 
for both genders (Figure 4). Overall significant results for producers and all participants were the 
same except for at 2 hours where in all participants there was no difference between treatments 
whereas in producers, RS5 was significantly lower than HA (p=0.0295) but not CS. For methane 
producers at 0 hours (baseline) RS5 was again significantly lower than HA but not significantly 
different from CS. At 4 hours HA was significantly higher from all other treatments, but no 
significant difference among treatments was observed at 8hours.  
 
SCFA 
No change in the production of SCFA acetate, propionate, and butyrate due to cracker 
treatments was observed for all three days.  However gender differences and treatment and 
gender interaction was observed. Figure 5 represents total production of SCFA profiles for Day 1 
and Day 2 grouped by treatment and gender, however, there were no significant treatment 
differences for SCFA production.  For total SCFA production, there was a gender effect 
(p=0.0358) only in day 2 in which the mean total SCFA production for all treatments was 149.20 
± 14.14 µmoles/g in males and 113.96 ± 15.61 µmoles/g for females.  There was a gender main 
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effect for acetate on day two (p=0.0386) and propionate on day one (p=0.0204), in which males 
produced more fecal SCFA than females but no main effect gender difference for butyrate on 
either day.  Treatment and gender interaction were evident only in propionate (p=0.0369) and 
butyrate (p=0.0191) on day two. HA produced more butyrate and propionate in males on day two 
than in females.  
 
Gastrointestinal Symptoms and Fecal Parameters 
There was no evidence of difference for bowel movement fecal frequency, fecal weight 
or fecal pH across treatments. Reports of gastrointestinal symptoms were minimal.  Summed 
gastrointestinal symptoms were not statistically different between cracker types.  The sum of all 
gastrointestinal symptoms indicated with a positive mean that there was gastrointestinal events 
were reported but at a low rate and severity (Table 2).  However investigation of each symptom 
showed RS5 crackers had more events of bloating reported than HA and CS (p<0.01).  For all 
gastrointestinal events, most severity scores were 0.  There was a higher frequency of severity 
score 0 for gastrointestinal symptoms pain and diarrhea than for bloating. Pain and diarrhea 
gastrointestinal symptoms were not different among all treatment and over three weeks 15 events 
were reported for pain and 4 events were reported for diarrhea.   
 
DISCUSSION 
RS content in RS5 and HA crackers were substantially different via AOAC 991.43 but 
similar when assessed with AOAC 2002.12. The difference in AOAC methods to measure RS 
content in starches and crackers was not particularly astonishing.  Discrepancies between the two 
methods and RS content have been cited.  Furthermore, AOAC 2002.12 resembles in vivo 
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digestion of resistant starch (McCleary and Monaghan, 2002) as shown in present study in which 
glucose AUC was not different for RS5 and HA.  However, what was particularly interesting 
was for HA and RS5 in 2002.12 method (Megazyme) RS content in crackers was reduced more 
than half when compared to respective raw starches, while in 991.43 method RS content in 
crackers and respective raw starches were comparable.  Cooking and preparation conditions can 
influence RS content (Parchure and Kulkarni, 1997) but cracker preparations employed low 
moisture, reducing significant gelatinization or even retrogradation. Though this reduction in RS 
content from raw starch to cracker product was noticed in 991.43 it was marginal compared to 
2002.12, which was reduced by half form starch to final cracker product.  Although writers 
propose no explanation for varied RS content, the results support the use of AOAC 2002.12 
method as reliable predictor of in vivo glucose digestion.   
 
Postprandial Glucose and insulin 
 Various human feeding studies using RS in a food product have reported the reduction of 
PPG either by AUC (Behall and Hallfrisch, 2002; Li et al., 2010; Marchini et al., 1998; Najjar et 
al., 2004; Raben et al., 1994) or by time point (Anderson et al., 2010; Brighenti et al., 2006; 
Robertson et al., 2003), while other studies have shown no change PPG after consumption of a 
RS meal (Bodinham et al., 2010; Higgins et al., 2004). This introduces the idea that some RS 
dose and/or types might not significantly modulate PPG.   We used two types of RS in present 
study HA (type II) and RS5 (type V) at approximate 8-9 grams RS per serving size, when 
analyzed by Megazyme. We observed a reduction in PPG AUC for both types of RS when 
compared to conventional starch.  Hasjim and associates (2010) fed a type V RS in a bread 
product to 20 males and also found a reduction in PPG.  Studies in which RS did not reduce 
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overall PPG, evaluation by time points also provided insightful results when considering if RS 
can lower glucose surge or reduce PPG faster after 90 minutes than other carbohydrates.  
Although we observed an overall reduction in PPG following consumption of HA or RS5 by 
AUC, there were also significant differences at given time points. Consumption of HA or RS5 
significantly reduced the postprandial glycaemia at 0-45 minutes compared to CS. However, 
plasma PPG after 90 minutes was the same for all treatments.  There was a gender difference 
observed in glucose AUC as evidenced by a higher PPG for males than females, but this did not 
interfere with significance observed in the main effect for treatment and the overall trend for 
genders was similar to pooled glucose AUC (CS > HA=RS5).   Dietary fat can lower glycemic 
response, as observed in a second meal effect (Ercan et al., 1994), and lipid-starch complexes 
will also drastically reduce PPG when compared to a control (Hasjim et al., 2010).  Consumption 
of RS5, which was produced by modifying raw starch with stearic acid, produced PPG only 
marginally lower with no statistical significance than its parent starch HA. Therefore, we surmise 
the 10 percent fat content of RS5 had a negligible effect on overall PPG response.  Although 
dietary fat can decrease PPG, inversely, it can increase PPI even in people with diabetes mellitus 
(Gannon et al., 1993). However, findings from Hasjim and associates (2010) found that lipid-
starch complex starch incorporated into a bread product reduced PPI when compared to 
conventional bread.  We did not find RS5 to be different from any of the other crackers with 
respect to PPI.  HA (type II) produced a PPI significantly lower than CS but PPI after the 
consumption of HA was not different from RS5.   Thus, our evidence does not support a change 
in PPI due to lipid-starch complex. Gender differences were observed for PPI. Insulin AUC for 
females was also greater than males. These data supports gender differences in glucose 
metabolism that have been reported between men and women (Basu et al., 2006).  Insulin 
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sensitivity was observed after RS meals in men but not in women (Maki et al., 2012) which is 
congruent with our observation that women had elevated PPG and PPI compared to men. Our 
difference found to increased PPG in women could be due to a set dose of RS was given to each 
participant and with males being larger than females RSg/kg could be higher; however, when 
tolerance meals were fed to men and women by to kcal/kg, women still had higher PPG than 
men (Basu et al., 2006).  
 
Fermentation, breath gases, and SCFA  
Fermentation was measured by breath hydrogen (H2) and methane (CH4) and SCFA 
(acetate, propionate, and butyrate). Consumption of RS5 produced more hydrogen from 4-8hrs 
than CS and HA.  HA was not different in fermentation from CS, based on utilization of the 
breath hydrogen after cracker consumption. Other human studies have shown an increase in 
breath hydrogen due to RS meals from type II – IV (Hylla et al., 1998; Li et al., 2010; Muir et 
al., 1994; Robertson et al., 2003).  What is notable is that HA a type II RS when assessing breath 
hydrogen was not fermentable, but RS5 type IV was fermentable over time.   
HA seemed to be the more fermentable fiber among methane producers, consistently 
producing more methane than RS5 and at time point 4 h producing more methane than CS.  This 
pattern was also the same when all participants were included for methane production (time point 
data not shown) except that at 2 hrs there were no treatment differences and HA was only 
marginally higher (p=0.0513) than RS5 in methane production.  
SCFA production has been implicated in its role to help in colon cancer prevention and 
possibly amelioration; however, a clinical study with 24 colon adenoma patients had no change 
in SCFA production from fecal samples collected 48 after a 4 week intervention (Grubben et al., 
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2001). RS starch fermentation studies in healthy humans have found increase in total SCFA 
production (Ahmed et al., 2000; McOrist et al., 2011), while others found no difference (Phillips 
et al., 1995).  Overall, RS types II-IV are generally fermentable fibers, however, to our 
knowledge there are no human feeding studies that have investigated lower gut fermentation 
using type IV RS. No difference in cracker and SCFA production was found in present study for 
individual SCFA (acetate, propionate, or butyrate) or total SCFA.  Gender differences, however, 
were found. The main effect for SCFA production was higher in males than females. 
Fermentation gender differences have been reported in other studies (McOrist et al., 2011; Pitt et 
al., 1980).  
No marker was used to estimate gut transit time, therefore complicating the estimate of 
when fermentation of cracker products actually took place. Furthermore, bowel movements for 
each participant were different.  Some participants showed signs of constipation with no bowel 
movements over the 3 days after cracker consumption.  To assess the cracker fermentation 
without aggressive sampling or use of medical devices, there was no true way of standardization 
fecal samples other than through time. Thus a sum of SCFA production by time (i.e., days) was 
the best estimate of SCFA production among all participants.   
 
Gastrointestinal symptoms and fecal parameters  
We found no difference for fecal frequency, fecal weight, or pH across treatments.  
Increase in fecal bulking/weight (Cummings et al., 1996; Jenkins et al., 1998; Phillips et al., 
1995), increased bowel movement frequency (Heijnen et al., 1996; Noakes et al., 1996), and 
decreased pH (Birkett et al., 1996; McOrist et al., 2011) have been observed after consumption 
of RS, as RS is a dietary fiber. McOrist and associates (2011) observed a change in fecal pH after 
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RS treatment although for males a decrease in pH was observed when RS treatment was 
compared to entry fecal samples and in women was lower than another dietary fiber (NSP).  
Unlike McOrist, we did not obtain entry fecal samples before treatments and found no fecal pH 
treatment difference, similar to other research groups (Grubben et al., 2001).  HA and RS5 were 
the dietary fiber cracker and overall were well tolerated with minimal reports of gastrointestinal 
symptoms (bloating pain, and diarrhea). The sum of all gastrointestinal symptoms indicated no 
difference in treatment for symptoms.  However RS5 crackers had more events of bloating 
reported than HA and CS (p<0.01) although reported events were mild on the severity scale. 
Chocolate crisp bars formulated with a wheat RS increased bloating when compared to the 
control (Karalus et al., 2012). Gastrointestinal distress has been reported after consumption of 
high RS meals (Muir et al., 1994), however our finding are similar to other acute RS feeding 
studies, were research groups found RS treatments to be well tolerated (Heacock et al., 2004; 
Stewart et al., 2010; Wolf et al., 2001).  
 
Conclusion 
Two types of RS when compared to a control starch expressed different responses by 
gender and to fermentation as measured by breath gases. Total SCFA production was not 
affected by treatment but over all production was different among genders.  Fermentation 
assessed by breath H showed RS5 to be more fermentable, but HA was more fermentable when 
assessed by breath methane.  Overall RS5 and HA proved to be to lower postprandial glucose, 
but HA seemed to be a viable dietary agent to lower postprandial glucose response over RS5. 
Both forms of RS were well tolerated although RS5 may mild induce bloating. This study 
supports the use of RS to lower postprandial glucose to aid in the diabetes and metabolic 
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syndrome.  Further research is necessary to understanding mechanisms to fermentation patters 
between RS types; however, this study supports the use of RS5 and HA as fermentable fibers.   
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FIGURES AND TABLES  
 
 
 
1.  Fasted 
2.  Arrive at NWRC 
3.  Blood Samples 
4.  Breath Samples 
5.  Lunch 
6.  Leave NWRC 
7.  Questionnaires 
8.  Fecal Samples 
-10 
Study Timeline 
Day 2 
2 4 6 8 24 48 72 HOURS 
Night  
before Day 3 Day 1 
Completed 
BL blood and breath sample ! eat crackers 
9 blood samples after BL 
3 breath samples after BL 
0 
Lunch 
 
Figure 1.  Time line of research week as explained to each participant. 1) Overnight fast 
required. 2) Upon arrival baseline (BL) samples will be taken then crackers eaten. 3) Total of 10 
blood samples were collected 4) Total of 4 breath samples were taken. 5) A standardized lunch 
provided. 6) Allowed to leave research facility, Nutrition and Wellness Research Center 
(NWRC). 7) After 24hrs questionnaires for food consumption and gastrointestinal symptoms 
were completed.  8) Fecal samples were collected for 72 hours after consumption of cracker.  
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Table 1. Method Comparison   
 RS Content (% of total starch)  Average RS intake (g) 
 AOAC 991.43 !"#$%&'"  AOAC 991.43 !"#$%&'" 
Raw Starch      
CS 1.1 ± 0.2a 1.5 ± 0.2a    
HA 28.4 ± 2.3b 36.7 ± 1.2b    
RS5 58.0 ± 0.6c 32.8 ± 1.7b    
      
Crackers      
CS 5.8 ± 1.2a 0.3 ± 0.0a  2.9 > 1 
HA 24.3 ± 1.0b 17.5 ± 0.2b  12.2 8.8 
RS5 57.8 ± 2.3c 16.4 ± 0.7b  28.9 8.2 
Mean ± SE for RS content with the same superscript within a column with in type (i.e., raw starch or 
crackers) are not significantly different from each other. Estimates for average RS intake was not 
expressed for raw starch since participants consumed cracker products.  Average RS intake was 
estimated from 50g starch/serving.  
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Figure 2.  A and C. Glucose and insulin response mean and SE by time for all participants 
(n=29), CS was significantly different from HA and RS5 at time point 0, 15, 30, and 45 for 
glucose response.  ** p < 0.0001 * p < 0.05 .   Insulin response by time point for all participants 
expressed treatment time point interactions between at 0- 45 minutes.  B and D. AUC mean and 
SE for postprandial glucose and postprandial insulin was expressed by gender. For total glucose 
AUC CS was significantly higher than HA and RS5 (p=0.0010).  Total insulin AUC CS was 
significantly higher than HA (p=0.0043) but RS5 insulin AUC was the same for CS and HA.    
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Figure 3. Breath hydrogen fermentation (ppm) represented as mean and SE (n=29).  RS5 was 
significantly higher at 4 (* p< 0.05) and 8 hours (** p<0.01) from CS and HA.  
 
         
 
 
 
 
 
 
 
 
 
 
* 
** 
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Figure 4. Methane production by time point for male and female producers mean and SE (n=15) 
showed treatment differences 0, 2, and 4h but none at 8h. Letters within time point (h) that are 
the same are not significantly different from each other. Notably HA was significantly higher 
than RS5 and CS at 4 h. 
 
 
 
 
 
 
 
 
 
 
 
   a     b 
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 b 
 ab  a 
   b 
   a    a 
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Figure 5.  Total fecal SCFA profiles for each treatment by gender and days.  A) From fecal 
samples received on day 1 of cracker treatment.  B) From fecal samples received on day 2, 24h 
after ingestion of cracker treatment.
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Table 2. Reported gastrointestinal symptoms and averaged severity. 
 
 Bloating All symptoms 
 Total Events Overall mean Total Events Overall mean 
 Reported Median Mean   Reported Median Mean   
CS 6 2.5 !"#$ 0.87 ± 0.44a 13 2 4.12 1.9815 ± 0.56 
HA 7 2 !"%& 1.01 ± 0.45a 13 2 4.15 2.1790 ± 0.62 
RS5 11 4 '"!( 1.84 ± 0.45b  17 4 4.06 2.6556 ± 0.62 
    p = 0.0245    p = 0.7143 
For all participants, bloating was the only gastrointestinal symptom that showed to have a difference among 
treatments.  Superscripts that are different within each column are significantly different in overall mean ± 
SE from each other (p<0.01).  All symptoms were averaged (bloating, diarrhea, and pain) and reported as 
overall mean ± SE. 
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APPENDIX  
 
 
Figure 1.  Gastrointestinal symptoms questionnaire 
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Table 1. Nutritional facts from Jimmy Johns website of turkey and cheese sandwiches 
(https://www.jimmyjohns.com/menu/#/).  
 
 
Nutrition Info 
Slim 4 (Turkey) 
Amount per serving  
Serving size 201 g 
Calories 410 
Total Fat 3 g 
Saturated Fat 0 g 
Cholesterol 30 mg 
Sodium 1070 mg 
Total Carbohydrate 65 g 
Dietary Fiber 0 g 
Protein 27 g 
 
 
 
Nutrition Info 
Slim 6 (Cheese) 
Amount per serving  
Serving size 194 g 
Calories 550 
Total Fat 18.5 g 
Saturated Fat 9 g 
Cholesterol 40 mg 
Sodium 990 mg 
Total Carbohydrate 66 g 
Dietary Fiber 0 g 
Protein 29 g 
      149 
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Table 2. Mean ± SE µmole/g of fecal SCFA production by gender across treatments, stratified by days. 
 
 
Day1 
 Male  Female  
 Acetate Propionate Butyrate  Acetate Propionate Butyrate  
CS !"#$%&'('#)$**' !"$)#'('#$+"' #$+,'('"$)*' ' !)&$)"'('#,$+# *$&)'('"$," %$#"'('"$+,'  
HA !"!$"+'( !-$#" !"$")'('#$*+' !"$*#'('#$+%' ' ++$#!'('!-$!, %$,"'('#$*+ -$"#'('#$++'  
RS5 !)+$-)'( !-$"- !)$"#'('#$%#' !!$!"'('#$-!' ' !))$,,'( #)$*& +$)#'('#$+% !)$%,'('"$)-'  
 ' ' ' ' ' ' '  
Day 2 
 Male'  Female'  
 Acetate' Propionate' Butyrate'  Acetate' Propionate' Butyrate'  
CS #&&$-#'('*"$&#' #*$&*'('%$") #*$,&'( !)$)- ' !##$--'('%%$%"' %$,+'('+$-&' !)$"!'('!#$"*  
HA "&!$,-'('%"$,+' #-$+#'( +$&* ,)$%*'( !!$*- ' !,%$)"'('%%$+,' !)$%-'('+$-*' !"$,#'( !#$"+  
RS5 198.10 ± 73.93 14.69 ± 8.51 !-$,"'('!!$%* ' #+,$-,'('%+$#!' #+$!%'('-$))' &&$%*'( !#$&&  
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CHAPTER 5.    IN VITRO SCREENING OF LIPID-MODIFIED RESISTANT STARCHES 
AND MEDIA COMPARISON ON SHORT CHAIN FATTY ACID PRODUCTION IN BATCH 
FERMENTATION 
 
A paper to be submitted to Journal of Food Science 
 
 
Esther Haugabrooks, Yongfeng Ai, Jay-lin Jane, Suzanne Hendrich 
 
Abstract 
Carbohydrate fermentation is a valuable function in human health.  Fermentable dietary 
fibers, such as resistant starch, have been heavily used to influence fermentation events of the 
large intestine to advance gastrointestinal health.  In vitro comparative studies have been 
conducted to estimate and screen potential efficacy of fermentable fibers in vivo.  Starch residues 
(SR), obtained by in vitro digestion of two novel lipid complexed starches and their parent 
starch, were used as substrates for anaerobic in vitro batch fecal fermentation. Fecal slurries were 
incubated in brain heart infusion (BHI), brain heart infusion without dextrose (BHI-D), or a basal 
nutrient growth (BNG) medium for 24 hrs.  Short chain fatty production (SCFA) and pH were 
evaluated at the end of incubation period for changes due to SR, media, or body mass index 
(BMI) of fecal donors. SCFA production was unaffected by SR treatment; however, media 
differences were found. BNG had the lowest SCFA production when compared to BHI and BHI-
D.  All treatments significantly lowered fecal inocula from baseline pH however, RS5 and HA in 
all 3 media caused the lowest pH.  Although no differences were found for SR fermentation 
between BMI groups, further investigation on in vitro SR fermentation is warranted.  Ultimately, 
fermentation comparison should be conducted between in vitro and in vivo conditions to 
establish effective in vitro fermentation methods for resistant starch screening.  
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Introduction 
With the discovery of resistant starch (RS) and the advent of the dietary fiber movement 
growing awareness has been given to evaluating the effects of human gut fermentation and gut 
microbiota. This has introduced opportunities not only for greater understanding of public health 
application but also for comparative screening for suitable fermentable conditions and substrates.   
Short chain fatty acids (SCFA) are microbial fermentation products that have been 
implicated in gastrointestinal functions and beneficial biological roles such as reducing the risk 
of colon cancer, gastrointestinal disorders, and cardiovascular disease (Cook and Sellin, 1998; 
Hosseini et al., 2011; Scheppach, 1994; Scheppach et al., 1995; Suzuki et al., 2008; Vinolo et al., 
2011).  In vitro fermentation by human gut microbiota has increased SCFA production with 
soygerm powder rich in phytoestrogenic isoflavones (Boever et al., 2000); agave fructans 
(Gomez et al., 2010); and various other dietary fibers (Barry et al., 1995) as substrates. Digestion 
resistant dietary fibers, such as resistant starches, have been recommended for their fermentative 
capability (Topping and Clifton, 2001) and are used as substrates to improve overall 
gastrointestinal health such as lesser transit time, increase fecal output, lower fecal pH, and 
higher fecal SCFA (Muir et al., 2004; Phillips et al., 1995).   
Resistant starch (RS) is defined as the ingested portion of starch indigestible in the small 
intestine (Asp, 1992).  In vitro techniques, batch and dynamic models, have been used to screen 
resistant fibers to predict their fermentative capabilities in vivo (Fässler et al., 2006a).  However, 
in vitro screening can be influenced by starting material (i.e., entry fecal specimen) or by in vitro 
conditions and preparation (i.e., media used for the assay).  Different methods and media 
selections, mineral salts, mineral salts with tryptone, complex yeast media, have been 
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documented for use in fermentation studies (Edwards et al., 1996), while in resistant starch 
fermentation studies both media and buffers have been used.  With the array of different 
fermentation methods and preparation of fecal inocula, no particular method has been outlined as 
the best for in vitro fermentation studies.  A standardized method would facilitate research that 
might rapidly predict in vivo effects by accurately stimulating lower gut conditions in vitro.  
Carbohydrates as a whole are fermentable by lower gut microbiota. Considering the 
positive association of carbohydrate fermentation and beneficial health effects, slower 
carbohydrate fermentation is a desirable trait. Glucose is fermented but much more quickly than 
in the form of dietary fibers.  Media with glucose as a source of energy can enhance growth and 
fermentation of some microbiota. Thus, for in vitro fermentation studies in which RS is 
evaluated as substrate, to what extent should glucose be limited in media?  Furthermore, the use 
of enriched media can be criticized for simulating conditions unrealistic to the gastrointestinal 
environment. 
Media is consequently a feasible influence on SCFA production.  For fecal in vitro 
fermentation incubations the inherent nature of the specimen may also influence SCFA 
production. There is evidence from human fecal evaluation that fermentation patterns are 
different among body type lean, overweight, and obese (Schwiertz et al., 2010).  SCFA 
production and overall carbohydrate fermentation is attributed to resident gut microbiota.  Due to 
different microbial communities that can exist across body type (Turnbaugh et al., 2006) 
different fermentation patters can be observed generally with more fermentation observed in 
overweight or obese individuals (Schwiertz et al., 2010). Although the mechanism is unclear, the 
phenomenon is slightly paradoxical since increased fermentation is generally perceived as a 
beneficial towards human health while obesity increases the risk of health problems. 
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 Fermentation studies have compared substrates in a predigested form in vitro (Sayar et 
al., 2007; Zhou et al., 2013); differences between body mass index (BMI) groupings for SCFA 
production (Payne et al., 2011; Schwiertz et al., 2002); and media selection (Kim et al., 2011; 
Nelson and George, 1995). However, RS fermentation studies comparing non-selective media 
are few.   Research has compared fermentable fibers among which have been RS types in vivo 
and in vitro.  RS types I-IV are fairly well studied, but fermentative capacity of RS type V is not 
known.  This study aims to investigate the effect of 3 starch residues (SR) form in vitro digestion 
on human fecal inocula from lean and obese humans through the use of 3 media. We hypothesize 
body type (BMI) and SR will influence the in vitro production of SCFA from gut microbial 
committees in fecal samples with little difference in fermentation across different media types.  
 
Materials and Methods 
Preparation of Starch residues 
Three starch residues (SR) were prepared from test starches HA7, stearic acid complexed 
(RS5) and octenyl succinic starch (OS).  HA7 is a native high-amylose maize starch, commercial 
product name AmyloGel 03003, courtesy of Cargill (Hammond, IN). RS5 and OS are lipid-
modified starches developed at Iowa State University by Jay-lin Jane’s laboratory.  RS5 and OS 
were prepared at pilot-plant scale from starting material high-amylose cornstarch.  Starting 
material for RS5 was suspended in distilled water (10%, w/w) and heated at 80°C in a stem-
jacketed kettle with vigorous agitation.  After 1hour it was cooled to 55°C, pullulanase (1.25%, 
dry starch basis, dsb) was added to suspension and incubated with agitation at 55-60°C for 24h in 
a hot-water-jacketed stainless steel tank (Model 70-gallon JOVC, ViatecTM, Belding, MI).  
Stearic acid (10%, dsb) and solution heated to 80°C for 1 hour to allow lipid complex to form.  
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Starch suspension was stored at 4°C for 48h RS5 was recovered by centrifugation.  Pasted was 
dried at 50°C in convection oven and ground to a powder.  Starting material for OS was 
suspended in distilled water to solid content of 35% (w/w, dsb), pH adjusted to 8.0 with 3% 
(w/w) NaOH.  Maintaining the pH at 8.0 ± 0.1 and temperature at 33 ± 1°C, octenyl succinic 
anhydride (10% of dry starch weight, w/w, dsb) was gradually added. After stabilization of pH 
the reaction was terminated with 1.0M HCl to pH of 6.5.  Starch suspension was centrifuged and 
washed twice with distilled water and 100% ethanol. Starch was dried in an oven at 35°C and 
ground to a powder. To obtain starch residues all test starches were digested with AOAC 991.43 
method to simulate human digestion of cooked starch. 
 
Participant Characteristics 
Participants (5 female, 1 male) were screened to be within 18-65 years of age, no 
gastrointestinal disease, not on any drugs or medication, no use of antibiotics within past 6 
month.  Inclusion criteria based on BMI and divided into two groups: Group 1, lean (BMI<25) 
and Group 2, overweight (BMI> 30).  Six participants considered healthy were selected for the 
study three in each group.  Participants summarize daily eating habits via a health and diet 
questionnaire. Specific participants characteristics and eating habits are found in Table 1. The 
Institutional Review Board of Iowa State University approved the study.  Each participant 
reviewed and signed informed consent prior to donation of fecal specimen.  
 
Fecal Collection 
Whole stools were collected from six participants.  Participants were instructed to a 
metabolic restroom at ISU where they would leave a fecal specimen in a commode specimen 
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collection system (Sage Products, Inc Crystal Lake IL) placed in the refrigerator at 4°C, and call 
a specific research telephone line.  Once participants placed a call to the research telephone line, 
fecal samples were immediately collected and transferred to Bactron I anaerobic chamber 
(Sheldon Manufacturing, Inc., Cornelius, OR) to be processed.  Fecal samples were transferred 
to anaerobic conditions in a one hour or less upon receipt. All processing of samples were done 
in anaerobic chamber including transfer of samples into media and application of SR treatments 
in crimper top test tubes.  
 
Batch fermentation/In vitro incubations 
Three media were selected: brain heart infusion (BHI), brain heart infusion without 
dextrose (BHI-D), and a basal nutrient growth media  (BNG).   BHI and BHI-D (Alpha 
biosciences, Baltimore, MD) were prepared according to manufacture’s directions.  Prior to 
autoclaving BHI and BHI-D, 50 ml/L of 8 % (w/v) NaHCO3, 20 ml/L of 1.25 % (w/v) cysteine 
hydrochloride, and 1mL of 0.01% (w/v) resazurin were added. BNG was prepared with 2 g/L 
peptone water, 2 g/L yeast extract, 0.1 g/L NaCl, 0.04 g/L KH2PO4, 0.04 g/L K2HPO4, 0.01 g/L 
MgSO4 · 7H2O, 0.01 g/L CaCl2 · 6H2O, 2 g/L NaHCO3, 2 ml/L Tween 80, 0.05 g/L hemin, 10 
µl/L vitamin K, 0.5 g/L L-cysteine hydrochloride, 0.5 g/L bile salts.  Prior to autoclaving BNG 
medium was adjusted to pH 6 and 4 ml 0.025% (w ⁄ v) resazurin was added.  Each prepared 
media was placed in a 2L aspirator bottled adapted for media sampling by Milton Allison, ISU 
Affiliate Professor.  All media were gassed with CO2 using sterile needles prior to autoclaving 
and post autoclaving during cooling.  When cooled media was transferred and stored in 
anaerobic chamber to equilibrate to anaerobic chamber gases for at least a day before use.  
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Crimper top test tubes with 100mg of SR were hydrated in 2mL of test media for 24 hours then 
flash frozen before stored at -80 °C until use.   Upon receipt of fecal sample, SR hydrates were 
thawed to temperature.  Fecal inocula were prepared immediately by diluting fecal specimens 
(1/10 w/v) in BHI, BHI-D, and BNG. Inoculum was stirred and filtered through 4 layers of 
cheesecloth to remove particles.  After fecal processing, 8mL of inoculum with corresponding 
media was added to SR hydrate, stoppered with butyl stoppers and crimped.  Treatments levels 
were 4 starches (SR-OS, SR-RS5, SR-HA7, and control with no SR) and 3 media. Therefore, 
each participant’s specimen received a combination of 12 treatments.  Baseline measurements 
were taken for each media.  Crimped test tubes were incubated for 24 hr at 37°C with gentle 
agitation.  Upon completion of batch incubation, inocula were centrifuged and aliquots of 
supernatant were frozen at -80 °C for SCFA analysis.  Remaining supernatants was measured for 
change in pH 
 
Chemical analysis of SCFA 
Supernatants from inoculum were subjected to silyl derivatization before GC analysis on 
Agilent 7890A GC system model (Agilent Technologies, Inc, USA). Silylation outlined as 
follows: 100 µL of 2-ethylbutyric acid (internal standard) added to 1ml supernatant, protonated 
with concentrated hydrochloric acid, silylated with N-(tert-butyldimethylsilyl)-N-
methyltrifluoro- acetamide (MTBSTFA), SCFA extracted with diethyl ether.  Derivatives 
incubated for 20 min at 80°C the stood at room temperature for 24 hours.  After derivatization 
was competed, samples were injected on a HP-5MSI column (30 m x 0.25 mm x 0.25 !m, 
Agilent Technologies). Helium was used as a carrier gas flow rate 1mL/min, with split mode 
(5:1) 1!L injection volume.  Injector (inlet) temperature was 250°C and MS detector 
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temperatures were and 230 °C and 150 for source and quad, respectively. Ion source was EI with 
voltage at 70 eV.  The column temperature was held at 40°C for 4 minutes the programed to rise 
to 240 °C at 25 °C/min, then to 320 °C at 30 °C/min. SCFA C2-C6 (as in acetate, propionate, 
butyrate, valerate and caproate) and isomers of C4 and C5 (isobutyrate and isovalerate) were 
present in detection.  However, due to known physiological relevance of C2-C4 only acetate, 
propionate, and butyrate concentration are reported.  Likewise, where SCFA total is reported it is 
only for the 3 SCFA of interest.  The ratio of peak area of a SCFA to internal standard (2-ethyl 
butyric acid) versus the SCFA concentration was used as a standard calibration curve to estimate 
the concentration of flavonoids in in vitro fecal fermentations. 
 
Statistical Analysis  
All data, SCFA and pH analysis, were run in duplicate.  Means were analyzed using SAS 
v. 9.2 (SAS Institute, Cary, NC) conducting analyses of variance (ANOVA) with a mixed linear 
model.  Mixed linear model for pH was defined where fixed effects were media, treatment, 
media treatment interaction and participants (BMI); with random terms participant (BMI) and 
participant media interaction.  Mixed linear model for SCFA was defined using BMI, baseline 
measurements, media, treatment, and treatment media interaction as fixed effects; and subject 
and subject media interaction as random terms.  Statistical differences were evaluated using least 
significant difference (LSD) with significance level was set at p < 0.05. 
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Results 
SCFA production in fecal inocula 
There was no difference in SCFA production by treatment.  Differences were found in 
SCFA production when media was compared (Table 2).  For total SCFA production BNG was 
the lowest and BHI with and without glucose performed the same.  This was also the trend for 
each individual SCFA (acetate, propionate, and butyrate).  There was no significant difference in 
media for butyrate production in fecal incubations.  However, butyrate was lower in BNG than 
BHI and BHI-D and almost differed from butyrate concentrations in BHI-D (p=0.0562) although 
not significantly.  BNG was significantly lowest in acetate production and lower from BHI-D in 
propionate production.  All concentrations for SCFA were analyzed as an increase from baseline. 
Therefore, overall the use of BNG for in vitro fermentation did not elevate microbial production 
of SCFA in 24h incubations compared to BHI and BHI-D. 
 
Change in pH 
Treatment differences were observed in pH.  Comparably, all media performed the same 
with respect to treatment differences in pH response (Figure 2).  As anticipated, pH decreased 
from baseline in all treatments (p<0.01) for all media.  The control (C) had the least change in 
pH compared to all other treatments. Likewise, OS was different from all other treatments.  RS5 
and HA7 had the lowest change from baseline when compared with OS and C.  RS5 and HA7 
did not differ from each other in effects on media pH.   SR had an effect on pH, but change in pH 
did affect total SCFA production (Figure 1). 
 
BMI  
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This study found no evidence to support a difference in SCFA fermentation due to BMI 
or SR. Groups analyzed by weight were lean versus obese assessed by BMI. When analyzing 
weight as a variable there was no difference in pH or SCFA production by media or SR 
treatment.  Therefore, results are represented as a sum of all participants within both weight 
categories.   
 
Discussion  
As a dietary fiber, RS has been heavily investigated for its fermentability, among other 
physiological effects.  Comparison of what type of RS has the greatest fermentative capacity has 
also been conducted.  In the present study we compared three different types of RS: stearic acid, 
RS5 in which we term RS type V, OS a type IV, and HA a type II RS.  RS underwent in vitro 
digestion to simulate the portion of the starch residue (SR) that would be encountered by lower 
intestinal microbiota for fermentation.  This study also aimed to compare SR, body weights, and 
media selection to see what variables had an effect on pH and SCFA production.  Results will be 
discussed in the order of SR, media, and body weight comparisons.  
The digestion resistant portion of RS can be fermentable.  Fecal SCFA production has 
increased in vivo on a high RS diet in comparison to a low RS diet (Ahmed et al., 2000).  
Increased SCFA production to RS treatments can also be observed in vitro from ilea effluent 
(Silvester et al., 1995).  In vitro studies utilize in vitro digestion methods to obtain SR, which are 
closer simulation to what lower gut microbes would encounter in vivo.  Overall no difference in 
SCFA production was found between SR treatments.  We did find that pH decline more in RS5 
and HA7 when compared to control. Fermentation of RS produces an acidic environment, which 
is expressed with the decline in pH, was observe from all SR treatments. However, RS5 and OS 
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were the lipid-starch complexed residues and were found to perform differently with respect to 
reduction of pH.  Substrates used in RS fermentation studies are often residues from RS II or RS 
III.  Little is known about the fermentability of RS type V or lipid-starch complex fermentation. 
Although anaerobic bacteria were targeted for fermentation, media selection of BHI, 
BHI-D, and BNG in present study was chosen for non-selective properties.  BHI and BHI-D are 
commercially available media and BNG has been used in other anaerobic fecal studies (Fooks 
and Gibson, 2003; Gomez et al., 2010).  An early media comparative study used selective and 
none-selective media to recover anaerobic bacteria in human clinical specimens from anaerobic 
infection and found certain selective media (laked blood-agar plate containing vancomycin and 
kanamycin and neomycin Brucella blood-agar plate) enhanced the appearance of some anaerobic 
bacteria easier isolation in specimens with heavy growth of facultative organisms; however, 
selective media overall decreased recovery of most anaerobic bacteria especially gram-positive 
rods (Rosenblatt et al., 1973).  
In a media comparison study for enumeration and isolation of anaerobic fecal bacteria of 
mice found using a plate-in- bottle method six non-selective media, one of which was BHI, 
colony counts and percent recoveries was higher among habitat-stimulating media which 
contained low concentration of organic matter than enriched media (i.e., BHI) (Itoh and 
Mitsuoka, 1985).  In addition, Itoh and Mitsuoka (1985) found that BHI and a media described 
by Wensinck & Ruselervan Embden (W&E agar) were more selective than other media 
secluding the growth of bacterial group Peptococcaccae in BHI and suppressing the growth 
Eubacteria in W&E agar. The use of BHI has also been compared in media comparison study to 
evaluate culture conditions to maintain metabolically active and diverse population of human 
bacteria in feces over an 18-24 hour bath incubation (Kim et al., 2011). Kim and associates 
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(2011) found that between BHI, a low-carbohydrate medium (LCM), and a high- carbohydrate 
medium (HCM) that LCM performed best in maintain a diverse metabolically active population 
and would be suitable for in vitro studies using human intestinal microbiota.  
In the present study we used BHI and two media we considered low carbohydrate, BHI-D 
and BNG.  We supplied each media with carbohydrate source of SR, one from RS type II and 
two from RS type II and also evaluated the SR fermentation against a blank control.  Considering 
main effects of media we found that BHI and BHI-D performed the same while BNG was 
consistently lower for individual SCFA and total SCFA production.  Molar ratios for each media 
were 146:13:17, 170:14:19, and 34:8:12 for BHI, BHI-D, and BNG respectively. We expected to 
see a slight elevation in SCFA production from BHI due to the carbohydrate source when 
compared to its counterpart depleted of dextrose.  However, we found no statistical difference 
between the two enriched media BHI and BHI-D.  
 Bacteria that contribute to fermentation in the colon are often obligate anaerobes that do 
not thrive in the presence of oxygen.  Obtaining fecal samples in oxygen-depleted environments 
for in vitro incubations are a challenge, and where mentioned methods have been poorly 
described. It can be concluded that fermentation contributions from strict anaerobic bacterial 
species including extremely oxygen-sensitive organisms cannot fully be accessed in vitro, which 
parallels the current understand in microbiology that only a fraction of gut microbiota is 
culturable.  At most, with quick and anaerobic fecal processing times, viable anaerobes that 
remain can be surmised to exert the main effects related to treatment differences.  
 We found no difference in SCFA production due to weight at entry level or after 24 h batch 
fermentation incubations. Li and associates (2010) compared in 15 lean to 9 overweight and 6 
obese individuals in an in vitro RS fermentation. Similar to our study they found no significant 
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differences in SCFA production between weight groups.  This study was conducted over 3 weeks 
in a semi-continuous fermentation system using BHI as media and also showed no change in 
SCFA production due to various SR (RS type II) treatments (Li, 2010b). Thus we do not believe 
longer incubation periods would have provided evidence to weight and SCFA fermentation 
differences, even though various RS in vitro studies utilize 24-hour incubation periods have 
produced varied results in SCFA production (Fässler et al., 2007; Laurentin and Edwards, 2004). 
 There is evidence that in vitro anaerobic fermentation in fecal samples from overweight or 
obese individuals tend to be greater than in lean individuals (Schwiertz et al., 2010).  Schwiertz 
and associates (2010) evaluated intestinal microbiota and fecal SCFA concentration of lean 
(n=30, 18.5-24.9 BMI), overweight (n=35, 24-30 BMI), and obese (n=33, BMI>30) individuals.  
They found total SCFA was significantly higher for overweight (98.7 ± 33.9 mmol/l) and obese 
(103.9 ± 34.3 mmol/l) when compared to lean individuals, furthermore propionate concentrations 
were elevated over lean individuals. The mechanism for this phenomenon is unclear. 
Furthermore, it does not bridge the discrepancy that if overweight and obese individuals tend to 
have increased fermentation, which have been postulated to lead to beneficial effects, why are 
they the subpopulation at higher risk for gastrointestinal complications such as colorectal cancer 
(Ma et al., 2013)? 
Eating habits of participants were similar, except for whole grain consumption.  Lean 
individuals consumed more whole grains servings/day than individuals with higher BMI, 
although individuals with a higher BMI seemed to consume more servings of fruit per day. 
Similar background diets could be an explanation to no difference in fermentation at entry level 
or after fecal incubation with SR.  Although Schwiertz and associates (2010) found SCFA 
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differences by weight, fermentation was assessed from participants on a background western 
diet, independent of strict diet normalization or fecal incubation with carbohydrate substrates.  
Currently a wide variety of methods are used for in vitro fermentation studies with no 
method clearly described as the best. Statements for biologically relevant substrates are being 
made when even in vivo results for suitable fermentable substrates are mixed. More comparative 
studies should be conducted but more over between in vitro screening leading into in vivo 
experiments.  Due to the fragile nature of the amount of human microbiota that can be cultured, 
it is hard to say which media or batch fermentation method best represent the complex 
environment of the gastrointestinal tract. However batch fermentations can be an easy and 
invaluable tool of in vitro results parallel in vivo findings.  Little is known about the fermentative 
capacity of RS type V, but per our in vitro results, we found no difference between type V, IV, or 
type II RS.  Dose response and in vivo comparisons would add to our understanding and 
knowledge of this new type of resistant starch.  
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Figures and Tables 
 
 
Table 1. Participant characteristics 
 Group 1 Group 2 
N 3 3 
Age (yr) 27 ± 3 (24-29) 27 ± 5 (22-32) 
BMI 23.3 ± 1.5 (22-25) 34.9 ± 0.9 (34-36) 
Height (cm) 166 ± 3.9 (162-171) 169 ± 6.4 (162-175) 
Weight (kg) 64.9 ± 5.1 (58-69) 98.1 ± 7.4 (89-104) 
   
Eating habits by serving size   
Meat (~3oz) " 2.7 " 2 
Fruit (~1/2 cup or one piece) 2 " 2.7 
Vegetables (~1/2 cup) 3.5 3.3 
Whole grains (~1/2 cup, 1 slice of bread) 4.7 2.7 
Dairy products (~1 cup) 1.3 1 
 
Characteristic of age, BMI, height, and weight are reported as mean ± SD (range).  Eating habits were reported by 
means.  Each participant reported daily serving sizes either from a range of 0-2 or >2 for meat 0-4 or >4 for fruit, 1-
5 or >5 for vegetables, 0, 2, 4, 6 or >6 for grains, and 0-3 or >3 for dairy products.  If one or more participant 
reported servings sizes ‘>2’, ‘>4’, ‘>5’, ‘>6’, and ‘>3’ for meat, fruit, vegetable, whole grains, and dairy products 
respectively the succeeding whole number was used to calculate the mean and expressed as " mean. (See Appendix 
C for health and diet questionnaire) 
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Figure 1. Total SCFA production and relation to pH by treatment within medium.  Left y-axis is 
SCFA acid concentration (mmole/L). Right y-axis is pH scale. BHI- brain heart infusion 
medium, BHI-D – brain heart infusion medium without dextrose, BNG- basal nutrient growth 
medium 
          
 
 
 
      169 
 
 
 
 
 
Table 2.  Media comparison of SCFA fermentation for all treatments  
 BHI BHI-D BNG P value 
Acetate 145.72 ± 32.7149a 170.39 ± 33.0553a 34.0361 ± 32.9499b 0.0100 
Propionate 12.5332 ± 1.8095ab 13.9238 ± 1.7818a 7.6328 ± 1.8066b 0.0695 
Butyrate 17.1515 ± 3.4951 18.7966 ± 3.2701 11.3514 ± 3.3032 0.1339 
Total 178.02 ± 38.8286a 203.32 ± 39.2102a 50.2008 ± 38.8974b 0.0100 
Values represented as means ± SE in mmoles/L.  Means with the same superscripts within row are not 
significantly different.  P value represents the main effect of media, whereas superscripts are differences of least 
square means (p < 0.05). 
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Figure 2.  Change in pH from baseline. Measured from fecal inocula of three SR and a blank 
control (C).   
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APPENDIX  
 
 
 
 
 
Figure 1. Health and diet questionnaire used to assess estimated daily food intake and if 
participant was eligible to be entered into the study. 
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CHAPTER 6.    SUMMARY AND CONCLUSIONS  
 
Digestion of resistant starches (RS) is a topic of great interest in science with a large 
number of implications for health and observable outcomes.  However, there are four different 
forms of RS that have the potential to respond differently to physiological responses, and this 
dissertation research examines human physiological responses to a new less common type of RS. 
Lipid-starch or lipid-amylose complexes are being proposed to be different from other types of 
RS and worthy to be classified in their own category, RS type V. The other types of RS are type I 
that are physically inaccessible starches not fractionated and/or refined, type II are starches with 
native resistant granules normally amylose rich, type 3 are retrogradated starches, and type IV 
are chemically modified starches. Research findings have built a framework that dietary fiber 
fermentation in the lower gut is beneficial to gastrointestinal health and may be helpful in 
prevention or amelioration of gastrointestinal diseases. RS can be used as a fermentable fiber.  
Furthermore, in metabolic disease and diabetes it is necessary to manage glucose and insulin 
responses: RS can be used to lower glucose and insulin response. These are the physiological 
responses we targeted through the use of dietary RS.  The overarching hypothesis of this 
dissertation is that RS (type II and V) can favorably impact human physiological responses of 
PPG, PPI, and lower gut microbial fermentation with minimal gastrointestinal distress. We tested 
this hypothesis through three research studies. 
  
Study One (1) entitled ‘Post-Prandial Affects Of Naturally Occurring Resistant Starch In Maize 
On Glycemic Response In Healthy Humans’ 
Objectives:  
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• Evaluate postprandial glucose response from RS content in corn starches derived from 
exotic corn lines or a conventionally crossbred line derived from these lines when 
compared to control corn starch 
• Make simple food product (pudding) to deliver test starches 
• Assess gastrointestinal symptoms associated with pudding treatments  
 
Study Two (2) entitled ‘Influence Of Crackers Containing Resistant Starch Type V On 
Postprandial Glucose, Insulin, And Fermentation Response In Healthy Humans’ 
Objectives:  
• Evaluate postprandial glucose response and insulin response from high amylose (type II 
RS) and stearic acid complexed RS (type V) 
• Make simple palatable food product (cracker) to deliver test starches 
• Evaluate fermentation via breath gases (H2, CH4, CO2) and fecal short chain fatty acid 
(SCFA) production. 
• Record fecal parameters (frequency, weight, pH) 
• Assess gastrointestinal symptoms associated with cracker treatments 
 
Study Three (3) entitled ‘In Vitro Screening of Lipid Modified Resistant Starches And Media 
Comparison On Short Chain Fatty Acid Production In Batch Fermentation’    
Objectives: 
• Prepare starch resides (SR) from high amylose starch (type II RS), stearic acid complexed 
starch (type V RS), and octenyl succinate (type IV) for 24 hour in vitro batch 
fermentation comparison  
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• Investigate if SCFA profiles are different between lean and obese individuals and if 
different type of RS have an effect on SCFA production 
• Compare the effects of media selections (brain heart infusion with and without dextrose 
and a basal nutrient growth) on SCFA production 
 
Postprandial glucose and insulin response and fermentation are some of the physiological 
responses that have also been targeted by other research groups with varied results.  The research 
submitted in this dissertation also found varied results.  Study 1 and 2 investigated glucose 
response.  In Study 1, total glucose AUC was unaffected by RS types when compared to a 
cornstarch control or other low RS corn starches.  However, there was a postprandial decrease 
from the cornstarch in participants ingesting pudding with the highest RS content.  Study 2 
showed that RS type 2 and RS type V were effective in lowering glucose AUC when compare to 
a control cornstarch.  
In Study 2, it was very evident that both forms of RS lowered glucose AUC. However, 
we also evaluated postprandial insulin response in Study two and noticed differences in RS type; 
HA significantly lowered insulin AUC when compared to the control starch but RS5 did not.  RS 
content measured by AOAC 2002.12 did not differ between the two high RS crackers.  HA was 
the parent starch complexed with stearic acid to obtain RS5.  Therefore, the only difference 
between these starches was the lipid content, which may have contributed to the lack of 
significant change in insulin AUC when compared to control even though RS5 produced a lesser 
glucose AUC than CS.  However, when insulin AUC was compared between RS5 and HA no 
difference was observed.  Overall both forms of RS did lower glucose response and further 
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investigation is needed to understand lipid-starch complexes on insulin and fermentation 
response in vivo.  
The use of RS type V in Study 2 and 3 was intended to advance what is known about 
physiological responses and practical application for the use of this new type of RS.  Overall the 
experimental designs compared type V to well-established RS type II and type IV (only in Study 
3) to evaluate in vivo or in vitro fermentation as well as in vivo glucose and insulin response in 
humans.  In Study 2 fermentation differences were found between RS type II and type V. Breath 
hydrogen measurements after RS5 were significantly higher than all other treatments between 4 
and 8 hours.  In breath methane production we found HA to generate greater response than other 
starches, especially at 4 hours.   But we found no fermentation differences between starches from 
analysis of fecal SCFA production.  In study 3 we only evaluated fermentation by SCFA 
production and also found no difference between type II, IV, and V when dose and RS content 
was the same.   
Study 1 and 2 assessed how well RS was tolerated.  No treatment differences were 
observed for adverse gastrointestinal effects in study 1.  Study 2 showed more events of bloating 
for RS5 than the other treatments, but these effects were very mild. Therefore these studies 
supported overall gastrointestinal tolerance of RS was good. 
The central question still remains, how effective is the consumption of RS in improving 
human health?  Cumulative literature supports the use of RS for improving human health. 
Furthermore, RS is already being manufactured and commercially distributed as additives and in 
food products, which supports the need for development of new RS.   The research presented in 
this dissertation evaluated the efficacy of new resistant starches from crossbreeding exotic corn 
lines or lipid modification on glucose and insulin response, colonic fermentation, and 
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gastrointestinal tolerance.  Study one used crossbred exotic corn lines with varied RS content.  
The objective was to test the starches for their efficacy in lowering postprandial glucose.   
Reduced postprandial glucose effects were observed in a parent line; however, crossbreeding did 
not improve RS content. The results from Study 1 did not support the use of the specific 
crossbred line (Guat/AR) for lowering glucose, however, suggests that crossbreeding to obtain 
starches with approximate RS content > 25% (similar to the parent line, Guat, with lowest 
postprandial peak) could produce new and effective starches. Results of this dissertation indicate 
that RS5, from raw starches with ~ 33% resistance, seems efficacious for glucose and 
fermentation responses.  The author supports RS5 as a strong candidate for further study in 
protecting the lower intestine from diseases through colonic fermentation, and in benefitting 
individuals with the need to control their blood glucose. 
